<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Mol Sci</journal-id><journal-id journal-id-type="iso-abbrev">Int J Mol Sci</journal-id><journal-id journal-id-type="pmc-domain-id">808</journal-id><journal-id journal-id-type="pmc-domain">ijms</journal-id><journal-id journal-id-type="publisher-id">ijms</journal-id><journal-title-group><journal-title>International Journal of Molecular Sciences</journal-title></journal-title-group><issn pub-type="epub">1422-0067</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC9863728</article-id><article-id pub-id-type="pmcid-ver">PMC9863728.1</article-id><article-id pub-id-type="pmcaid">9863728</article-id><article-id pub-id-type="pmcaiid">9863728</article-id><article-id pub-id-type="pmid">36675218</article-id><article-id pub-id-type="doi">10.3390/ijms24021701</article-id><article-id pub-id-type="publisher-id">ijms-24-01701</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Recombinant Protein Vaccines against Human Betacoronaviruses: Strategies, Approaches and Progress</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-9786-7652</contrib-id><name name-style="western"><surname>Kovalenko</surname><given-names initials="A">Angelina</given-names></name></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-2683-8285</contrib-id><name name-style="western"><surname>Ryabchevskaya</surname><given-names initials="E">Ekaterina</given-names></name></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-0679-6818</contrib-id><name name-style="western"><surname>Evtushenko</surname><given-names initials="E">Ekaterina</given-names></name></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-9626-2336</contrib-id><name name-style="western"><surname>Nikitin</surname><given-names initials="N">Nikolai</given-names></name><xref rid="c1-ijms-24-01701" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-0605-9033</contrib-id><name name-style="western"><surname>Karpova</surname><given-names initials="O">Olga</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Sancho</surname><given-names initials="J">Javier</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name name-style="western"><surname>Cutruzzola</surname><given-names initials="F">Francesca</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-ijms-24-01701">Department of Virology, Faculty of Biology, Lomonosov Moscow State University, 119234 Moscow, Russia</aff><author-notes><corresp id="c1-ijms-24-01701"><label>*</label>Correspondence: <email>nikitin@mail.bio.msu.ru</email></corresp></author-notes><pub-date pub-type="epub"><day>15</day><month>1</month><year>2023</year></pub-date><pub-date pub-type="collection"><month>1</month><year>2023</year></pub-date><volume>24</volume><issue>2</issue><issue-id pub-id-type="pmc-issue-id">427086</issue-id><elocation-id>1701</elocation-id><history><date date-type="received"><day>11</day><month>11</month><year>2022</year></date><date date-type="rev-recd"><day>12</day><month>1</month><year>2023</year></date><date date-type="accepted"><day>12</day><month>1</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>15</day><month>01</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>22</day><month>01</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-09-29 02:25:45.337"><day>29</day><month>09</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; 2023 by the authors.</copyright-statement><copyright-year>2023</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="ijms-24-01701.pdf"/><abstract><p>Betacoronaviruses have already troubled humanity more than once. In 2002&#8211;2003 and 2012, the SARS-CoV and MERS-CoV, respectively, caused outbreaks of respiratory syndromes with a fatal outcome. The spread of the SARS-CoV-2 coronavirus has become a pandemic. These three coronaviruses belong to the genus Betacoronavirus and have a zoonotic origin. The emergence of new coronavirus infections in the future cannot be ruled out, and vaccination is the main way to prevent the spread of the infection. Previous experience in the development of vaccines against SARS and MERS has helped to develop a number of vaccines against SARS-CoV-2 in a fairly short time. Among them, there are quite a few recombinant protein vaccines, which seem to be very promising in terms of safety, minimization of side effects, storage and transportation conditions. The problem of developing a universal betacoronavirus vaccine is also still relevant. Here, we summarize the information on the designing of vaccines based on recombinant proteins against highly pathogenic human betacoronaviruses SARS-CoV, MERS-CoV and SARS-CoV-2.</p></abstract><kwd-group><kwd>human betacoronaviruses</kwd><kwd>SARS-CoV</kwd><kwd>MERS-CoV</kwd><kwd>SARS-CoV-2</kwd><kwd>COVID-19</kwd><kwd>recombinant protein vaccines</kwd><kwd>adjuvants</kwd><kwd>S protein</kwd><kwd>RBD</kwd><kwd>multi-epitope vaccines</kwd></kwd-group><funding-group><award-group><funding-source>Russian Foundation for Basic Research and Moscow city Government</funding-source><award-id>21-34-70004</award-id></award-group><funding-statement>This work was supported by the Russian Foundation for Basic Research and Moscow city Government (Grant No. 21-34-70004).</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-ijms-24-01701"><title>1. Introduction</title><p>In December 2019, cases of pneumonia of unknown cause were reported in Wuhan, China [<xref rid="B1-ijms-24-01701" ref-type="bibr">1</xref>]. It was soon discovered that the infectious agent was a new betacoronavirus, which was named as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by the International Committee on Taxonomy of Viruses [<xref rid="B2-ijms-24-01701" ref-type="bibr">2</xref>]. In March 2020, the World Health Organization declared the outbreak of the coronavirus disease 2019 (COVID-19) a pandemic [<xref rid="B3-ijms-24-01701" ref-type="bibr">3</xref>]. SARS-CoV-2 belongs to the family <italic toggle="yes">Coronaviridae</italic>, the representatives of which (SARS-CoV and MERS-CoV viruses) have previously caused outbreaks of high-mortality respiratory syndrome cases. In 2002&#8211;2003, there was an outbreak of severe acute respiratory syndrome (SARS) caused by the SARS-CoV virus in China. In 2012, cases of the Middle East respiratory syndrome (MERS) caused by the MERS-CoV virus were first reported in Saudi Arabia [<xref rid="B4-ijms-24-01701" ref-type="bibr">4</xref>]. The MERS-CoV virus remains a concern, especially in Saudi Arabia and neighboring countries since individual cases of MERS are still being diagnosed [<xref rid="B5-ijms-24-01701" ref-type="bibr">5</xref>]. A large number of vaccine candidates against SARS-CoV and MERS-CoV were developed. There are developments based on inactivated and live attenuated viruses, as well as protein vaccines, DNA-based vaccines, viral vector vaccines and virus-like particle (VLP) vaccines. Only a few vaccines against SARS and MERS have been subjected to clinical trials. These are an inactivated virus vaccine by Sinovac (Beijing, China) and a DNA vaccine by NIAID (Rockville, MD, USA) against SARS, and a DNA vaccine (GeneOne Life Science/Inovio Pharmaceuticals, Seoul, Republic of Korea/Plymouth Meeting, PA, USA) and several viral vector vaccines against MERS (MVA-MERS-S vaccine, CTC North GmbH &amp; Co. KG, Hamburg, Germany; ChAdOx1 MERS vaccine, King Abdullah International Medical Research Center/University of Oxford, Riyadh, Saudi Arabia/Oxford, Great Britain; BVRS-GamVac-Combi vaccine, Gamaleya Research Institute of Epidemiology and Microbiology/Acellena Contract Drug Research and Development, Moscow/St. Petersburg, Russia) [<xref rid="B6-ijms-24-01701" ref-type="bibr">6</xref>]. Currently, phase 1 of the clinical trials has begun for the inactivated SARS vaccine (no NCT ID) and for the DNA-based vaccine (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00099463">NCT00099463</ext-link>) against SARS [<xref rid="B6-ijms-24-01701" ref-type="bibr">6</xref>]. As far as vaccines against MERS are concerned, phase 1 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02670187">NCT02670187</ext-link>) and phase 1/2a (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03721718">NCT03721718</ext-link>) of clinical trials have been completed for DNA-based MERS vaccine. Phase 1 of clinical trials was also completed for viral vector vaccines MVA-MERS-S (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03615911">NCT03615911</ext-link>) and ChAdOx1 MERS (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04170829">NCT04170829</ext-link>). The information about the 1/2 phase research (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04128059">NCT04128059</ext-link>) for the BVRS-GamVac-Combi vaccine is on the site ClinicalTrials.gov (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04128059">https://clinicaltrials.gov/ct2/show/NCT04128059</uri>, accessed on 5 January 2023). No vaccine against SARS and MERS has been approved for use.</p><p>To fight SARS-CoV-2, researchers focused their efforts on the development of various vaccines. Vaccine candidates include live-attenuated and inactivated vaccines, which have already become traditional, and also vaccines of new generations, such as recombinant protein vaccines, VLP vaccines, nucleic acid vaccines and vector vaccines [<xref rid="B7-ijms-24-01701" ref-type="bibr">7</xref>]. In particular, mRNA vaccines, having not been previously applied in clinical practice, were approved. Two of them&#8212;Spikevax (Moderna, Cambridge, MA, USA) and Comirnaty (Pfizer/BioNTech, New York, NY, USA/Mainz, Germany)&#8212;became wildly used (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://covid19.trackvaccines.org/vaccines/approved/#vaccine-list">https://covid19.trackvaccines.org/vaccines/approved/#vaccine-list</uri>, accessed on 5 January 2023). Both contain nucleoside-modified mRNA, which codes the S protein of SARS-CoV-2 and are delivered within lipid nanoparticles [<xref rid="B6-ijms-24-01701" ref-type="bibr">6</xref>]. Vaccines that are based on a non-replicating adenovirus vector carrying the SARS-CoV-2 S protein coding sequence are also actively applied. A case in point is Sputnik V (Gamaleya, Moscow, Russia), Jcovden (Janssen (Johnson &amp; Johnson), Leiden, Netherlands/New Brunswick, NJ, USA) and Vaxzevria (Oxford/AstraZeneca, Oxford, Great Britain/Cambridge, Great Britain/S&#246;dert&#228;lje, Sweden) (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://covid19.trackvaccines.org/vaccines/approved/#vaccine-list">https://covid19.trackvaccines.org/vaccines/approved/#vaccine-list</uri>, accessed on 5 January 2023).</p><p>A large group of new generation COVID-19 vaccines are recombinant protein vaccines, which are the subject of this current review. These are vaccines that are considered to be among the most promising in terms of safety and side-effects avoidance. In addition to a high safety profile, recombinant protein vaccines have other advantages: they are more stable in comparison to mRNA vaccines and, in contrast to virus vector-based vaccines, potentially do not have application limitations concerning the use of the same vector in revaccination. Moreover, the production of protein recombinant vaccines does not require live virus cultivation since virus proteins, being vaccine components, are obtained in various recombinant expression systems. According to some research opinions, vaccines based on virus-like particles could also be included among the recombinant protein vaccines. However, in this review, the authors define &#8220;recombinant protein vaccines&#8221; as vaccines that contain isolated and purified coronavirus proteins and may otherwise be named &#8220;protein subunit vaccines&#8221;.</p><p>This review considers the principles of development and some examples of recombinant protein vaccines against human-pathogenic betacoronaviruses SARS-CoV, MERS-CoV and SARS-CoV-2. The review also presents the results of pre-clinical studies and clinical trials.</p></sec><sec id="sec2-ijms-24-01701"><title>2. S Protein of Betacoronaviruses</title><p>Highly human-pathogenic coronaviruses SARS-CoV, MERS-CoV and SARS-CoV-2 belong to the genus <italic toggle="yes">Betacoronavirus</italic>, from the family <italic toggle="yes">Coronaviridae</italic>. SARS-CoV and SARS-CoV-2 belong to the subgenus <italic toggle="yes">Sarbecovirus</italic>, while MERS-CoV belongs to the subgenus <italic toggle="yes">Merbecovirus</italic>. Their genome (approximately 30 kb in size) is represented by positive-sense single-stranded RNA and encodes the following structural proteins: spike (S) protein, envelope (E) protein, membrane (M) protein and nucleocapsid (N) protein [<xref rid="B8-ijms-24-01701" ref-type="bibr">8</xref>]. The S protein (spike protein) is a glycoprotein required for the virus to bind to receptors and enter the host cell. The M and E proteins are involved in the morphogenesis and assembly of virions, while the N protein plays a fundamental role in viral RNA packaging [<xref rid="B9-ijms-24-01701" ref-type="bibr">9</xref>,<xref rid="B10-ijms-24-01701" ref-type="bibr">10</xref>]. In addition to structural proteins, the betacoronavirus genome also encodes 16 non-structural proteins (Nsp1&#8211;16) and accessory ORFs proteins [<xref rid="B8-ijms-24-01701" ref-type="bibr">8</xref>]. It is known that antibodies specific to the structural S and N proteins are detected in the serum of patients who have had COVID-19. A study by Jiang et al., (2020) also reported the detection of antibodies specific to the accessory ORF9b protein and non-structural Nsp5 protein [<xref rid="B11-ijms-24-01701" ref-type="bibr">11</xref>]. The Nsp5 protein, also known as the 3CLpro protein, is the main protease of coronaviruses, a chymotrypsin-like enzyme [<xref rid="B8-ijms-24-01701" ref-type="bibr">8</xref>,<xref rid="B12-ijms-24-01701" ref-type="bibr">12</xref>]. The interaction of the accessory SARS-CoV-2 ORF9b protein with the human mitochondrial TOM70 protein inactivates type I interferon production [<xref rid="B13-ijms-24-01701" ref-type="bibr">13</xref>]. However, of all the betacoronavirus proteins, the S protein appears to be the most promising antigen in the development of recombinant vaccines, since it induces the production of neutralizing antibodies that block the virus&#8217; entry into the cell [<xref rid="B10-ijms-24-01701" ref-type="bibr">10</xref>].</p><p>The S protein contains 1255, 1353 and 1273 amino acids in SARS-CoV, MERS-CoV and SARS-CoV-2, respectively [<xref rid="B14-ijms-24-01701" ref-type="bibr">14</xref>]. The SARS-CoV-2 S protein is 35% identical to the MERS-CoV S protein and 76% identical to the SARS-CoV S protein [<xref rid="B15-ijms-24-01701" ref-type="bibr">15</xref>]. The S protein of betacoronaviruses contains an ectodomain consisting of two functional subunits, S1 and S2 (subunits 1 and 2), a transmembrane domain (TM) and a cytoplasmic tail (CT) [<xref rid="B16-ijms-24-01701" ref-type="bibr">16</xref>]. The S1 subunit is required for the binding to a cellular receptor, which is represented by the angiotensin-converting enzyme 2 (ACE2) for SARS-CoV and SARS-CoV-2, and the dipeptidyl peptidase-4 (DPP4) molecule for MERS-CoV [<xref rid="B4-ijms-24-01701" ref-type="bibr">4</xref>]. The S1 subunit (14&#8211;685 amino acid residues for SARS-CoV-2) contains an N-terminal domain (NTD), a receptor-binding domain (RBD) and subdomains 1 and 2 (SD1 and SD2). The S2 subunit (686&#8211;1211 amino acid residues for SARS-CoV-2) is required for the virus membrane fusion with the cell membrane; it contains the fusion peptide (FP), heptad repeat 1 (HR1), central helix (CH), connector domain (CD) and heptad repeat 2 (HR2) (<xref rid="ijms-24-01701-f001" ref-type="fig">Figure 1</xref>A) [<xref rid="B17-ijms-24-01701" ref-type="bibr">17</xref>].</p><p>The S protein of betacoronaviruses is present in the virion as trimers (<xref rid="ijms-24-01701-f001" ref-type="fig">Figure 1</xref>A). It belongs to class I viral fusion proteins, along with the human immunodeficiency virus (HIV) envelope glycoprotein (Env) and influenza virus hemagglutinin (HA) [<xref rid="B17-ijms-24-01701" ref-type="bibr">17</xref>]. For the virus to enter the cell, the S protein must be cleaved by cellular proteases into S1 and S2 subunits. Proteolytic activation of the SARS-CoV S protein occurs either after virion attachment to the cell surface due to the transmembrane serine protease 2 (TMPRSS2), or in the lysosome due to cathepsin proteases [<xref rid="B20-ijms-24-01701" ref-type="bibr">20</xref>]. For SARS-CoV-2, this S protein activation occurs even at the stage of virion assembly in the Golgi apparatus of an infected cell, which is possibly due to the presence of a multibasic, furin-cleavage site (RRAR) at the S1/S2 junction. In a mature viral particle, the S1 and S2 subunits remain non-covalently associated [<xref rid="B21-ijms-24-01701" ref-type="bibr">21</xref>,<xref rid="B22-ijms-24-01701" ref-type="bibr">22</xref>]. This aspect distinguishes SARS-CoV-2 from SARS-CoV. MERS-CoV furin-cleavage site (RSVR) is similar to the one of SARS-CoV-2 [<xref rid="B21-ijms-24-01701" ref-type="bibr">21</xref>]. Therefore, SARS-CoV-2 progeny virions with the pre-activated S protein are able to infect different cells in the body, which provides a high pathogenic potential for SARS-CoV-2 [<xref rid="B23-ijms-24-01701" ref-type="bibr">23</xref>].</p><p>The betacoronaviruses S protein exists in two conformations: prefusion (&#8216;before fusion&#8217;) and postfusion (&#8216;after fusion&#8217;). The receptor-binding domain (RBD), which is part of the S1 subunit, is responsible for binding to the cellular receptor. In the context of the COVID-19 pandemic, structural studies of the SARS-CoV-2 S protein have become particularly relevant. The RBD mobility of the SARS-CoV-2 S protein in the prefusion conformation has been demonstrated using cryo-electron microscopy. Previously, seemingly stochastic RBD movements have been observed in the structural characterization of SARS-CoV and MERS-CoV [<xref rid="B16-ijms-24-01701" ref-type="bibr">16</xref>]. It has been shown that, in the closed prefusion conformation, all three RBD trimers of the SARS-CoV-2 S protein are &#8216;down&#8217; (lying down) and cannot bind to the ACE2 receptor. For the successful viral infection of the host cell, there should be at least one RBD &#8216;up&#8217; (standing up) [<xref rid="B23-ijms-24-01701" ref-type="bibr">23</xref>]. This S protein conformation is called open prefusion conformation. Some researchers believe that D614G mutation promotes the increase of the portion of the S protein in the open state with one RBD in the &#171;up&#187; conformation, which can explain the enhanced infectivity of the D614G variants of SARS-CoV-2 [<xref rid="B22-ijms-24-01701" ref-type="bibr">22</xref>]. For SARS-CoV-2, it has been shown that its S protein also interacts with heparan sulfate, a negatively charged linear polysaccharide that is a component of many organs and tissues, via RBD. This interaction promotes the formation of the open S protein conformation required for binding to ACE2 [<xref rid="B24-ijms-24-01701" ref-type="bibr">24</xref>]. According to a hypothetical scheme, the binding of one RBD up to ACE2 initiates the opening and binding of the RBD of the second, and then the third, S protein monomers to ACE2 molecules. As a result, S1 subunit shedding is induced and the S2&#8217; sites within the S2 subunits that were previously deeply hidden in the spike are exposed [<xref rid="B23-ijms-24-01701" ref-type="bibr">23</xref>,<xref rid="B25-ijms-24-01701" ref-type="bibr">25</xref>]. Site-specific hydrolysis of the S protein occurs at the S2&#8217; site immediately before the highly conserved S-F-I-E-D-L-L-F sequence [<xref rid="B26-ijms-24-01701" ref-type="bibr">26</xref>]. In SARS-CoV-2, this process is catalyzed either by the TMPRSS2 protease in the case of virus penetration into cells through the cell membrane, or by lysosome cathepsins in the case of internalization by clathrin-mediated endocytosis. Cleavage at the S2&#8217; site exposes the fusion peptide and dissociation of the S1 subunit that causes major conformational changes in the S2 subunit from prefusion to postfusion. The fusion peptide is propelled into the cell membrane, and the virus envelope and the cell membrane fuse [<xref rid="B22-ijms-24-01701" ref-type="bibr">22</xref>]. Therefore, the interaction between an RBD and a specific cell surface receptor, which differs for different betacoronaviruses, causes major conformational changes in the S protein, which leads to the fusion of the coronavirus and host cell membranes.</p></sec><sec id="sec3-ijms-24-01701"><title>3. Strategies for Obtaining Recombinant Protein Vaccines against Betacoronaviruses</title><p>There are three main strategies for the development of recombinant protein vaccines against a betacoronavirus infection. The first strategy is to use the full-length S protein as an antigen in the vaccine. It is believed that the prefusion conformation of the S protein trimer is the most optimal for inducing the maximum immune response, and it is proposed as one of the main targets for vaccine development. However, the prefusion state tends to be very unstable [<xref rid="B27-ijms-24-01701" ref-type="bibr">27</xref>]. There are several protein engineering approaches that can solve this problem. The first approach is to introduce two proline residues (positions 986 and 987 for SARS-CoV-2) into the S2 subunit sequence between the heptad repeat 1 and the central helix. These mutations do not inhibit RBD motion in SARS-CoV-2 [<xref rid="B27-ijms-24-01701" ref-type="bibr">27</xref>]. The other two approaches to stabilize the prefusion state of the isolated S protein are to remove the multibasic furin-cleavage site (SARS-CoV-2 and MERS-CoV) and replace the TM and CT domain sequences with an artificial motif of trimerization [<xref rid="B28-ijms-24-01701" ref-type="bibr">28</xref>,<xref rid="B29-ijms-24-01701" ref-type="bibr">29</xref>].</p><p>Earlier, in a study of the development of a SARS-CoV vaccine based on the full-length S protein, it was shown that an adverse effect, such as the antibody-dependent enhancement (ADE) of infection, was associated with the use of this vaccine [<xref rid="B30-ijms-24-01701" ref-type="bibr">30</xref>]. The second strategy in the development of vaccines against betacoronavirus infections is to not use the full-length S protein as an antigen, but to instead use its fragments and exclude unwanted epitopes in the design of genetically engineered constructs. Thus, it has been proved for SARS-CoV, that antibodies specific to the S597-603 S1 subunit epitope are responsible for ADE [<xref rid="B31-ijms-24-01701" ref-type="bibr">31</xref>]. In the classic case of ADE, specific IgGs form low affinity complexes with the virus, mediating its entering into cells of the immune system that displayed the Fc&#947;RII receptor [<xref rid="B32-ijms-24-01701" ref-type="bibr">32</xref>]. The effect of ADE is associated with non-neutralizing antibodies or neutralizing antibodies at suboptimal concentrations [<xref rid="B33-ijms-24-01701" ref-type="bibr">33</xref>]. Since the most robust virus-neutralizing antibodies are specific to RBD [<xref rid="B34-ijms-24-01701" ref-type="bibr">34</xref>,<xref rid="B35-ijms-24-01701" ref-type="bibr">35</xref>], scientists often use this antigenic determinant as a target when developing vaccines against betacoronaviruses. However, a recent study by Wan et al., (2020) described a new ADE mechanism, showing that a neutralizing monoclonal antibody (mAb) specific to MERS-CoV RBD mediated virus entry into immune cells <italic toggle="yes">in vitro</italic>. The mAb recognized the S protein RBD exclusively in the fusion-promoting &#8216;up&#8217; orientation. Interaction with the S protein induced its conformational changes with the mAb binding to the Fc receptor, and the antibody/Fc receptor complex that functionally mimicked the viral receptor, mediated virus entry into immune cells. In addition, in the same study a neutralizing mAb specific for the SARS-CoV RBD was also shown to mediate the entry of the SARS-CoV pseudovirus. The authors of the study consider that the ADE of coronaviruses is mediated by neutralizing mAbs targeting the RBD of the S protein. They also demonstrated that for MERS-CoV entry into cells expressing both DPP4 and Fc receptors, there is a balance between DPP4-dependent and antibody-dependent entry pathways that can be determined by mAb dosages. A high dose of antibodies might help reduce the effect of ADE in MERS-CoV. In general, the researchers suggest that the ADE of viruses depends on the doses of antibodies, the level of expression of viral and Fc receptors in specific tissues, and some intrinsic characteristics of the antibodies [<xref rid="B36-ijms-24-01701" ref-type="bibr">36</xref>]. Therefore, the dynamic nature of RBD should be taken into account when developing vaccines and therapeutics, and it can be assumed that the effect of ADE is less likely if antibodies target other regions of the S protein and do not cause changes in its conformation.</p><p>There is also an approach to engineering vaccines based on mapped linear B and T cell epitopes. For this purpose, partially overlapping short peptides are synthesized and immunogenic ones are identified among them. For example, Li et al., (2021) synthesized 211 such partially overlapping short peptide fragments and determined whether each peptide reacted with anti-SARS-CoV-2 antibodies in the blood sera of COVID-19 patients. This is how linear B epitopes of the S protein were identified. Two regions rich in linear epitopes were revealed: C-terminus of S1 subunit and a region close to the S2&#8217; cleavage site and fusion peptide. The fact that there were almost no linear B epitopes in the RBD domain was an interesting result [<xref rid="B37-ijms-24-01701" ref-type="bibr">37</xref>]. The mapping of T-epitopes is technically more difficult than B-epitopes. However, for SARS-CoV-2 proteins, the T-epitopes map has been made and very few CD4+ T cell epitopes have been shown in an RBD, while CD8+ T cell epitopes are evenly distributed among various coronavirus antigens [<xref rid="B38-ijms-24-01701" ref-type="bibr">38</xref>]. When developing vaccines, a bioinformatic analysis is used to identify significant epitopes among all coronavirus proteins. Such multi-epitope vaccines are represented by peptides, which are corresponding the immunogenic epitopes of coronaviruses predicted by <italic toggle="yes">in silico</italic> methods, or their tandem repeats.</p><p>Recombinant antigens for protein vaccines can be produced in various expression systems, such as <italic toggle="yes">Escherichia coli</italic>, yeast, plants, insect cells and mammalian cells. <italic toggle="yes">E. coli</italic> is one of the earliest and most widely used expression systems for producing recombinant proteins. However, <italic toggle="yes">E. coli</italic> does not provide such post-translational modifications of expressed proteins such as glycosylation, which may affect the nature of the immune response and the formation of disulfide bonds, which affects the correctness of protein folding and, consequently, its solubility and stability [<xref rid="B39-ijms-24-01701" ref-type="bibr">39</xref>]. It is nevertheless worth noting that He et al., (2021) characterized the structure of recombinant SARS-CoV-2 RBDs expressed in <italic toggle="yes">E. coli</italic> and mammalian HEK293 cells, and evaluated the ability of both recombinant proteins to bind to the ACE2 receptor, in their recent paper. The authors found no significant differences in the secondary and tertiary structure of proteins and their ability to bind to the receptor, despite the fact that the RBD expressed in <italic toggle="yes">E. coli</italic> was not glycosylated [<xref rid="B40-ijms-24-01701" ref-type="bibr">40</xref>]. The surface of the S protein is known to be extensively shielded by glycans from antibody recognition, with the exception of the RBD, which explains the immunodominance of its epitopes [<xref rid="B41-ijms-24-01701" ref-type="bibr">41</xref>]. At the same time, the protein yield in <italic toggle="yes">E. coli</italic> was 13.3 mg/L in bacterial culture and only 5 mg/L in mammalian cells [<xref rid="B40-ijms-24-01701" ref-type="bibr">40</xref>]. <italic toggle="yes">E. coli</italic> as an expression system for recombinant betacoronavirus RBD has been successfully used in a number of studies [<xref rid="B42-ijms-24-01701" ref-type="bibr">42</xref>,<xref rid="B43-ijms-24-01701" ref-type="bibr">43</xref>]. Therefore, the protein produced in <italic toggle="yes">E. coli</italic>, which is a recombinant S protein RBD, can be used for the development of vaccines, along with proteins produced in other expression systems.</p><p>Insect cells are often used to express a recombinant antigen for a betacoronavirus vaccine. The Sf9 cell line obtained from the ovaries of the fall armyworm (<italic toggle="yes">Spodoptera frugiperda</italic>) [<xref rid="B44-ijms-24-01701" ref-type="bibr">44</xref>] is very popular. Sf9 cells were used, for example, to express the recombinant antigen in the production of COVID-19 vaccines, such as the NVX-CoV2373 (full-length S protein vaccine) and the West China Hospital COVID-19 vaccine (RBD vaccine). However, for most current COVID-19 vaccines, recombinant proteins have been expressed in mammalian cell cultures, which, in recent years, have often been used for the production of various biopharmaceuticals, including antibodies and vaccine antigens. Cell lines such as HEK293 (human embryonic kidney 293) and its variants (293F and 293T), BHK cells (baby hamster kidney cells) and CHO cells (Chinese hamster ovary cells) are often used for the production of betacoronavirus vaccines. For example, recombinant antigens have been generated in CHO cells for the production of COVID-19 vaccines such as the MVC-COV1901 (S protein trimer vaccine) and ZF2001 (RBD dimer vaccine).</p><p>Since individual recombinant proteins usually elicit a weak immune response, most vaccines are developed in combination with various adjuvants that increase the immunogenicity of vaccines. There are adjuvants based on mineral salts, emulsions, microparticles, saponins, cytokines and chemokines, microbial components/products, liposomes, nucleic acids and nucleotides, polysaccharides, etc. However, only a few adjuvants are licensed for use in vaccines [<xref rid="B45-ijms-24-01701" ref-type="bibr">45</xref>,<xref rid="B46-ijms-24-01701" ref-type="bibr">46</xref>]. In pre-clinical studies of recombinant protein betacoronavirus vaccines, scientists have used various adjuvants, such as: Complete Freund&#8217;s Adjuvant (CFA); Incomplete Freund&#8217;s Adjuvant (IFA); Sigma Adjuvant System (SAS, an alternative to Freund&#8217;s adjuvant); monophosphoryl lipid A (MPL) in combination with trehalose dicorynomycolate (TDM); structurally modified plant viruses, etc. <xref rid="ijms-24-01701-t001" ref-type="table">Table 1</xref> shows examples of adjuvants in recombinant COVID-19 vaccines approved for clinical trials.</p><p>The selection of an adjuvant is an important stage in the development of effective and safe protein and inactivated vaccines. For example, a study by Honda-Okubo et al., (2015) showed that a delta inulin polysaccharide adjuvant not only increased the titer of neutralizing antibodies, but also reduced eosinophilic immunopathology in the lungs [<xref rid="B54-ijms-24-01701" ref-type="bibr">54</xref>], an adverse vaccine-induced effect that was observed, for example, in the study of an inactivated SARS-CoV vaccine [<xref rid="B55-ijms-24-01701" ref-type="bibr">55</xref>]. The data obtained in the study by Iwata-Yoshikawa et al., (2014) suggested that the same effect can be avoided when TLR agonist adjuvants are included in the vaccine [<xref rid="B56-ijms-24-01701" ref-type="bibr">56</xref>].</p></sec><sec id="sec4-ijms-24-01701"><title>4. Recombinant SARS and MERS Vaccines</title><sec id="sec4dot1-ijms-24-01701"><title>4.1. Full-Length S Protein Vaccines</title><p>Full-length S protein recombinant vaccines have been developed against both SARS [<xref rid="B30-ijms-24-01701" ref-type="bibr">30</xref>,<xref rid="B57-ijms-24-01701" ref-type="bibr">57</xref>,<xref rid="B58-ijms-24-01701" ref-type="bibr">58</xref>] and MERS [<xref rid="B28-ijms-24-01701" ref-type="bibr">28</xref>].</p><p>In the study by He et al., (2006), the recombinant full-length S protein (FL-S) and its ectodomain (EC-S) (i.e., S protein without TM and CT domains) of the SARS-CoV virus were obtained. Recombinant proteins were expressed in insect cells and MPL and TDM was used as an adjuvant. The study demonstrated that both recombinant proteins induced high titers of neutralizing antibodies against SARS pseudoviruses constructed with the S proteins of Tor2, GD03T13 and SZ3, the representative strains of 2002 to 2003 and 2003 to 2004 human SARS-CoV and palm civet SARS-CoV, respectively [<xref rid="B57-ijms-24-01701" ref-type="bibr">57</xref>].</p><p>It is known that when the recombinant ectodomain is expressed in eukaryotic systems, the resulting protein exists mainly in the monomeric form. Li et al., (2013) obtained a monomer of the SARS-CoV S protein ectodomain (S) and its trimerized form by combining the T4 fibritin trimerization motif (foldon) with the S protein ectodomain (S-foldon). To obtain secreted recombinant proteins, Sf9 insect cells were used in combination with a baculovirus expression system. In immunized mice, S-foldon induced a significantly higher titer of neutralizing antibodies than the monomeric S protein ectodomain. The authors also investigated the protective efficacy of recombinant proteins. Mice were immunized intramuscularly four times with S and S-foldon antigens in combination with an aluminum hydroxide gel and MPL adjuvant. After the fourth immunization, mice were intranasally infected with the SARS-CoV virus and were euthanized, and the level of viral load in the lungs was assessed. In groups of mice immunized with S and S-foldon antigens, the virus was not detected in the lungs, but was detected in the control group immunized with PBS buffer and adjuvant [<xref rid="B58-ijms-24-01701" ref-type="bibr">58</xref>].</p><p>A similar approach using the T4 fibrin trimerization motif was used by Pallesen et al., (2017) to obtain a trimerized ectodomain of the MERS-CoV S protein (S-2P). The authors obtained a soluble trimerized S protein in the prefusion conformation that was stabilized due to two proline mutations (V1060P and L1061P) and a furin-cleavage site replacement (748-RSVR-751 -&gt; ASVG). The recombinant protein expressed in mammalian 293F cells, in combination with the SAS adjuvant, following mice immunization induced a high titer of antibodies with neutralizing activity detected against various MERS-CoV pseudoviruses in an <italic toggle="yes">in vitro</italic> assay [<xref rid="B28-ijms-24-01701" ref-type="bibr">28</xref>].</p><p>Kam et al., (2007) developed a recombinant vaccine (triSpike) based on a full-length S protein trimer expressed in BHK cells. The vaccine, in combination with an aluminum hydroxide gel adjuvant, induced the production of neutralizing antibodies against the SARS-CoV virus [<xref rid="B30-ijms-24-01701" ref-type="bibr">30</xref>]. However, anti-S protein antibodies promoted the entry of the virus into B cells, thereby mediating the effect of ADE, which raised serious concerns about the use of the full-length S protein as a target for the SARS vaccine [<xref rid="B30-ijms-24-01701" ref-type="bibr">30</xref>,<xref rid="B59-ijms-24-01701" ref-type="bibr">59</xref>]. The authors of the study also note that it is especially necessary to unravel which viral epitopes or immunoglobulin isotypes are responsible for the enhanced infection. A possible strategy to prevent ADE is to use individual S protein fragments to obtain a vaccine antigen. Vaccines based on individual antigenic determinants of coronaviruses can be designed in such a way as to exclude the epitopes responsible for ADE (in particular, the aforementioned epitope S597-603 in the case of the SARS-CoV S protein).</p></sec><sec id="sec4dot2-ijms-24-01701"><title>4.2. RBD Vaccines</title><p>The attention of many investigators has been focused on the RBD, since it is this domain that mediates the interaction between the virus and the cellular receptor. Most neutralizing antibodies against coronaviruses target the S protein RBD and block its binding to the receptor [<xref rid="B60-ijms-24-01701" ref-type="bibr">60</xref>]. There are many developments of recombinant protein SARS-CoV and MERS-CoV vaccines based on the S protein RBD. These vaccines induce the production of high titers of neutralizing antibodies, while no pronounced immunopathological effects associated with the use of such vaccines were reported [<xref rid="B42-ijms-24-01701" ref-type="bibr">42</xref>,<xref rid="B61-ijms-24-01701" ref-type="bibr">61</xref>,<xref rid="B62-ijms-24-01701" ref-type="bibr">62</xref>,<xref rid="B63-ijms-24-01701" ref-type="bibr">63</xref>].</p><p>Du et al., (2009) expressed recombinant SARS-CoV RBDs (rRBDs) in various expression systems, such as mammalian (293T), insect (Sf9) and <italic toggle="yes">E. coli</italic> cells, comparing the rRBDs obtained when testing their efficacy in a mouse model. All three rRBD proteins retained their native conformation. When administered with the SAS adjuvant, they induced a potent immune response and protected mice against SARS-CoV, neutralizing antibodies suppressed virus replication in lung tissues. The authors concluded that any of the expression systems presented in the study could be used to produce recombinant protein rRBD vaccines against SARS [<xref rid="B42-ijms-24-01701" ref-type="bibr">42</xref>].</p><p>In the study performed by Lan et al., (2014) the immunogenicity of a recombinant protein vaccine based on the MERS-CoV rRBD obtained using a baculovirus expression system in combination with various adjuvants in mice was tested. Intramuscular injection of the rRBD in combination with aluminum hydroxide and CpG ODN mediated the induction of RBD-specific humoral and cellular immunity. The rRBD in combination with IFA and CpG ODN, after subcutaneous injection, induced potent RBD-specific antibodies and T cell response, but the level of neutralizing antibodies was low [<xref rid="B64-ijms-24-01701" ref-type="bibr">64</xref>]. A vaccine candidate based on the MERS-CoV rRBD, in combination with aluminum hydroxide, induced a high level of neutralizing antibodies and T cell immunity in rhesus monkeys, and also alleviated the course of pneumonia and reduced the viral load during MERS-CoV infection [<xref rid="B65-ijms-24-01701" ref-type="bibr">65</xref>].</p><p>The trimerized RBD-Fd protein obtained through MERS-CoV RBD fusion with the T4 fibritin trimerization motif was described in the paper by Tai et al., (2016). Mammalian 293T cells were used as the expression system. The RBD-Fd bound to DPP4, a molecule acting as a receptor for MERS-CoV, induced the production of strong RBD-specific neutralizing antibodies in mice, and in combination with an aluminum-based adjuvant, protected transgenic mice (with human dipeptidyl peptidase 4 (hDPP4)) from death when infected with MERS-CoV [<xref rid="B63-ijms-24-01701" ref-type="bibr">63</xref>].</p><p>A paper by Dai et al., (2020) described a strategy for obtaining the dimeric form of the MERS-CoV RBD and the dimeric form of the SARS-CoV RBD, coined tandem repeat single chain dimer (sc-dimer) by the authors. Mammalian HEK293T cells were used as the expression system. Mice were immunized with the recombinant protein in combination with the AddaVax adjuvant (similar to MF-59). It was shown that the dimeric form of RBD, compared to the monomeric form, had greater immunogenicity, and induced significantly higher titers of neutralizing antibodies [<xref rid="B66-ijms-24-01701" ref-type="bibr">66</xref>].</p><p>One approach to the development of vaccines is the production of fusion proteins containing the target antigen and the fragment crystallizable region (Fc) of human immunoglobulin G (IgG). The presence of the Fc domain increases the plasma half-life of the protein, which prolongs its therapeutic activity [<xref rid="B67-ijms-24-01701" ref-type="bibr">67</xref>] and leads to slower renal clearance for large molecules [<xref rid="B68-ijms-24-01701" ref-type="bibr">68</xref>]. The Fc domain promotes the proper folding of the fusion protein and can improve the solubility and stability of the partner molecule [<xref rid="B69-ijms-24-01701" ref-type="bibr">69</xref>]. The attached Fc domain also enables the interaction of fusion proteins with the Fc receptors (FcRs) located on immune cells, which is particularly important for their use in vaccines [<xref rid="B70-ijms-24-01701" ref-type="bibr">70</xref>]. An approach using the human IgG1 Fc fragment was taken to develop a number of RBD-based SARS and MERS vaccines. RBD-Fc was shown to induce neutralizing antibodies against SARS-CoV in immunized rabbits and mice [<xref rid="B61-ijms-24-01701" ref-type="bibr">61</xref>]. Du et al., (2007) showed that, after immunization with RBD-Fc, neutralizing antibodies could persist for 12 months, protecting most immunized mice against SARS-CoV [<xref rid="B62-ijms-24-01701" ref-type="bibr">62</xref>]. A similar approach using the Fc fragment was also applied in the development of MERS-CoV vaccines [<xref rid="B71-ijms-24-01701" ref-type="bibr">71</xref>,<xref rid="B72-ijms-24-01701" ref-type="bibr">72</xref>,<xref rid="B73-ijms-24-01701" ref-type="bibr">73</xref>,<xref rid="B74-ijms-24-01701" ref-type="bibr">74</xref>,<xref rid="B75-ijms-24-01701" ref-type="bibr">75</xref>,<xref rid="B76-ijms-24-01701" ref-type="bibr">76</xref>]. In particular, Zhang et al., (2016) conducted a study to determine the adjuvant that would most optimally increase the immunogenicity of the S377-588-Fc protein (the MERS-CoV RBD fused to the Fc fragment). Thus, the authors compared several commercially available adjuvants, including Freund&#8217;s adjuvant, aluminum hydroxide, MPL, Montanide ISA51 and MF59, in terms of their ability to increase the immunogenicity of the developed recombinant protein vaccine. MF59 was shown to be the most potent since it induced the highest titers of IgG1 and IgG2a antibodies and neutralizing antibodies. A significant enhancement of the S377-588-Fc antigen immunogenicity after the MF59 adjuvant addition and the protection of immunized mice with hDPP4 against MERS-CoV after infection led the authors to suggest that MF59 was the optimal adjuvant for MERS-CoV RBD-based vaccines [<xref rid="B75-ijms-24-01701" ref-type="bibr">75</xref>].</p></sec><sec id="sec4dot3-ijms-24-01701"><title>4.3. S Protein Fragment Vaccines</title><p>Recombinant protein vaccines based on the S1 subunit demonstrated immunogenicity and a protective effect against betacoronaviruses. Li et al., (2013), who have been mentioned during the discussion of vaccines based on the full-length S protein, also obtained recombinant S1 and S1-foldon proteins, which contributed to the production of neutralizing antibodies and along with full-length S and S-foldon proteins, provided protection against SARS-CoV in mice [<xref rid="B58-ijms-24-01701" ref-type="bibr">58</xref>]. Wang et al., (2015) demonstrated that a recombinant protein based on the MERS-CoV S1 subunit, in combination with an aluminum phosphate adjuvant, induced a high titer of neutralizing antibodies and protected non-human primates against severe lung disease after MERS-CoV infection [<xref rid="B77-ijms-24-01701" ref-type="bibr">77</xref>]. A study by Adney et al., (2019) reported on a protein vaccine based on the MERS-CoV S1 subunit used in combination with Advax HCXL and SAS adjuvants. The recombinant vaccine provided alpacas with complete protection against MERS-CoV that correlated with high serum titers of neutralizing antibodies. Lower titers of neutralizing antibodies were found in dromedary camels, but virus replication in immunized animals was limited mainly to the nasal turbinate; this contrasts with non-immunized animals, in which MERS-CoV spread deeper through the respiratory tract into the trachea [<xref rid="B78-ijms-24-01701" ref-type="bibr">78</xref>].</p><p>Kim et al., (2020) developed several variants of the MERS vaccine based on the S1 subunit fused to the foldon trimerization motif. The sequences of either the RS09 peptide (mimics lipopolysaccharide and is TLR4 agonist) or flagellin (TLR5 agonist) were added to the constructs. Recombinant proteins were expressed in the HEK293 cells. The immunogenicity of vaccine candidates was tested in mice using two methods of vaccine administration: traditional subcutaneous injection and using a dissolving microneedle array, which is a plate with carboxymethylcellulose-based needles loaded with a recombinant antigen. The study authors reported that the administration of vaccines using microneedles elicited a more effective humoral immune response and more efficient production of neutralizing antibodies than a subcutaneous injection, regardless of the presence of additional TLR binding sites in the antigen sequence. However, the inclusion of the RS09 sequence led to an enhanced immune response, and a significant induction of neutralizing antibodies, when compared with the antigen without RS09 when administered subcutaneously. Interestingly, the inclusion of the flagellin sequence did not affect the immunogenicity of subcutaneously administered vaccines [<xref rid="B79-ijms-24-01701" ref-type="bibr">79</xref>].</p><p>Jiaming et al., (2017) obtained a recombinant N-terminal domain (rNTD), which is part of the S1 subunit of the MERS-CoV S protein. The MERS-CoV rNTD, in combination with aluminum hydroxide and CpG, was shown to induce potent cellular immunity and antigen-specific neutralizing antibodies in mice. Moreover, the rNTD demonstrated protection against MERS-CoV infection in transgenic mice with hDPP4 that was comparable to the rRBD, resulting in a reduced pulmonary pathology. Thus, rNTD is another potential antigen for MERS vaccines [<xref rid="B80-ijms-24-01701" ref-type="bibr">80</xref>].</p><p>Some studies have focused on the development of S2 subunit vaccines, but no positive results have been obtained regarding the ability of these vaccines to elicit neutralizing antibodies or induce protective reactions [<xref rid="B58-ijms-24-01701" ref-type="bibr">58</xref>]. Guo et al., (2005) showed that the recombinant fragment of the SARS-CoV S2 subunit (amino acid residues 681&#8211;980) expressed in <italic toggle="yes">E. coli</italic> cells was specifically recognized by the blood serum of people who had had SARS. In combination with the IFA adjuvant, the recombinant protein induced a Th2-dominant response in mice, but no neutralizing antibody titer was detected [<xref rid="B81-ijms-24-01701" ref-type="bibr">81</xref>]. However, some monoclonal antibodies to the highly conserved HR1 and HR2 domains of the S2 subunit are known to have a broad spectrum of neutralizing activity against various SARS-CoV isolates [<xref rid="B82-ijms-24-01701" ref-type="bibr">82</xref>,<xref rid="B83-ijms-24-01701" ref-type="bibr">83</xref>]. This indicates the potential of the S2 subunit as a target for the development of a universal vaccine against various betacoronaviruses.</p></sec><sec id="sec4dot4-ijms-24-01701"><title>4.4. Vaccines Based on Non-S Structural Proteins</title><p>Although most papers focus on vaccines based on the S protein or its fragments, there are also data relating to the development of vaccines based on the structural N and M proteins. The SARS-CoV N protein expressed in <italic toggle="yes">Nicotiana benthamiana</italic> induced IgG1 and IgG2a antibodies in mice, with CFA used for the first immunization and IFA used for the second immunization. No adjuvants were used during the third and fourth doses of the vaccine. The induction of a cellular immune response was also shown [<xref rid="B84-ijms-24-01701" ref-type="bibr">84</xref>]. In the study by Liu et al., (2006), the recombinant SARS-CoV nucleocapsid protein (rN) expressed in E. coli, in combination with Montanide ISA51 and CpG adjuvants, induced mainly IgG2a isotype antibodies in immunized mice. In contrast, after immunization with the rN protein in PBS without adjuvants, the antibodies produced were mainly of the IgG1 isotype. These results showed that immunization with the rN protein in combination with Montanide ISA51 and CpG adjuvants elicited a Th1-biased immune response [<xref rid="B85-ijms-24-01701" ref-type="bibr">85</xref>]. In a study by He et al., (2005), two synthetic peptides corresponding to the main immunodominant epitopes of the SARS-CoV M protein (M1-31 and M132-161) were produced. Both peptides induced high antibody titers in immunized rabbits [<xref rid="B86-ijms-24-01701" ref-type="bibr">86</xref>]. Thus, the immunogenicity of SARS and MERS protein vaccines based on N and M proteins has been demonstrated, but the protective efficacy of these vaccine candidates is unknown. It is possible to use N and M proteins in the development of vaccines, but for full protection against coronavirus infection, it is necessary to obtain virus-neutralizing antibodies that are produced only when immunized with the S protein or its individual fragments.</p></sec><sec id="sec4dot5-ijms-24-01701"><title>4.5. Multi-Epitope Vaccines</title><p>The use of bioinformatic approaches for SARS and MERS suggested the design of multivalent vaccines containing T and B cell epitopes of S, E, M, N and ORFs proteins. Using <italic toggle="yes">in silico</italic> methods, the selected epitopes were tested for the possibility of their molecular interaction with alleles of the major histocompatibility complex (HLA, human leucocyte antigens). A stable molecular interaction with the TLR2 and TLR4 receptors for SARS-CoV protein epitopes and with the TLR3 receptor for MERS-CoV protein epitopes was also predicted. Probably, the decision of the study authors to analyze for molecular interaction with certain TLRs could be explained by the presence of different adjuvant sequences: a truncated <italic toggle="yes">Onchocerca volvulus</italic> activation-associated secreted protein-1 and human &#946;-defensin within SARS and MERS vaccines, respectively. Nevertheless, it is likely that in both cases, more than one or two types of the TLR as well as others pattern-recognition receptors could contribute to activation of innate immune mechanisms. The analysis of the nucleotide sequence encoding the predicted epitopes showed that this sequence was able to provide a high level of expression in mammalian cells. The authors believe that, since vaccines contain T- and B-cell epitopes, they should induce both cellular and humoral immune responses [<xref rid="B87-ijms-24-01701" ref-type="bibr">87</xref>,<xref rid="B88-ijms-24-01701" ref-type="bibr">88</xref>]. However, the results of <italic toggle="yes">in vivo</italic> trials of these vaccines are currently not publicly available. Bioinformatic methods enable vaccine developers to analyze the coronavirus proteome and based on the information obtained, select the most immunogenic peptides, which can help in the design of a potentially effective vaccine candidate in a fairly short time, the immunogenicity and protectivity of which should be tested in animal models.</p></sec></sec><sec id="sec5-ijms-24-01701"><title>5. Recombinant COVID-19 Vaccines</title><p>Amid the pandemic of the novel coronavirus infection, there is a need to create effective COVID-19 vaccines. Due to the COVID-19 pandemic, the number of SARS-CoV-2 vaccines that have been developed and that have been subjected to clinical trials, is far greater than the number of SARS and MERS vaccines. The results of the development of recombinant SARS and MERS vaccines have become the starting point for the creation of a relevant vaccine against the novel coronavirus infection. As of October 25, 2022, 18 of the 49 COVID-19 vaccines approved for use are recombinant protein vaccines (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://covid19.trackvaccines.org/">https://covid19.trackvaccines.org/</uri>). Most of the vaccines being developed and vaccines at different stages of pre-clinical and clinical studies include the S protein or its RBD domain as an antigen. <xref rid="ijms-24-01701-f001" ref-type="fig">Figure 1</xref>B&#8211;G illustrates the approaches used to develop COVID-19 vaccines (approved for phase 3 clinical trials or already approved for use) based on the SARS-CoV-2 S protein and its fragments. <xref rid="ijms-24-01701-t002" ref-type="table">Table 2</xref> shows examples of some recombinant protein COVID-19 vaccines.</p><sec id="sec5dot1-ijms-24-01701"><title>5.1. Full-Length S Protein Vaccines</title><p>Novavax (USA) has developed a recombinant NVX-CoV2373 (Nuvaxovid) vaccine based on prefusion-stabilized S protein trimers assembled into nanoparticles. Protein stability was achieved by replacing the furin-cleavage site (682-RRAR-685 -&gt; QQAQ) and introducing two proline mutations (K986P and V987P) (<xref rid="ijms-24-01701-f001" ref-type="fig">Figure 1</xref>B). The recombinant protein was expressed in Sf9 insect cells. The Matrix-M adjuvant was used in the vaccine [<xref rid="B89-ijms-24-01701" ref-type="bibr">89</xref>]. Successful trials in animal models made it possible to conduct clinical trials of the vaccine, which confirmed the efficacy and safety of NVX-CoV2373 [<xref rid="B90-ijms-24-01701" ref-type="bibr">90</xref>]. The NVX-CoV2373 vaccine provides 89.7% (according to the published results of phase 3 clinical trials conducted in the UK: EUCTR2020-004123-16 and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04583995">NCT04583995</ext-link>) [<xref rid="B91-ijms-24-01701" ref-type="bibr">91</xref>] and 92.6% (according to the results of phase 3 clinical trials conducted in the USA and Mexico: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04611802">NCT04611802</ext-link>) [<xref rid="B92-ijms-24-01701" ref-type="bibr">92</xref>] protection against the SARS-CoV-2 infection. The NVX-CoV2373 vaccine has been approved for use in 40 countries (October 25, 2022).</p><p>The MVC-COV1901 vaccine, developed by the Medigen Vaccine Biologics Corporation (Taiwan) with the support of the NIAID (USA), is represented by a prefusion-stabilized trimerized ectodomain (S-2P protein) (amino acid residues 1&#8211;1208). In order to improve antigen stability, two substitutions of K986P and V987P were made, and the furin-cleavage site was mutated (682-RRAR-685 -&gt; GSAS) at the S1/S2 junction (<xref rid="ijms-24-01701-f001" ref-type="fig">Figure 1</xref>C). The T4 fibrin trimerization motif, HRV3C protease cleavage site, octa-histidine tag and TwinStrep96 tag (tags necessary for the affinity purification of the recombinant protein, which were then removed using the HRV3C protease), were added to the sequence. The protein was expressed in mammalian CHO cells. The recombinant protein is used in the vaccine in combination with the CpG 1018 (Dynavax, USA) and aluminum hydroxide adjuvant [<xref rid="B93-ijms-24-01701" ref-type="bibr">93</xref>]. Phase 2 clinical trials (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04695652">NCT04695652</ext-link>) have shown that the MVC-COV1901 vaccine induces high titers of neutralizing antibodies, is safe, is well-tolerated and rarely causes a fever in both young and elderly people [<xref rid="B94-ijms-24-01701" ref-type="bibr">94</xref>]. Phase 3 clinical trials are ongoing (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05426343">NCT05426343</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05198596">NCT05198596</ext-link> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05011526">NCT05011526</ext-link>); the MVC-COV1901 vaccine has already been approved for use in four countries (Eswatini, Paraguay, Somaliland and Taiwan).</p><p>The COVAX-19 (SpikoGen) vaccine (Vaxine Pty Ltd./CinnaGen Co., Australia/Iran) is based on the S protein ectodomain (ECD) with the removed furin-cleavage site (<xref rid="ijms-24-01701-f001" ref-type="fig">Figure 1</xref>F) expressed in Tni insect cells. It is interesting that according to the authors, the study of the engineered recombinant antigen by molecular dynamics simulation showed its ability to form a stable trimer, despite the absence of transmembrane and cytoplasmic domains and a trimerization motif. The Advax-CpG55.2 adjuvant is used in the vaccine. Pre-clinical studies have demonstrated that the vaccine induced high titers of neutralizing antibodies and the formation of CD4+ and CD8+ memory T cells in mice [<xref rid="B95-ijms-24-01701" ref-type="bibr">95</xref>]. Immunized hamsters infected with SARS-CoV-2 showed a decreased viral load in the oropharynx, the nasal turbinate and lungs [<xref rid="B96-ijms-24-01701" ref-type="bibr">96</xref>]. Data from phase 1 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04453852">NCT04453852</ext-link>) and phase 2 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04944368">NCT04944368</ext-link>) clinical trials have shown that the COVAX-19 vaccine has an acceptable safety and tolerability profile, without serious side effects [<xref rid="B97-ijms-24-01701" ref-type="bibr">97</xref>]. The COVAX-19 vaccine is currently undergoing phase 3 clinical trials (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05005559">NCT05005559</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05542862">NCT05542862</ext-link> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05175625">NCT05175625</ext-link>) and is approved for use in Iran.</p><p>The Razi Cov Pars vaccine (Razi Vaccine and Serum Research Institute, Iran), which is at the stage of phase 3 clinical trials (IRCT20201214049709N3), has also been approved for use in Iran. This vaccine differs in that it simultaneously contains three immunogenic components: S1 and S2 subunits fused to the Fc fragment of human IgG (expressed in Expi293F human cells) and the trimerized SARS-CoV-2 S protein (expressed in ExpiCHO-S&#8482; Cells) (<xref rid="ijms-24-01701-f001" ref-type="fig">Figure 1</xref>E). The RAS-01 adjuvant (Razi Adjuvant System-01) is an oil-in-water emulsion comprised of sesame, olive and soybean oils, as well as the non-ionic surfactant Tween 80 (Polysorbate 80). The vaccine&#8217;s effectiveness was evaluated in various animal models. The vaccine induced the production of neutralizing antibodies. The protective effect has also been shown in experiments with the SARS-CoV-2 infection. The vaccination schedule is worthy of note. There were two intramuscular injections and one intranasal injection of the vaccine [<xref rid="B98-ijms-24-01701" ref-type="bibr">98</xref>].</p><p>Trimer-Tag technology (C-propeptide of human type I(&#945;) collagen) makes it possible to express recombinant trimerized proteins in mammalian cells and purify them using affinity chromatography. The S trimer, in combination with AS03 (GlaxoSmithKline, United Kingdom) or CpG 1018 (Dynavax, USA) and aluminum hydroxide as adjuvants, induced high levels of neutralizing antibodies and a Th1-mediated cellular immune response in model animals, and also protected non-human primates against the SARS-CoV-2 infection [<xref rid="B99-ijms-24-01701" ref-type="bibr">99</xref>]. Phase 1 clinical trials (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04405908">NCT04405908</ext-link>) found that both variants of the SCB-2019 vaccine (with added AS03 or CpG and aluminum hydroxide) elicited robust humoral and cellular immune responses against SARS-CoV-2, with high virus-neutralizing activity [<xref rid="B100-ijms-24-01701" ref-type="bibr">100</xref>]. In phase 2/3 clinical trials (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04672395">NCT04672395</ext-link>), the SCB-2019 vaccine was used in combination with the CpG 1018 and aluminum hydroxide adjuvant. Two doses of the SCB-2019 vaccine were shown to provide protection against SARS-CoV-2, with an average efficacy of 67.2% [<xref rid="B101-ijms-24-01701" ref-type="bibr">101</xref>]. The SCB-2019 vaccine is currently undergoing phase 3 clinical trials (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05188677">NCT05188677</ext-link> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05470803">NCT05470803</ext-link>).</p><p>The Nanocovax vaccine, by Nanogen Pharmaceutical Biotechnology JSC (Vietnam), is represented by the recombinant SARS-CoV-2 S protein ectodomain in the prefusion conformation; the stabilization of which was achieved by K986P and V987P substitutions and mutations in the furin-cleavage site (682-RRAR-685 -&gt; QQAQ) (<xref rid="ijms-24-01701-f001" ref-type="fig">Figure 1</xref>F). The protein was expressed in CHO cells, and aluminum hydroxide acts as an adjuvant in the vaccine. The vaccine&#8217;s safety and efficacy were demonstrated on three model organisms (BALB/c mice, Syrian hamsters and <italic toggle="yes">Macaca leonina</italic> primates). The vaccine induced high levels of S protein-specific IgG and neutralizing antibodies. When studying the protective efficacy of the vaccine in hamsters, it was also shown that it protected the upper respiratory tract against the SARS-CoV-2 infection [<xref rid="B102-ijms-24-01701" ref-type="bibr">102</xref>]. According to the data from phase 1/2 clinical trials (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04683484">NCT04683484</ext-link>), no serious side effects were reported in the study participants after vaccination. The Nanocovax vaccine induced the production of S protein-specific and virus-neutralizing antibodies [<xref rid="B103-ijms-24-01701" ref-type="bibr">103</xref>]. The Nanocovax vaccine is currently undergoing phase 3 clinical trials (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04922788">NCT04922788</ext-link>).</p><p>Sanofi Pasteur (France) in collaboration with GlaxoSmithKline (United Kingdom), developed a SARS-CoV-2 recombinant protein vaccine <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-protein" xlink:href="VAT00002">VAT00002</ext-link> (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-protein" xlink:href="VAT00008">VAT00008</ext-link>, Vidprevtyn) based on a prefusion-stabilized S protein trimer (K986P and V987P substitutions were made, 682-RRAR-685 was replaced by GSAS, and the T4 fibrin trimerization motif was added) (<xref rid="ijms-24-01701-f001" ref-type="fig">Figure 1</xref>C). A prefusion-stabilized S protein trimer was produced in the baculovirus expression system and the vaccine formulation includes an AS03 adjuvant [<xref rid="B104-ijms-24-01701" ref-type="bibr">104</xref>]. The preliminary results of phase 1/2 clinical trials (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04537208">NCT04537208</ext-link>) were unexpected, in that the vaccine failed to elicit an effective immune response in people over 60 years of age and a higher-than-expected reactogenicity was noted after the second vaccination. A study of the final drug substance characteristics revealed that the level of residual proteins of the producer cells was higher than had been stated before the start of clinical trials, meaning that the antigen concentration in the vaccine formulation was significantly lower (about four to six times) than planned. By the time this was discovered, the study participants had received at least one dose of the vaccine. Thus, in order to continue clinical trials of the vaccine, it was necessary to optimize its composition [<xref rid="B105-ijms-24-01701" ref-type="bibr">105</xref>]. Further data from phase 2 clinical trials showed that the vaccine had an acceptable immunogenicity, safety and reactogenicity profile, including in people aged 60 years and older and those highly susceptible to diseases (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04762680">NCT04762680</ext-link>) [<xref rid="B106-ijms-24-01701" ref-type="bibr">106</xref>]. The vaccine being developed by Sanofi/GSK is currently undergoing phase 3 clinical trials. The <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04904549">NCT04904549</ext-link> study is registered on the <italic toggle="yes">ClinicalTrials.gov</italic> website and has two stages. At the first stage, a monovalent vaccine is evaluated, which contains the S antigen of the SARS-CoV-2 D614G variant; at the second stage, a bivalent vaccine is evaluated, which includes the S protein of the D614G variant and the S protein of the SARS-CoV-2 beta variant (B.1.351).</p><p>The PIKA COVID-19 Vaccine, developed by Yisheng Biopharma (China), contains a prefusion-stabilized trimerized S protein ectodomain expressed in CHO cells, and the PIKA acts as an adjuvant. The T4 fibrin trimerization motif was added to the nucleotide sequence encoding the target protein; K986P and V987P substitutions were made to stabilize the protein in the prefusion conformation; 682-RRAR-685 was replaced by GSAS in the furin-cleavage site. Pre-clinical studies have shown that the vaccine induces sustained cellular and humoral immune responses, as well as the production of neutralizing antibodies, which remain at a high level for at least 400 days. A study of the protective efficacy of the vaccine in non-human primates showed that vaccine-induced neutralizing antibodies that protected against virus replication in the lungs of animals after the SARS-CoV-2 infection [<xref rid="B107-ijms-24-01701" ref-type="bibr">107</xref>]. The vaccine is undergoing phase 2/3 clinical trials (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05463419">NCT05463419</ext-link>).</p><p>Another example of a trimerized S protein ectodomain vaccine is the ZR-202-CoV (202-CoV) vaccine, developed by Shanghai Zerun Biotechnology/Walvax Biotechnology (China), which is undergoing phase 2 clinical trials (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04990544">NCT04990544</ext-link>). The ectodomain was trimerized by including the T4 fibrin trimerization motif in the sequence. K986P and V987P substitutions, as well as the replacement of 682-RRAR-685 with GGSG at the furin-cleavage site, contributed toward protein stabilization in the prefusion conformation. The recombinant protein was produced in CHO cells, and it is used in the vaccine in combination with an adjuvant based on aluminum hydroxide and CpG 7909. Pre-clinical studies have shown that the vaccine induced the formation of CD4+ T cells and the production of neutralizing antibodies in both mice and primates, and neutralizing antibodies remained at a high level for at least six months. Studies on the protective efficacy of the vaccine have demonstrated a reduction in the viral load and inflammation in the lungs of immunized Syrian golden hamsters after the SARS-CoV-2 infection [<xref rid="B108-ijms-24-01701" ref-type="bibr">108</xref>].</p><p>The SpFN COVID-19 vaccine, developed by the US Army Medical Research and Development Command (USA), which is undergoing phase 1 clinical trials (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04784767">NCT04784767</ext-link>), is represented by <italic toggle="yes">Helicobacter pylori</italic> ferritin nanoparticles containing the S protein ectodomain region (amino acid residues 12&#8211;1158), modified by the introduction of two proline residues (K986P and V987P) and the furin-cleavage site replacement (682-RRAR-685 -&gt; GSAS). The combination of the antigen with ferritin ensures the formation of trimers. Stabilization of trimers formation on the ferritin molecule was achieved by introducing mutations (P1143S, F1148I, Y1155I, F1156H) into the sequence of the C-terminal heptad repeat of the S protein, to increase the coiled coil interactions. Expi293F human cells were selected as the expression system; the vaccine contains the ALFQ adjuvant [<xref rid="B109-ijms-24-01701" ref-type="bibr">109</xref>]. Pre-clinical studies have demonstrated the immunogenicity of the vaccine, its ability to induce the production of neutralizing antibodies and the formation of T cells [<xref rid="B110-ijms-24-01701" ref-type="bibr">110</xref>,<xref rid="B111-ijms-24-01701" ref-type="bibr">111</xref>]. A study in primates showed the protective effect of the vaccine, specifically the rapid elimination of the virus from the respiratory tract and lungs after infection with high doses of SARS-CoV-2 [<xref rid="B111-ijms-24-01701" ref-type="bibr">111</xref>].</p><p>Ambiguous results were obtained in phase 1 clinical trials of the Sclamp vaccine (University of Queensland, Australia) based on a trimerized S protein ectodomain stabilized using a &#8216;molecular clamp&#8217;. The &#8216;molecular clamp&#8217; is a trimerization motif comprising fragments of the HIV-1 gp41 glycoprotein (amino acid residues 540&#8211;576 and 619&#8211;656), which form a stable six-helix bundle. The inclusion of these sequences makes it possible to obtain a trimerized S protein stabilized in the prefusion conformation [<xref rid="B150-ijms-24-01701" ref-type="bibr">150</xref>]. In general, this recombinant vaccine, in combination with the MF59 adjuvant, elicited a strong immune response, but the gp41 glycoprotein sequences present in the &#8216;clamp&#8217; created obstacles for the diagnostic test for HIV, which prevented the further use of this vaccine [<xref rid="B151-ijms-24-01701" ref-type="bibr">151</xref>], so the project was discontinued.</p></sec><sec id="sec5dot2-ijms-24-01701"><title>5.2. RBD Vaccines</title><p>Given that the effect of ADE was observed when using SARS vaccines based on the full-length S protein [<xref rid="B30-ijms-24-01701" ref-type="bibr">30</xref>,<xref rid="B59-ijms-24-01701" ref-type="bibr">59</xref>], scientists tend to use individual fragments of the S protein when developing COVID-19 vaccines in order to minimize possible adverse immunopathology. The S protein RBD is an attractive target in the development of such vaccines. The Abdala vaccine (CIGB-66) (Center for Genetic Engineering and Biotechnology, Cuba) is approved for use in six countries and is an example of a vaccine based on the RBD monomer (<xref rid="ijms-24-01701-f001" ref-type="fig">Figure 1</xref>G) expressed in <italic toggle="yes">P. pastoris</italic> yeast cells. The vaccine contains an aluminum hydroxide-based adjuvant. The results of phase 1/2 clinical trials (RPCEC00000346) have shown that the vaccine is safe, well-tolerated and induces a humoral immune response [<xref rid="B112-ijms-24-01701" ref-type="bibr">112</xref>]. The Abdala vaccine is undergoing phase 3 clinical trials (RPCEC00000359).</p><p>Since the RBD immunogenicity is rather limited, Dai et al., (2020), using the already mentioned sc-dimer strategy that was applied to develop the MERS-CoV RBD dimer and the SARS-CoV RBD dimer, with the support of Anhui Zhifei Longcom Biopharmaceutical (China), developed the ZF2001 (Zifivax) vaccine against COVID-19, which is a SARS-CoV-2 RBD dimer (<xref rid="ijms-24-01701-f001" ref-type="fig">Figure 1</xref>G). Pre-clinical studies have shown that the dimeric form of the SARS-CoV-2 RBD induces a 10- to 100-fold increase in neutralizing antibody titers compared with the monomer [<xref rid="B66-ijms-24-01701" ref-type="bibr">66</xref>]. The recombinant vaccine protein is expressed in CHO cells and used in combination with an aluminum hydroxide adjuvant. Phase 1 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04445194">NCT04445194</ext-link>) and phase 2 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04466085">NCT04466085</ext-link>) clinical trials have shown that the vaccine does not cause serious side effects. After three-stage vaccination, the level of seroconversion of neutralizing antibodies reached 93&#8211;100%. The vaccine also induced a cellular immune response, as demonstrated by the balanced production of cytokines associated with Th1- and Th2-cells [<xref rid="B113-ijms-24-01701" ref-type="bibr">113</xref>]. The results of phase 3 clinical trials (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04646590">NCT04646590</ext-link>) have shown that the vaccine is safe and effective against COVID-19 for at least six months after full vaccination [<xref rid="B114-ijms-24-01701" ref-type="bibr">114</xref>]. Phase 3 clinical trials are ongoing (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05128643">NCT05128643</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05091411">NCT05091411</ext-link> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05107375">NCT05107375</ext-link>). The ZF2001 vaccine against COVID-19 is approved for use in China, Colombia, Indonesia and Uzbekistan.</p><p>The FINLAY-FR-2 (Soberana 02) vaccine, developed by the Instituto Finlay de Vacunas (Cuba), is approved for use in four countries (Cuba, Iran, Nicaragua and Venezuela). This is a vaccine based on multiple copies of recombinant RBD (expressed in CHO cells) that is conjugated with tetanus toxoid to maintain its stability (<xref rid="ijms-24-01701-f001" ref-type="fig">Figure 1</xref>G). Aluminum hydroxide is used as an adjuvant. The vaccine has demonstrated immunogenicity in pre-clinical studies [<xref rid="B115-ijms-24-01701" ref-type="bibr">115</xref>]. According to the published results of phase 1 and phase 2a clinical trials, the Soberana 02 vaccine is safe and elicits an immune response in people aged 19&#8211;80 years and it induces neutralizing antibodies and a specific T-cell response [<xref rid="B116-ijms-24-01701" ref-type="bibr">116</xref>]. The results of phase 3 clinical trials have shown the effectiveness of two doses of the Soberana 02 vaccine to be at 71.0%, while the addition of the Soberana Plus vaccine as a third dose (SARS-CoV-2 RBD dimer in combination with aluminum hydroxide) increases the effectiveness to 92.4% (IFV/COR/09) [<xref rid="B117-ijms-24-01701" ref-type="bibr">117</xref>].</p><p>The Corbevax (BECOV2A) vaccine, which is manufactured by the Indian company Biological E. Limited and is approved for use in Botswana and India with an aluminum hydroxide and CpG 1018 adjuvant, can be mentioned as an example of the successful expression of recombinant RBD (<xref rid="ijms-24-01701-f001" ref-type="fig">Figure 1</xref>G) in <italic toggle="yes">P. pastoris</italic> yeast cells. Mutations that reduce glycosylation (deletion of the N331 residue) and aggregation (C538A substitution) were introduced into the RBD sequence. The recombinant RBD219-N1C1 protein obtained was equivalent to the wild-type recombinant RBD protein (RBD219-WT) in an <italic toggle="yes">in vitro</italic> ACE-2 binding assay. The vaccine was shown to induce high levels of antigen-specific IgG and neutralizing antibodies in mice. When using the vaccine in combination with aluminum hydroxide, a Th2-biased immune response was noted. Therefore, when testing the vaccine in clinical trials, the CpG 1018 adjuvant was added to its composition, in addition to aluminum hydroxide, to induce a preferable Th1 immune response [<xref rid="B118-ijms-24-01701" ref-type="bibr">118</xref>,<xref rid="B119-ijms-24-01701" ref-type="bibr">119</xref>]. Data from phase 1/2 clinical trials (CTRI/2020/11/029032) have confirmed the immunogenicity and safety of the vaccine [<xref rid="B120-ijms-24-01701" ref-type="bibr">120</xref>]. Phase 3 clinical trials (CTRI/2021/08/036074) evaluated the effectiveness of the Corbevax vaccine in comparison with the Covishield adenovirus vector vaccine (ChAdOx1 nCoV-19, Oxford&#8211;AstraZeneca COVID19 vaccine) (United Kingdom), which is licensed in many countries. According to the study results, both vaccines have a comparable safety profile and anti-RBD IgG seroconversion rate. In addition, Corbevax induced higher titers of neutralizing antibodies [<xref rid="B121-ijms-24-01701" ref-type="bibr">121</xref>].</p><p>The GBP510 (SKYCovione) vaccine (SK Bioscience Co., Ltd., Republic of Korea, jointly with the University of Washington (USA)) was developed based on self-assembling protein nanoparticles that expose 60 copies of the RBD in order to increase its immunogenicity (<xref rid="ijms-24-01701-f001" ref-type="fig">Figure 1</xref>G). The protein nanoparticle model (I53-50) was developed using computational design. It is an icosahedral nanoparticle constructed from trimers (I53-50A) and pentamers (I53-50B). The RBD domain was linked to the I53-50A component by a glycine&#8211;serine linker, and this construct was expressed in human Expi293F cells. To initiate the assembly of nanoparticles, the recombinant RBD-I53-50A protein obtained was mixed with an I53-50B pentamer isolated from <italic toggle="yes">E. coli</italic>. The vaccine contains the AS03 adjuvant. Pre-clinical studies have shown that the vaccine induces an effective humoral response. It was found that nanoparticle-specific antibodies were also produced, but their level was approximately comparable with, or slightly lower than, the level of RBD-specific antibodies produced. Vaccine-induced neutralizing antibody titers were ten times higher than those induced by the prefusion-stabilized trimerized S protein ectodomain [<xref rid="B122-ijms-24-01701" ref-type="bibr">122</xref>]. The vaccine&#8217;s protective efficacy was confirmed in rhesus monkeys. In animals given two doses of the vaccine, anti-nanoparticle antibody titers positively correlated with anti-S antibody titers and viral neutralizing activity, suggesting that pre-existing anti-nanoparticle antibody responses do not affect antigen-specific antibody responses during boosting [<xref rid="B123-ijms-24-01701" ref-type="bibr">123</xref>]. The vaccine was approved for clinical trials, which demonstrated its immunogenicity and good tolerability [<xref rid="B124-ijms-24-01701" ref-type="bibr">124</xref>]. The GBP510 vaccine is currently undergoing phase 3 clinical trials (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05007951">NCT05007951</ext-link> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05501522">NCT05501522</ext-link>) and is approved for use in the Republic of Korea.</p><p>The West China Hospital COVID-19 vaccine (West China Hospital, Sichuan University, China), presented by an RBD (<xref rid="ijms-24-01701-f001" ref-type="fig">Figure 1</xref>G), expressed in Sf9 insect cells and having an aluminum hydroxide adjuvant, has been shown to be effective in pre-clinical studies, inducing a humoral response in immunized mice, rabbits and non-human primates. Furthermore, the sera of immunized animals had a virus-neutralizing impact on both the SARS-CoV-2 pseudovirus and live SARS-CoV-2 virus in <italic toggle="yes">in vitro</italic> assays. The vaccine has also demonstrated its protective efficacy in experiments on primates with the SARS-CoV-2 infection [<xref rid="B128-ijms-24-01701" ref-type="bibr">128</xref>]. Successful pre-clinical studies have enabled clinical trials of the vaccine and it is currently undergoing phase 3 clinical trials (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04904471">NCT04904471</ext-link> and NCT04887207).</p><p>A study by Marlin et al., (2021) reported on the &#945;CD40.RBD vaccine candidate, which is an anti-human CD40 humanized 12E12 IgG4 antibody C-terminally fused to the SARS-CoV-2 RBD. This construct makes it possible to target the antigen at dendritic cells via the CD40 surface receptor. The immunogenicity of the &#945;CD40.RBD vaccine co-administered with the Poly-IC adjuvant (polyinosinic-polycytidylic acid) was shown in humanized mice in which the vaccine elicited specific T and B cell responses. It was also shown that a single dose of the vaccine administered without an adjuvant was sufficient to significantly increase the titers of neutralizing antibodies in macaques that had been infected with SARS-CoV-2 six months earlier. Vaccine-induced antibodies were shown <italic toggle="yes">in vitro</italic> to cross-neutralize various SARS-CoV-2 variants, including D614G, B1.1.7 and, to a lesser extent, B1.351 [<xref rid="B144-ijms-24-01701" ref-type="bibr">144</xref>].</p><p>As in the case of SARS and MERS, developers use approaches to develop COVID-19 vaccines based on the combination of an RBD and Fc fragment. The V-01 vaccine (Livzon Mabpharm Inc, China) is a hybrid vaccine in which the RBD is fused to IFN&#945; at the N-terminus and to the Fc fragment of human IgG1 at the C-terminus, due to which dimerization occurs (<xref rid="ijms-24-01701-f001" ref-type="fig">Figure 1</xref>G). The construct also includes the PADRE epitope (pan HLA DR-binding epitope) to enhance the response of CD4+ T cells [<xref rid="B152-ijms-24-01701" ref-type="bibr">152</xref>]. The recombinant protein is expressed in mammalian CHO cells and used with aluminum hydroxide as an adjuvant [<xref rid="B125-ijms-24-01701" ref-type="bibr">125</xref>]. Pre-clinical studies have shown the protective efficacy of the vaccine candidate, which has made it possible to proceed to clinical trials of the vaccine [<xref rid="B126-ijms-24-01701" ref-type="bibr">126</xref>]. The results of phase 1 clinical trials have shown the vaccine&#8217;s immunogenicity, its ability to induce high titers of neutralizing antibodies and its safety and good tolerability [<xref rid="B125-ijms-24-01701" ref-type="bibr">125</xref>]. The V-01 vaccine is currently undergoing phase 3 clinical trials and has been shown to induce sustained humoral immunity in study participants vaccinated with the inactivated vaccine (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05096832">NCT05096832</ext-link>) [<xref rid="B127-ijms-24-01701" ref-type="bibr">127</xref>]. It has been approved for use in China.</p><p>The RBD and Fc fusion approach was also applied in the AKS-452 vaccine (University Medical Center Groningen, the Netherlands), which is undergoing phase 2/3 clinical trials (CTRI/2021/10/037269). The protein is expressed in CHO cells and the vaccine contains the Montanide ISA 720 adjuvant. The vaccine&#8217;s protectivity was confirmed in pre-clinical studies [<xref rid="B129-ijms-24-01701" ref-type="bibr">129</xref>]. Data from phase 1/2 clinical trials (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04681092">NCT04681092</ext-link>) have also shown its immunogenicity and a favorable safety profile [<xref rid="B130-ijms-24-01701" ref-type="bibr">130</xref>].</p><p>Kentucky Bioprocessing (USA) used a unique approach in the production of the KBP-201 vaccine, consisting of the chemical conjugation of the recombinant RBD-Fc antigen expressed in <italic toggle="yes">N. benthamiana</italic> with tobacco mosaic virus (TMV) virions modified by the introduction of reactive lysine into the N-terminal region of the coat protein. Before conjugation, the modified viral particles were exposed to ultraviolet radiation to inactivate the viral RNA. Pre-clinical studies of the vaccine&#8217;s immunogenicity have demonstrated that it induces an effective immune response in immunized mice, both with and without the CpG 7909 adjuvant. The vaccine without an adjuvant induced a balanced Th1/Th2 response, while the vaccine with an adjuvant induced a Th1-biased response. Both vaccine variants induced the production of virus-neutralizing antibodies [<xref rid="B131-ijms-24-01701" ref-type="bibr">131</xref>]. The protective efficacy of the vaccine was proven in studies with humanized mice expressing the human angiotensin-converting enzyme 2 (hACE2). The vaccine protected the mice from death after the SARS-CoV-2 infection [<xref rid="B132-ijms-24-01701" ref-type="bibr">132</xref>]. The KBP-201 vaccine (with the CpG adjuvant) is undergoing phase 1/2 clinical trials (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04473690">NCT04473690</ext-link>).</p><p>In a study by Siriwattananon et al., (2021), the RBD-Fc fusion protein was obtained by fusing the SARS-CoV-2 RBD with the Fc domain of human IgG1. The genetic construct encoding the fusion protein was cloned into a geminivirus vector for expression in <italic toggle="yes">N. benthamiana</italic> plants. Plant-produced RBD-Fc, together with aluminum hydroxide as an adjuvant, elicited an effective humoral and cellular response in mice and macaques (<italic toggle="yes">Macaca fascicularis</italic>) [<xref rid="B134-ijms-24-01701" ref-type="bibr">134</xref>]. The vaccine protectivity was demonstrated in transgenic mice with hACE2, monkeys and Wistar rats [<xref rid="B135-ijms-24-01701" ref-type="bibr">135</xref>]. The study was supported by Baiya Phytopharm Co Ltd. (Thailand); the Baiya SARS-CoV-2 Vax 1 vaccine is currently undergoing phase 1 clinical trials (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04953078">NCT04953078</ext-link>).</p><p>The development of the recombinant Betuvax-CoV-2 vaccine (Human Stem Cell Institute, Russia), based on the RBD and SD1 domain (important for RBD mobility) of the SARS-CoV-2 virus fused to the Fc fragment of human IgG1, was described by Krasilnikov et al., (2022). The antigen is expressed in CHO cells, adsorbed on a plant-derived adjuvant, betulin (pentacyclic triterpenoid) that forms spherical particles (betuspheres). The authors showed that the vaccine induced the production of high titers of antibodies (RBD-specific and SARS-CoV-2-neutralizing) and the development of T cell immunity in mice [<xref rid="B133-ijms-24-01701" ref-type="bibr">133</xref>]. The Betuvax-CoV-2 vaccine is undergoing phase 1/2 clinical trials (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05270954">NCT05270954</ext-link>).</p><p>Ma et al., (2020) developed <italic toggle="yes">H. pylori</italic> ferritin nanoparticles that conjugated with the RBD and conserved fragments of the S2 subunit, heptad repeats (HR) (RBD-HR nanoparticles) and RBD-conjugated ferritin nanoparticles (RBD nanoparticles), using SpyTag/SpyCatcher technology. SpyTag (ST, peptide comprising13 amino acids) reacts with the SpyCatcher protein (SC, protein comprising138 amino acids) to form an intermolecular isopeptide bond. In order to obtain nanoparticles for the vaccine, SC ferritin was expressed in <italic toggle="yes">E. coli</italic>, while ST-RBD and ST-HR were expressed in CHO-S cells. The incubation of SC ferritin with ST antigens leads to irreversible conjugation of ferritin and antigens and the formation of nanoparticles. In combination with the SAS adjuvant (an alternative to Freund&#8217;s adjuvant), RBD-HR nanoparticles were found to induce humoral and cellular responses after two immunizations of mice. Both types of nanoparticles protected transgenic mice with hACE2 from the SARS-CoV-2 infection, but only RBD-HR nanoparticles induced the formation of neutralizing antibodies not only to SARS-CoV-2, but also to other coronaviruses. The induction of the production of antibodies to ferritin was also shown [<xref rid="B146-ijms-24-01701" ref-type="bibr">146</xref>]. The study suggests that <italic toggle="yes">H. pylori</italic> ferritin and its antibodies are likely not to be toxic <italic toggle="yes">in vivo</italic>, since two influenza vaccines based on <italic toggle="yes">H. pylori</italic> ferritin nanoparticles are known to have been clinically evaluated (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03186781">NCT03186781</ext-link> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03814720">NCT03814720</ext-link>) and no serious side effects have been reported. Nevertheless, this issue needs to be investigated and discussed further.</p><p>A vaccine candidate based on three recombinant proteins (Co1, PE and CoF) was designed and analyzed by Kovalenko et al. (2022) [<xref rid="B43-ijms-24-01701" ref-type="bibr">43</xref>]. The Co1 protein contains a sequence corresponding to the SARS-CoV-2 RBD (amino acid residues 319&#8211;541, GenBank accession number: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-protein" xlink:href="YP_009724390.1">YP_009724390.1</ext-link>). The polyepitope (PE) protein contains highly conserved fragments of the SARS-CoV-2 S2 subunit (amino acid residues 950&#8211;1041 and amino acid residues 1157&#8211;1210) that include previously predicted partially overlapping T and B cell epitopes [<xref rid="B15-ijms-24-01701" ref-type="bibr">15</xref>,<xref rid="B153-ijms-24-01701" ref-type="bibr">153</xref>]. The CoF protein contains the RBD and the S2 subunit epitope (amino acid residues 1182&#8211;1210). Recombinant proteins were expressed in <italic toggle="yes">E. coli</italic> cells. Structurally modified spherical particles (SPs) formed during tobacco mosaic virus (TMV) thermal remodeling are used in the vaccine as an adjuvant. The authors suggested that SPs function as an antigen depot. The vaccine candidate immunogenicity was demonstrated in mice. The titers of antibodies to coronavirus antigens were significantly higher when immunized with compositions than when immunized with individual antigens. In this case, the immune response was produced mainly to coronavirus antigens and not to the adjuvant. Pre-clinical studies showed serum neutralizing activity against SARS-CoV-2 in hamsters immunized with the vaccine candidate [<xref rid="B43-ijms-24-01701" ref-type="bibr">43</xref>].</p></sec><sec id="sec5dot3-ijms-24-01701"><title>5.3. S Protein Fragment Vaccines</title><p>Kim et al., (2020) developed recombinant protein vaccines against SARS-CoV-2 based on the S1 subunit and the S1 subunit fused to the RS09 sequence, using the approach that was used for MERS vaccine engineering, with a microneedle array being employed for transdermal vaccine administration. The vaccines developed induced the effective production of antigen-specific antibodies in mice as soon as two weeks after immunization, but the inclusion of the RS09 adjuvant did not significantly affect the effectiveness of vaccination [<xref rid="B79-ijms-24-01701" ref-type="bibr">79</xref>].</p><p>Ren et al., (2020) evaluated the immunogenicity of a recombinant protein based on the SARS-CoV-2 S1 subunit fused to the Fc fragment (S1-Fc) in preclinical studies. The protein was expressed in CHO cells. Rabbits were immunized with the S1-Fc protein and the AD20Gold+ adjuvant (nanoemulsion with synthetic MPL). For non-human primates, CFA was used for the first immunization and AD11.10 (saponin-based microemulsion) was used for the second immunization. The recombinant S1-Fc protein was shown to induce high antibody titers. The sera of immunized rabbits and primates had a high level of virus-neutralizing activity [<xref rid="B143-ijms-24-01701" ref-type="bibr">143</xref>].</p><p>It is believed that the S2 subunit is less immunogenic than the S1 subunit since it is more strongly shielded by N-glycans and less accessible for interaction with the immune system. The S2 subunit cannot induce an effective humoral response; however, due to the high conservation of its sequence among different coronaviruses, it is a target for cross-reactive antibodies and CD4+ T cells that recognize SARS-CoV-2 and other coronaviruses [<xref rid="B41-ijms-24-01701" ref-type="bibr">41</xref>]. Therefore, due to its high conservation, the S2 subunit may be of interest in terms of developing a universal coronavirus vaccine.</p></sec><sec id="sec5dot4-ijms-24-01701"><title>5.4. Vaccines Based on Non-S Structural Proteins</title><p>The N, M and E protein sequences are similar for SARS-CoV, MERS-CoV and SARS-CoV-2, which may indicate their potential as vaccine targets for a universal betacoronavirus vaccine. Several T cell epitopes have been identified in these proteins in previous studies on SARS-CoV and MERS-CoV [<xref rid="B154-ijms-24-01701" ref-type="bibr">154</xref>], so their inclusion in a SARS-CoV-2 vaccine may help enhance the T cell response and improve cross-protection [<xref rid="B41-ijms-24-01701" ref-type="bibr">41</xref>]. The development of the Convacell vaccine based on the N protein (St. Petersburg Research Institute of Vaccines and Sera, Russia), which is expressed in <italic toggle="yes">E. coli</italic> [<xref rid="B141-ijms-24-01701" ref-type="bibr">141</xref>], has also been reported. The recombinant protein obtained has immunogenic properties. It is used with an adjuvant based on squalane, &#945;-tocopherol and polysorbate 80 [<xref rid="B142-ijms-24-01701" ref-type="bibr">142</xref>]. The protective properties of the recombinant N protein were studied in Syrian hamsters. It has been reported that, in immunized animals after the SARS-CoV-2 infection, a decrease in the severity of lung damage was noted. The vaccine is undergoing phase 1/2 clinical trials (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05156723">NCT05156723</ext-link>). In mass studies, the approach to the N protein vaccine development was not widely accepted. However, the N protein can be used as an additional vaccine antigen. The N protein is highly conserved among coronaviruses in comparison to the S protein, and although N protein vaccines generally do not induce neutralizing antibodies, its use in a universal coronavirus vaccine may contribute to the induction of T cell immunity.</p></sec><sec id="sec5dot5-ijms-24-01701"><title>5.5. Multi-Epitope Vaccines</title><p>A different approach to the development of COVID-19 vaccines should be considered separately. This relates to multi-epitope vaccines. The approach is based on a bioinformatic analysis, which makes it possible to identify the antigenic determinants of SARS-CoV-2 T and B cell epitopes. T cell epitopes that elicit a long-term immune response of CD4+ and CD8+ T cells are most often analyzed. The prediction of B cell epitopes (both linear and conformational) is considered to be less reliable, and they do not induce a strong humoral response [<xref rid="B155-ijms-24-01701" ref-type="bibr">155</xref>]. Potential T cell epitopes can be predicted for both structural and non-structural proteins; however, in most cases, the S protein is analyzed as the main target of coronavirus vaccines. The use of <italic toggle="yes">in silico</italic> methods optimizes the vaccine development process, allowing only immunogenic T and B cell epitopes of the coronavirus to be included in its composition for effective stimulation of cellular and humoral responses. Multi-epitope vaccines have the potential to help avoid the adverse effect of ADE. Epitope selection should be made using rational filtering criteria based on the SARS-CoV-2 biology, which include predicted immunogenicity, location of epitopes, glycosylation sites and polymorphic sites. Candidate epitopes that are located within or adjacent to functional domains with evidence of antibody-mediated viral neutralization should be selected [<xref rid="B156-ijms-24-01701" ref-type="bibr">156</xref>]. Some examples of such vaccines will be discussed below.</p><p>Some investigators have presented designs of multi-epitope vaccines developed using bioinformatic methods, but these vaccines&#8217; <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic> efficacy is currently unknown [<xref rid="B157-ijms-24-01701" ref-type="bibr">157</xref>,<xref rid="B158-ijms-24-01701" ref-type="bibr">158</xref>,<xref rid="B159-ijms-24-01701" ref-type="bibr">159</xref>]. Using bioinformatic methods, Enayatkhani et al., (2020) engineered a multi-epitope vaccine based on T and B cell epitope-enriched N, ORF3a and M (NOM) protein domains that could potentially induce a CD4+ and CD8+ T cell immune response. A molecular dynamics simulation confirmed the stability of the engineered NOM protein complexes with the TLR4 innate immunity receptor and the HLA-A*11:01 cellular immunity receptor [<xref rid="B157-ijms-24-01701" ref-type="bibr">157</xref>]. Kalita et al., (2020) presented a vaccine design consisting of 18 CTL (cytotoxic T lymphocyte), 6 HTL (helper T lymphocyte) and 9 B cell epitopes of SARS-CoV-2 N, M and S proteins connected by linkers and a human &#946;-defensin sequence (an adjuvant). The molecular dynamics simulation confirmed the vaccine construct stability [<xref rid="B158-ijms-24-01701" ref-type="bibr">158</xref>]. Sarkar et al., (2020) used computational experiments to analyze the sequences of N, M, ORF3a and S proteins of the SARS-CoV-2 virus and selected T and B cell epitopes of the N and S proteins for inclusion in the vaccine construct, which also contains the PADRE sequence, the universal epitope AKFVAAWTLKAAA. The results of molecular docking conducted to determine whether all selected epitopes can bind to HLA class I and II molecules were positive [<xref rid="B159-ijms-24-01701" ref-type="bibr">159</xref>].</p><p>Coleon et al., (2022) demonstrated the immunogenicity and efficacy of a bioinformatically engineered vaccine in pre-clinical studies. The authors used <italic toggle="yes">in silico</italic> methods to identify conserved T and B cell epitopes of the S and N proteins, highly homologous among 38 sarbecoviruses, to develop a recombinant protein vaccine (CD40.CoV2) targeting antigens to dendritic cells through the CD40 surface receptor. For this purpose, they used an anti-human CD40 humanized 12E12 IgG4 antibody. Mammalian CHO-S cells were selected for the vaccine construct expression. Poly-IC was used as an adjuvant since this adjuvant enhances APC maturation. Immunization with CD40.CoV2 elicited high levels of antibodies with cross-neutralizing activity against SARS-CoV-2 (Wuhan, <italic toggle="yes">&#945;, &#946;, &#947;, &#948;</italic> and <italic toggle="yes">&#954;</italic>) and SARS-CoV variants in transgenic mice with hACE2, which was associated with survival after the SARS-CoV-2 infection. The ability of CD40.CoV2 to induce the response of cytotoxic memory T cells was also demonstrated [<xref rid="B145-ijms-24-01701" ref-type="bibr">145</xref>].</p><p>Multi-epitope vaccines have also shown their efficacy in clinical trials. The EpiVacCorona vaccine by the Vector State Research Center of Virology and Biotechnology (Russia) consists of short peptides carrying conserved linear B cell epitopes of the SARS-CoV-2 S protein, the choice of which was based on the published spatial structures of the SARS-CoV S protein and data on the SARS-CoV-2 genetic sequences. The following SARS-CoV-2 S protein epitopes are used in the vaccine (overlapping parts are in bold):<list list-type="order"><list-item><p><sup>454</sup>RLFRKSNLKPFERDISTEIYQAGS<sup>477</sup>&#8212;epitope from the RBD region;</p></list-item><list-item><p><sup>1181</sup>KEIDRLNEVA<bold>KNLNESLIDLQE</bold><sup>1202</sup>&#8212;epitope from the heptad repeat 2 (HR2) region;</p></list-item><list-item><p><sup>1191</sup><bold>KNLNESLIDLQE</bold>LGKYEQYIK<sup>1211</sup>&#8212;epitope from the HR2 region.</p></list-item></list></p><p>Based on these epitopes, peptides for the vaccine were chemically synthesized, then conjugated with a carrier protein (a fusion product of the maltose-binding protein and the SARS-CoV-2 N protein) and adsorbed on aluminum hydroxide [<xref rid="B136-ijms-24-01701" ref-type="bibr">136</xref>]. Pre-clinical studies have shown that the vaccine accelerates virus elimination from the upper respiratory tract in ferrets and prevents the development of pneumonia after SARS-CoV-2 infection in hamsters and lower primates [<xref rid="B137-ijms-24-01701" ref-type="bibr">137</xref>]. The EpiVacCorona vaccine has passed phase 1/2 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04527575">NCT04527575</ext-link>) [<xref rid="B138-ijms-24-01701" ref-type="bibr">138</xref>] and phase 3 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05021016">NCT05021016</ext-link> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04780035">NCT04780035</ext-link>) clinical trials. It has been approved for use in Russia, Cambodia, Turkmenistan and Venezuela.</p><p>The UB-612 peptide vaccine (COVAXX and United Biomedical Inc. Asia, USA/Taiwan) contains the RBD fused to the Fc domain of human IgG1, produced in CHO cells and synthetic immunogenic peptides based on highly conserved sequences of the S2 subunit of the S protein, N and M proteins (<xref rid="ijms-24-01701-f001" ref-type="fig">Figure 1</xref>G). The vaccine also includes a peptide derived from the measles fusion protein, to enhance the immune response (patented UBITh1a<sup>&#174;</sup> technology) and a CpG and aluminum phosphate adjuvant (AdjuPhos<sup>&#174;</sup>) [<xref rid="B139-ijms-24-01701" ref-type="bibr">139</xref>]. In phase 1 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04545749">NCT04545749</ext-link> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04967742">NCT04967742</ext-link>) and phase 2 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04773067">NCT04773067</ext-link>) clinical trials, the vaccine demonstrated a favorable safety profile, efficacy against Delta and Omicron variants and prolonged B and T cell immunity [<xref rid="B140-ijms-24-01701" ref-type="bibr">140</xref>]. The UB-612 vaccine is undergoing phase 3 clinical trials (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05293665">NCT05293665</ext-link>).</p><p>The CoVac-1 vaccine, developed by the University of T&#252;bingen (Germany), which is undergoing phase 1/2 clinical trials (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04954469">NCT04954469</ext-link>), is a vaccine of chemically synthesized six peptides based on T cell epitopes of the N, S, E, M and ORF8 proteins. Synthetic lipopeptide XS15 emulsified in Montanide ISA51 VG was used as an adjuvant. The results of phase 1 trials (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04546841">NCT04546841</ext-link>) showed no serious side effects after vaccination. In all study participants, the vaccine induced a T cell response mediated by the Th-1 and cytotoxic T cells [<xref rid="B53-ijms-24-01701" ref-type="bibr">53</xref>].</p><p>Here, we looked at 25 COVID-19 recombinant protein vaccines at different stages of clinical trials. Primarily, these vaccines are based on SARS-CoV-2 S protein (10 vaccines) or its receptor-binding domain (RBD) (11 vaccines). To solve the well-known problem of RBDs low immunogenicity, various approaches such as the dimerization of RBD, its fusion to the human IgG Fc-fragment or the designing of nanoparticles displaying multiple RBD copies were used. The vaccines effectiveness was demonstrated in clinical trials. For both S protein-based and RBD-based vaccines, there are examples of the high efficacy achievement: a 92.6% and 92.4% efficacy was revealed for NVX-CoV2373 (S protein-based) and Soberana 02 Plus (RBD-based), respectively. Therefore, both the S protein and RBD seem to be promising antigens for vaccine development. The main argument in favor of the S protein use is keeping the recombinant antigen state corresponding to the native one. The researchers&#8217; interest in an RBD-based vaccine is perhaps driven by the ease of the RBD production procedure compared to the full-size S protein and is probably due to the concerns about undesirable immune reactions previously observed during the study of SARS-CoV vaccines based on the full-size S protein. Nevertheless, clinical trials data evidenced the appropriate safety for all types of COVID-19 vaccines; the observed side effects were minor. Furthermore, three examples of multi-epitope vaccines and the example of the vaccine based on the SARS-CoV-2 N protein were considered in the current review. At present, these approaches to the development of coronavirus vaccines are not widespread, though they could be helpful for the further design of a universal vaccine against coronaviruses.</p><p>The above-cited results of the various recombinant protein vaccine developments against COVID-19 studies demonstrate the relevance and highly promising potential of this technological platform.</p></sec></sec><sec sec-type="conclusions" id="sec6-ijms-24-01701"><title>6. Conclusions</title><p>The development of COVID-19 vaccines remains a crucial task since vaccination is the most effective way to prevent infectious diseases and protect the population from epidemics. Since the beginning of the COVID-19 pandemic, the development of recombinant protein vaccines has received less attention than, for example, the development of nucleic acid vaccines or vector vaccines. However, recombinant protein vaccines have certain advantages, primarily a high safety profile. Recombinant protein vaccines can also serve as a useful supplement to two-stage (prime-boost) vaccination. Finally, recombinant protein vaccines, unlike mRNA and viral vector vaccines, are less demanding of the production, storage and transportation processes.</p><p>Most COVID-19 vaccines are based on the inclusion of either the full-length S protein or its individual fragments, in particular the RBD domain, in their composition as a vaccine antigen. Previous experience in the development of protein vaccines against SARS has shown that the use of vaccines based on the full-length S protein may be associated with an undesirable effect, such as ADE. Therefore, when creating COVID-19 vaccines, developers try to use individual fragments of the S protein while the focus is shifted to the RBD, the main target of neutralizing antibodies. Approaches using structural N, M and E proteins as vaccine antigens have not been widely used; however, due to the conservation of these proteins, they can be used as additional antigenic determinants in order to induce a T cell response by the vaccine. Furthermore, using <italic toggle="yes">in silico</italic> approaches, multi-epitope vaccines containing the main T and B cell epitopes of coronaviruses have been developed, while unwanted epitopes that may potentially cause various immunopathologies can be excluded when engineering a vaccine antigen. The inclusion of highly conserved regions of various human pathogenic coronaviruses in a multi-epitope vaccine may be an important step toward the development of a universal vaccine, since the risk of new coronavirus infections in the future remains. Therefore, the presence of a panel of vaccines obtained using various approaches can provide effective protection against COVID-19, and the use of structural protein regions that are conserved for the three main betacoronaviruses (SARS-CoV, MERS-CoV and SARS-CoV-2) may help develop a universal vaccine that will protect not only against SARS, MERS and COVID-19, but also against other betacoronaviruses that are not yet circulating in the human population.</p><p>Antigens for recombinant protein vaccines against COVID-19 have been produced in different expression systems, with more traditional systems such as mammalian or insect cells being particularly popular. However, some developers use alternative approaches, such as the use of tobacco plants as an expression system of recombinant antigens for a vaccine.</p><p>The use of suitable adjuvants in recombinant protein vaccines makes it possible to solve the problem of the low immunogenicity of these vaccines. As can be seen from the examples presented in this review, protein vaccines against COVID-19 include a variety of adjuvants, and all these vaccines have proved to be quite successful. Since different adjuvants have different mechanisms of action, it is rather difficult to compare protein vaccines in terms of efficacy. The correct choice of an adjuvant is important for creating an effective, but also a safe vaccine, since it is important to prevent the development of a Th2-biased immune response, which is associated with the development of pulmonary immunopathologies [<xref rid="B160-ijms-24-01701" ref-type="bibr">160</xref>]. Even vaccines that have already been approved for clinical trials may show ambiguous results, and projects may be suspended or even terminated. However, only the development and testing of a wide range of vaccines, including recombinant protein vaccines, will make it possible to control the situation with the incidence of COVID-19.</p></sec></body><back><ack><title>Acknowledgments</title><p>The work was carried out within the framework of the following scientific directions: Interdisciplinary Scientific and Educational School of Moscow University &#171;Molecular Technologies of the Living Systems and Synthetic Biology&#187;, Scientific Project of the State Order of the Government of RF to Lomonosov MSU &#171;Plant viruses and artificial virus-like particles: a study of the biological and structural features and application in biotechnology&#187; #121032500078-5.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#8217;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, A.K., E.R., E.E., N.N. and O.K.; writing&#8212;original draft preparation, A.K.; writing&#8212;review and editing, A.K., E.R., E.E., N.N. and O.K. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>Not applicable.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-ijms-24-01701"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>P.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>Z.-L.</given-names></name></person-group><article-title>Characteristics of SARS-CoV-2 and COVID-19</article-title><source>Nat. Rev. Microbiol.</source><comment>Erratum in <italic toggle="yes">Nat. Rev. Microbiol.</italic><bold>2022</bold>, <italic toggle="yes">20</italic>, 315</comment><year>2021</year><volume>19</volume><fpage>141</fpage><lpage>154</lpage><pub-id pub-id-type="doi">10.1038/s41579-020-00459-7</pub-id><pub-id pub-id-type="pmid">33024307</pub-id><pub-id pub-id-type="pmcid">PMC7537588</pub-id></element-citation></ref><ref id="B2-ijms-24-01701"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Coronaviridae Study Group of the International Committee on Taxonomy of Viruses</collab></person-group><article-title>The species Severe acute respiratory syndrome-related coronavirus: Classifying 2019-nCoV and naming it SARS-CoV-2</article-title><source>Nat. Microbiol.</source><year>2020</year><volume>5</volume><fpage>536</fpage><lpage>544</lpage><pub-id pub-id-type="doi">10.1038/s41564-020-0695-z</pub-id><pub-id pub-id-type="pmid">32123347</pub-id><pub-id pub-id-type="pmcid">PMC7095448</pub-id></element-citation></ref><ref id="B3-ijms-24-01701"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Habas</surname><given-names>K.</given-names></name><name name-style="western"><surname>Nganwuchu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Shahzad</surname><given-names>F.</given-names></name><name name-style="western"><surname>Gopalan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Haque</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rahman</surname><given-names>S.</given-names></name><name name-style="western"><surname>Majumder</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Nasim</surname><given-names>T.</given-names></name></person-group><article-title>Resolution of coronavirus disease 2019 (COVID-19)</article-title><source>Expert Rev. Anti-Infective Ther.</source><year>2020</year><volume>18</volume><fpage>1201</fpage><lpage>1211</lpage><pub-id pub-id-type="doi">10.1080/14787210.2020.1797487</pub-id><pub-id pub-id-type="pmid">32749914</pub-id></element-citation></ref><ref id="B4-ijms-24-01701"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rabaan</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Al-Ahmed</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Haque</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sah</surname><given-names>R.</given-names></name><name name-style="western"><surname>Tiwari</surname><given-names>R.</given-names></name><name name-style="western"><surname>Malik</surname><given-names>Y.S.</given-names></name><name name-style="western"><surname>Dhama</surname><given-names>K.</given-names></name><name name-style="western"><surname>Yatoo</surname><given-names>M.I.</given-names></name><name name-style="western"><surname>Bonilla-Aldana</surname><given-names>D.K.</given-names></name><name name-style="western"><surname>Rodriguez-Morales</surname><given-names>A.J.</given-names></name></person-group><article-title>SARS-CoV-2, SARS-CoV, and MERS-COV: A comparative overview</article-title><source>Infez. Med.</source><year>2020</year><volume>28</volume><fpage>174</fpage><lpage>184</lpage><pub-id pub-id-type="pmid">32275259</pub-id></element-citation></ref><ref id="B5-ijms-24-01701"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rabaan</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Al-Ahmed</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Sah</surname><given-names>R.</given-names></name><name name-style="western"><surname>Alqumber</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Haque</surname><given-names>S.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Pathak</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tiwari</surname><given-names>R.</given-names></name><name name-style="western"><surname>Yatoo</surname><given-names>M.I.</given-names></name><name name-style="western"><surname>Haq</surname><given-names>A.U.</given-names></name><etal/></person-group><article-title>MERS-CoV: Epidemiology, molecular dynamics, therapeutics, and future challenges</article-title><source>Ann. Clin. Microbiol. Antimicrob.</source><year>2021</year><volume>20</volume><fpage>1</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1186/s12941-020-00414-7</pub-id><pub-id pub-id-type="pmid">33461573</pub-id><pub-id pub-id-type="pmcid">PMC7812981</pub-id></element-citation></ref><ref id="B6-ijms-24-01701"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y.-D.</given-names></name><name name-style="western"><surname>Chi</surname><given-names>W.-Y.</given-names></name><name name-style="western"><surname>Su</surname><given-names>J.-H.</given-names></name><name name-style="western"><surname>Ferrall</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hung</surname><given-names>C.-F.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>T.-C.</given-names></name></person-group><article-title>Coronavirus vaccine development: From SARS and MERS to COVID-19</article-title><source>J. Biomed. Sci.</source><year>2020</year><volume>27</volume><fpage>104</fpage><pub-id pub-id-type="doi">10.1186/s12929-020-00695-2</pub-id><pub-id pub-id-type="pmid">33341119</pub-id><pub-id pub-id-type="pmcid">PMC7749790</pub-id></element-citation></ref><ref id="B7-ijms-24-01701"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yadav</surname><given-names>T.</given-names></name><name name-style="western"><surname>Srivastava</surname><given-names>N.</given-names></name><name name-style="western"><surname>Mishra</surname><given-names>G.</given-names></name><name name-style="western"><surname>Dhama</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Puri</surname><given-names>B.</given-names></name><name name-style="western"><surname>Saxena</surname><given-names>S.K.</given-names></name></person-group><article-title>Recombinant vaccines for COVID-19</article-title><source>Hum. Vaccines Immunother.</source><year>2020</year><volume>16</volume><fpage>2905</fpage><lpage>2912</lpage><pub-id pub-id-type="doi">10.1080/21645515.2020.1820808</pub-id><pub-id pub-id-type="pmcid">PMC7711739</pub-id><pub-id pub-id-type="pmid">33232211</pub-id></element-citation></ref><ref id="B8-ijms-24-01701"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kirtipal</surname><given-names>N.</given-names></name><name name-style="western"><surname>Bharadwaj</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>S.G.</given-names></name></person-group><article-title>From SARS to SARS-CoV-2, insights on structure, pathogenicity and immunity aspects of pandemic human coronaviruses</article-title><source>Infect. Genet. Evol.</source><year>2020</year><volume>85</volume><fpage>104502</fpage><pub-id pub-id-type="doi">10.1016/j.meegid.2020.104502</pub-id><pub-id pub-id-type="pmid">32798769</pub-id><pub-id pub-id-type="pmcid">PMC7425554</pub-id></element-citation></ref><ref id="B9-ijms-24-01701"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nakagawa</surname><given-names>S.</given-names></name><name name-style="western"><surname>Miyazawa</surname><given-names>T.</given-names></name></person-group><article-title>Correction to: Genome evolution of SARS-CoV-2 and its virological characteristics</article-title><source>Inflamm. Regen.</source><year>2020</year><volume>40</volume><fpage>41</fpage><comment>Erratum in <italic toggle="yes">Inflamm. Regen</italic>. <bold>2020</bold>, <italic toggle="yes">40</italic>, 17</comment><pub-id pub-id-type="doi">10.1186/s41232-020-00151-6</pub-id><pub-id pub-id-type="pmid">33349265</pub-id><pub-id pub-id-type="pmcid">PMC7751742</pub-id></element-citation></ref><ref id="B10-ijms-24-01701"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mart&#237;nez-Flores</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zepeda-Cervantes</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cruz-Res&#233;ndiz</surname><given-names>A.</given-names></name><name name-style="western"><surname>Aguirre-Sampieri</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sampieri</surname><given-names>A.</given-names></name><name name-style="western"><surname>Vaca</surname><given-names>L.</given-names></name></person-group><article-title>SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and Implications of New Viral Variants</article-title><source>Front. Immunol.</source><year>2021</year><volume>12</volume><fpage>701501</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2021.701501</pub-id><pub-id pub-id-type="pmid">34322129</pub-id><pub-id pub-id-type="pmcid">PMC8311925</pub-id></element-citation></ref><ref id="B11-ijms-24-01701"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>H.-W.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.-N.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Qi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name><name name-style="western"><surname>Men</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tao</surname><given-names>S.-C.</given-names></name></person-group><article-title>SARS-CoV-2 proteome microarray for global profiling of COVID-19 specific IgG and IgM responses</article-title><source>Nat. Commun.</source><year>2020</year><volume>11</volume><fpage>3581</fpage><pub-id pub-id-type="doi">10.1038/s41467-020-17488-8</pub-id><pub-id pub-id-type="pmid">32665645</pub-id><pub-id pub-id-type="pmcid">PMC7360742</pub-id></element-citation></ref><ref id="B12-ijms-24-01701"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Wilde</surname><given-names>A.H.</given-names></name><name name-style="western"><surname>Snijder</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Kikkert</surname><given-names>M.</given-names></name><name name-style="western"><surname>van Hemert</surname><given-names>M.J.</given-names></name></person-group><article-title>Host Factors in Coronavirus Replication</article-title><source>Curr. Top. Microbiol. Immunol.</source><year>2018</year><volume>419</volume><fpage>1</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1007/82_2017_25</pub-id><pub-id pub-id-type="pmid">28643204</pub-id><pub-id pub-id-type="pmcid">PMC7119980</pub-id></element-citation></ref><ref id="B13-ijms-24-01701"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>H.-W.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.-N.</given-names></name><name name-style="western"><surname>Meng</surname><given-names>Q.-F.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Y.-X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.-N.</given-names></name><name name-style="western"><surname>Qi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><etal/></person-group><article-title>SARS-CoV-2 Orf9b suppresses type I interferon responses by targeting TOM70</article-title><source>Cell Mol. Immunol.</source><year>2020</year><volume>17</volume><fpage>998</fpage><lpage>1000</lpage><pub-id pub-id-type="doi">10.1038/s41423-020-0514-8</pub-id><pub-id pub-id-type="pmid">32728199</pub-id><pub-id pub-id-type="pmcid">PMC7387808</pub-id></element-citation></ref><ref id="B14-ijms-24-01701"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hatmal</surname><given-names>M.</given-names></name><name name-style="western"><surname>Alshaer</surname><given-names>W.</given-names></name><name name-style="western"><surname>Al-Hatamleh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hatmal</surname><given-names>M.</given-names></name><name name-style="western"><surname>Smadi</surname><given-names>O.</given-names></name><name name-style="western"><surname>Taha</surname><given-names>M.</given-names></name><name name-style="western"><surname>Oweida</surname><given-names>A.</given-names></name><name name-style="western"><surname>Boer</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mohamud</surname><given-names>R.</given-names></name><name name-style="western"><surname>Plebanski</surname><given-names>M.</given-names></name></person-group><article-title>Comprehensive Structural and Molecular Comparison of Spike Proteins of SARS-CoV-2, SARS-CoV and MERS-CoV, and Their Interactions with ACE2</article-title><source>Cells</source><year>2020</year><volume>9</volume><elocation-id>2638</elocation-id><pub-id pub-id-type="doi">10.3390/cells9122638</pub-id><pub-id pub-id-type="pmid">33302501</pub-id><pub-id pub-id-type="pmcid">PMC7763676</pub-id></element-citation></ref><ref id="B15-ijms-24-01701"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grifoni</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sidney</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Scheuermann</surname><given-names>R.H.</given-names></name><name name-style="western"><surname>Peters</surname><given-names>B.</given-names></name><name name-style="western"><surname>Sette</surname><given-names>A.</given-names></name></person-group><article-title>A Sequence Homology and Bioinformatic Approach Can Predict Candidate Targets for Immune Responses to SARS-CoV-2</article-title><source>Cell Host Microbe.</source><year>2020</year><volume>27</volume><fpage>671</fpage><lpage>680.e2</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2020.03.002</pub-id><pub-id pub-id-type="pmid">32183941</pub-id><pub-id pub-id-type="pmcid">PMC7142693</pub-id></element-citation></ref><ref id="B16-ijms-24-01701"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wrapp</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Corbett</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Goldsmith</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Hsieh</surname><given-names>C.-L.</given-names></name><name name-style="western"><surname>Abiona</surname><given-names>O.</given-names></name><name name-style="western"><surname>Graham</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>McLellan</surname><given-names>J.S.</given-names></name></person-group><article-title>Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation</article-title><source>Science</source><year>2020</year><volume>367</volume><fpage>1260</fpage><lpage>1263</lpage><pub-id pub-id-type="doi">10.1126/science.abb2507</pub-id><pub-id pub-id-type="pmid">32075877</pub-id><pub-id pub-id-type="pmcid">PMC7164637</pub-id></element-citation></ref><ref id="B17-ijms-24-01701"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Duan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Niu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name></person-group><article-title>The SARS-CoV-2 Spike Glycoprotein Biosynthesis, Structure, Function, and Antigenicity: Implications for the Design of Spike-Based Vaccine Immunogens</article-title><source>Front. Immunol.</source><year>2020</year><volume>11</volume><fpage>576622</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2020.576622</pub-id><pub-id pub-id-type="pmid">33117378</pub-id><pub-id pub-id-type="pmcid">PMC7575906</pub-id></element-citation></ref><ref id="B18-ijms-24-01701"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berman</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Westbrook</surname><given-names>J.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Gilliland</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bhat</surname><given-names>T.N.</given-names></name><name name-style="western"><surname>Weissig</surname><given-names>H.</given-names></name><name name-style="western"><surname>Shindyalov</surname><given-names>I.N.</given-names></name><name name-style="western"><surname>Bourne</surname><given-names>P.E.</given-names></name></person-group><article-title>The Protein Data Bank</article-title><source>Nucleic Acids Res.</source><year>2000</year><volume>28</volume><fpage>235</fpage><lpage>242</lpage><pub-id pub-id-type="doi">10.1093/nar/28.1.235</pub-id><pub-id pub-id-type="pmid">10592235</pub-id><pub-id pub-id-type="pmcid">PMC102472</pub-id></element-citation></ref><ref id="B19-ijms-24-01701"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Han</surname><given-names>W.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Q.</given-names></name><etal/></person-group><article-title>Conformational dynamics of SARS-CoV-2 trimeric spike glycoprotein in complex with receptor ACE2 revealed by cryo-EM</article-title><source>Sci. Adv.</source><year>2021</year><volume>7</volume><fpage>eabe5575</fpage><pub-id pub-id-type="doi">10.1126/sciadv.abe5575</pub-id><pub-id pub-id-type="pmid">33277323</pub-id><pub-id pub-id-type="pmcid">PMC7775788</pub-id></element-citation></ref><ref id="B20-ijms-24-01701"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>G.</given-names></name><name name-style="western"><surname>Geng</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Auerbach</surname><given-names>A.</given-names></name><name name-style="western"><surname>Li</surname><given-names>F.</given-names></name></person-group><article-title>Cell entry mechanisms of SARS-CoV-2</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2020</year><volume>117</volume><fpage>11727</fpage><lpage>11734</lpage><pub-id pub-id-type="doi">10.1073/pnas.2003138117</pub-id><pub-id pub-id-type="pmid">32376634</pub-id><pub-id pub-id-type="pmcid">PMC7260975</pub-id></element-citation></ref><ref id="B21-ijms-24-01701"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coutard</surname><given-names>B.</given-names></name><name name-style="western"><surname>Valle</surname><given-names>C.</given-names></name><name name-style="western"><surname>de Lamballerie</surname><given-names>X.</given-names></name><name name-style="western"><surname>Canard</surname><given-names>B.</given-names></name><name name-style="western"><surname>Seidah</surname><given-names>N.G.</given-names></name><name name-style="western"><surname>Decroly</surname><given-names>E.</given-names></name></person-group><article-title>The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade</article-title><source>Antivir. Res.</source><year>2020</year><volume>176</volume><fpage>104742</fpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2020.104742</pub-id><pub-id pub-id-type="pmid">32057769</pub-id><pub-id pub-id-type="pmcid">PMC7114094</pub-id></element-citation></ref><ref id="B22-ijms-24-01701"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jackson</surname><given-names>C.B.</given-names></name><name name-style="western"><surname>Farzan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>B.</given-names></name><name name-style="western"><surname>Choe</surname><given-names>H.</given-names></name></person-group><article-title>Mechanisms of SARS-CoV-2 entry into cells</article-title><source>Nat. Rev. Mol. Cell Biol.</source><year>2021</year><volume>23</volume><fpage>3</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1038/s41580-021-00418-x</pub-id><pub-id pub-id-type="pmid">34611326</pub-id><pub-id pub-id-type="pmcid">PMC8491763</pub-id></element-citation></ref><ref id="B23-ijms-24-01701"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kordyukova</surname><given-names>L.V.</given-names></name><name name-style="western"><surname>Shanko</surname><given-names>A.V.</given-names></name></person-group><article-title>COVID-19: Myths and Reality</article-title><source>Biochem.</source><year>2021</year><volume>86</volume><fpage>800</fpage><lpage>817</lpage><pub-id pub-id-type="doi">10.1134/S0006297921070026</pub-id><pub-id pub-id-type="pmid">34284707</pub-id><pub-id pub-id-type="pmcid">PMC8265000</pub-id></element-citation></ref><ref id="B24-ijms-24-01701"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clausen</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Sandoval</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Spliid</surname><given-names>C.B.</given-names></name><name name-style="western"><surname>Pihl</surname><given-names>J.</given-names></name><name name-style="western"><surname>Perrett</surname><given-names>H.R.</given-names></name><name name-style="western"><surname>Painter</surname><given-names>C.D.</given-names></name><name name-style="western"><surname>Narayanan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Majowicz</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Kwong</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>McVicar</surname><given-names>R.N.</given-names></name><etal/></person-group><article-title>SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2</article-title><source>Cell</source><year>2020</year><volume>183</volume><fpage>1043</fpage><lpage>1057.e15</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.09.033</pub-id><pub-id pub-id-type="pmid">32970989</pub-id><pub-id pub-id-type="pmcid">PMC7489987</pub-id></element-citation></ref><ref id="B25-ijms-24-01701"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Benton</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Wrobel</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>P.</given-names></name><name name-style="western"><surname>Roustan</surname><given-names>C.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Rosenthal</surname><given-names>P.B.</given-names></name><name name-style="western"><surname>Skehel</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Gamblin</surname><given-names>S.J.</given-names></name></person-group><article-title>Receptor binding and priming of the spike protein of SARS-CoV-2 for membrane fusion</article-title><source>Nature</source><year>2020</year><volume>588</volume><fpage>327</fpage><lpage>330</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2772-0</pub-id><pub-id pub-id-type="pmid">32942285</pub-id><pub-id pub-id-type="pmcid">PMC7116727</pub-id></element-citation></ref><ref id="B26-ijms-24-01701"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>J.</given-names></name><name name-style="western"><surname>He</surname><given-names>W.-T.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lai</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ji</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhai</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>G.</given-names></name><name name-style="western"><surname>Suchard</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>J.</given-names></name><etal/></person-group><article-title>COVID-19: Epidemiology, Evolution, and Cross-Disciplinary Perspectives</article-title><source>Trends Mol. Med.</source><year>2020</year><volume>26</volume><fpage>483</fpage><lpage>495</lpage><pub-id pub-id-type="doi">10.1016/j.molmed.2020.02.008</pub-id><pub-id pub-id-type="pmid">32359479</pub-id><pub-id pub-id-type="pmcid">PMC7118693</pub-id></element-citation></ref><ref id="B27-ijms-24-01701"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Riley</surname><given-names>T.P.</given-names></name><name name-style="western"><surname>Chou</surname><given-names>H.-T.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bzymek</surname><given-names>K.P.</given-names></name><name name-style="western"><surname>Correia</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Partin</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Li</surname><given-names>D.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Enhancing the Prefusion Conformational Stability of SARS-CoV-2 Spike Protein Through Structure-Guided Design</article-title><source>Front. Immunol.</source><year>2021</year><volume>12</volume><fpage>660198</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2021.660198</pub-id><pub-id pub-id-type="pmid">33968063</pub-id><pub-id pub-id-type="pmcid">PMC8100506</pub-id></element-citation></ref><ref id="B28-ijms-24-01701"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pallesen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Corbett</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Wrapp</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kirchdoerfer</surname><given-names>R.N.</given-names></name><name name-style="western"><surname>Turner</surname><given-names>H.L.</given-names></name><name name-style="western"><surname>Cottrell</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Becker</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>W.</given-names></name><etal/></person-group><article-title>Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2017</year><volume>114</volume><fpage>E7348</fpage><lpage>E7357</lpage><pub-id pub-id-type="doi">10.1073/pnas.1707304114</pub-id><pub-id pub-id-type="pmid">28807998</pub-id><pub-id pub-id-type="pmcid">PMC5584442</pub-id></element-citation></ref><ref id="B29-ijms-24-01701"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chakraborty</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mallajosyula</surname><given-names>V.</given-names></name><name name-style="western"><surname>Tato</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>G.S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>T.T.</given-names></name></person-group><article-title>SARS-CoV-2 vaccines in advanced clinical trials: Where do we stand?</article-title><source>Adv. Drug Deliv. Rev.</source><year>2021</year><volume>172</volume><fpage>314</fpage><lpage>338</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2021.01.014</pub-id><pub-id pub-id-type="pmid">33482248</pub-id><pub-id pub-id-type="pmcid">PMC7816567</pub-id></element-citation></ref><ref id="B30-ijms-24-01701"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kam</surname><given-names>Y.W.</given-names></name><name name-style="western"><surname>Kien</surname><given-names>F.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cheung</surname><given-names>Y.C.</given-names></name><name name-style="western"><surname>Lamirande</surname><given-names>E.W.</given-names></name><name name-style="western"><surname>Vogel</surname><given-names>L.</given-names></name><name name-style="western"><surname>Chu</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Tse</surname><given-names>J.</given-names></name><name name-style="western"><surname>Guarner</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zaki</surname><given-names>S.R.</given-names></name><etal/></person-group><article-title>Antibodies against trimeric S glycoprotein protect hamsters against SARS-CoV challenge despite their capacity to mediate Fc&#947;RII-dependent entry into B cells in vitro</article-title><source>Vaccine</source><year>2007</year><volume>25</volume><fpage>729</fpage><lpage>740</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2006.08.011</pub-id><pub-id pub-id-type="pmid">17049691</pub-id><pub-id pub-id-type="pmcid">PMC7115629</pub-id></element-citation></ref><ref id="B31-ijms-24-01701"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kuwahara</surname><given-names>K.</given-names></name><name name-style="western"><surname>Li</surname><given-names>L.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Li</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Immunodominant SARS Coronavirus Epitopes in Humans Elicited both Enhancing and Neutralizing Effects on Infection in Non-human Primates</article-title><source>ACS Infect. Dis.</source><year>2016</year><volume>2</volume><fpage>361</fpage><lpage>376</lpage><comment>Erratum in <italic toggle="yes">ACS Infect. Dis.</italic><bold>2020</bold>, <italic toggle="yes">6</italic>, 1284&#8211;1285</comment><pub-id pub-id-type="doi">10.1021/acsinfecdis.6b00006</pub-id><pub-id pub-id-type="pmid">27627203</pub-id><pub-id pub-id-type="pmcid">PMC7075522</pub-id></element-citation></ref><ref id="B32-ijms-24-01701"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nechipurenko</surname><given-names>Y.D.</given-names></name><name name-style="western"><surname>Anashkina</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Matveeva</surname><given-names>O.V.</given-names></name></person-group><article-title>Change of Antigenic Determinants of SARS-CoV-2 Virus S-Protein as a Possible Cause of Antibody-Dependent Enhancement of Virus Infection and Cytokine Storm</article-title><source>Biophysics</source><year>2020</year><volume>65</volume><fpage>703</fpage><lpage>709</lpage><pub-id pub-id-type="doi">10.1134/S0006350920040119</pub-id><pub-id pub-id-type="pmid">33100352</pub-id><pub-id pub-id-type="pmcid">PMC7569100</pub-id></element-citation></ref><ref id="B33-ijms-24-01701"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vangelista</surname><given-names>L.</given-names></name><name name-style="western"><surname>Secchi</surname><given-names>M.</given-names></name></person-group><article-title>Prepare for the Future: Dissecting the Spike to Seek Broadly Neutralizing Antibodies and Universal Vaccine for Pandemic Coronaviruses</article-title><source>Front. Mol. Biosci.</source><year>2020</year><volume>7</volume><fpage>226</fpage><pub-id pub-id-type="doi">10.3389/fmolb.2020.00226</pub-id><pub-id pub-id-type="pmid">33033717</pub-id><pub-id pub-id-type="pmcid">PMC7490329</pub-id></element-citation></ref><ref id="B34-ijms-24-01701"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Robbiani</surname><given-names>D.F.</given-names></name><name name-style="western"><surname>Gaebler</surname><given-names>C.</given-names></name><name name-style="western"><surname>Muecksch</surname><given-names>F.</given-names></name><name name-style="western"><surname>Lorenzi</surname><given-names>J.C.C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>A.</given-names></name><name name-style="western"><surname>Agudelo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Barnes</surname><given-names>C.O.</given-names></name><name name-style="western"><surname>Gazumyan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Finkin</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Convergent antibody responses to SARS-CoV-2 in convalescent individuals</article-title><source>Nature</source><year>2020</year><volume>584</volume><fpage>437</fpage><lpage>442</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2456-9</pub-id><pub-id pub-id-type="pmid">32555388</pub-id><pub-id pub-id-type="pmcid">PMC7442695</pub-id></element-citation></ref><ref id="B35-ijms-24-01701"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zost</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Gilchuk</surname><given-names>P.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>Case</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Reidy</surname><given-names>J.X.</given-names></name><name name-style="western"><surname>Trivette</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nargi</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Sutton</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>Suryadevara</surname><given-names>N.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>E.C.</given-names></name><etal/></person-group><article-title>Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein</article-title><source>Nat. Med.</source><year>2020</year><volume>26</volume><fpage>1422</fpage><lpage>1427</lpage><pub-id pub-id-type="doi">10.1038/s41591-020-0998-x</pub-id><pub-id pub-id-type="pmid">32651581</pub-id><pub-id pub-id-type="pmcid">PMC8194108</pub-id></element-citation></ref><ref id="B36-ijms-24-01701"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tai</surname><given-names>W.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Geng</surname><given-names>Q.</given-names></name><name name-style="western"><surname>He</surname><given-names>L.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry</article-title><source>J. Virol.</source><year>2020</year><volume>94</volume><fpage>e02015-19</fpage><pub-id pub-id-type="doi">10.1128/JVI.02015-19</pub-id><pub-id pub-id-type="pmid">31826992</pub-id><pub-id pub-id-type="pmcid">PMC7022351</pub-id></element-citation></ref><ref id="B37-ijms-24-01701"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Lei</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>W.</given-names></name><name name-style="western"><surname>Lai</surname><given-names>D.Y.</given-names></name><name name-style="western"><surname>Hou</surname><given-names>H.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Z.W.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Linear epitope landscape of the SARS-CoV-2 Spike protein constructed from 1,051 COVID-19 patients</article-title><source>Cell Rep.</source><year>2021</year><volume>34</volume><fpage>108915</fpage><pub-id pub-id-type="doi">10.1016/j.celrep.2021.108915</pub-id><pub-id pub-id-type="pmid">33761319</pub-id><pub-id pub-id-type="pmcid">PMC7953450</pub-id></element-citation></ref><ref id="B38-ijms-24-01701"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tarke</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sidney</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kidd</surname><given-names>C.K.</given-names></name><name name-style="western"><surname>Dan</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Ramirez</surname><given-names>S.I.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>E.D.</given-names></name><name name-style="western"><surname>Mateus</surname><given-names>J.</given-names></name><name name-style="western"><surname>da Silva Antunes</surname><given-names>R.</given-names></name><name name-style="western"><surname>Moore</surname><given-names>E.</given-names></name><name name-style="western"><surname>Rubiro</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases</article-title><source>Cell Rep. Med.</source><year>2021</year><volume>2</volume><fpage>100204</fpage><pub-id pub-id-type="doi">10.1016/j.xcrm.2021.100204</pub-id><pub-id pub-id-type="pmid">33521695</pub-id><pub-id pub-id-type="pmcid">PMC7837622</pub-id></element-citation></ref><ref id="B39-ijms-24-01701"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pollet</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W.-H.</given-names></name><name name-style="western"><surname>Strych</surname><given-names>U.</given-names></name></person-group><article-title>Recombinant protein vaccines, a proven approach against coronavirus pandemics</article-title><source>Adv. Drug Deliv. Rev.</source><year>2021</year><volume>170</volume><fpage>71</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2021.01.001</pub-id><pub-id pub-id-type="pmid">33421475</pub-id><pub-id pub-id-type="pmcid">PMC7788321</pub-id></element-citation></ref><ref id="B40-ijms-24-01701"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Qi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>T.</given-names></name></person-group><article-title>Purification and characterization of the receptor-binding domain of SARS-CoV-2 spike protein from <italic toggle="yes">Escherichia coli</italic></article-title><source>Eng. Life Sci.</source><year>2021</year><volume>21</volume><fpage>453</fpage><lpage>460</lpage><pub-id pub-id-type="doi">10.1002/elsc.202000106</pub-id><pub-id pub-id-type="pmid">34140855</pub-id><pub-id pub-id-type="pmcid">PMC8182281</pub-id></element-citation></ref><ref id="B41-ijms-24-01701"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dai</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>G.F.</given-names></name></person-group><article-title>Viral targets for vaccines against COVID-19</article-title><source>Nat. Rev. Immunol.</source><year>2020</year><volume>21</volume><fpage>73</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1038/s41577-020-00480-0</pub-id><pub-id pub-id-type="pmid">33340022</pub-id><pub-id pub-id-type="pmcid">PMC7747004</pub-id></element-citation></ref><ref id="B42-ijms-24-01701"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Du</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>G.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>H.</given-names></name><name name-style="western"><surname>He</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>B.-J.</given-names></name><etal/></person-group><article-title>Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunity</article-title><source>Virology</source><year>2009</year><volume>393</volume><fpage>144</fpage><lpage>150</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2009.07.018</pub-id><pub-id pub-id-type="pmid">19683779</pub-id><pub-id pub-id-type="pmcid">PMC2753736</pub-id></element-citation></ref><ref id="B43-ijms-24-01701"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kovalenko</surname><given-names>A.O.</given-names></name><name name-style="western"><surname>Ryabchevskaya</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Evtushenko</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Manukhova</surname><given-names>T.I.</given-names></name><name name-style="western"><surname>Kondakova</surname><given-names>O.A.</given-names></name><name name-style="western"><surname>Ivanov</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Arkhipenko</surname><given-names>M.V.</given-names></name><name name-style="western"><surname>Gushchin</surname><given-names>V.A.</given-names></name><name name-style="western"><surname>Nikitin</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Karpova</surname><given-names>O.V.</given-names></name></person-group><article-title>Vaccine Candidate Against COVID-19 Based on Structurally Modified Plant Virus as an Adjuvant</article-title><source>Front. Microbiol.</source><year>2022</year><volume>13</volume><fpage>845316</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2022.845316</pub-id><pub-id pub-id-type="pmid">35295298</pub-id><pub-id pub-id-type="pmcid">PMC8919459</pub-id></element-citation></ref><ref id="B44-ijms-24-01701"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Agathos</surname><given-names>S.</given-names></name></person-group><article-title>Production scale insect cell culture</article-title><source>Biotechnol. Adv.</source><year>1991</year><volume>9</volume><fpage>51</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1016/0734-9750(91)90404-J</pub-id><pub-id pub-id-type="pmid">14543739</pub-id></element-citation></ref><ref id="B45-ijms-24-01701"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Apostolico</surname><given-names>J.D.S.</given-names></name><name name-style="western"><surname>Lunardelli</surname><given-names>V.A.S.</given-names></name><name name-style="western"><surname>Coirada</surname><given-names>F.C.</given-names></name><name name-style="western"><surname>Boscardin</surname><given-names>S.B.</given-names></name><name name-style="western"><surname>Rosa</surname><given-names>D.S.</given-names></name></person-group><article-title>Adjuvants: Classification, <italic toggle="yes">Modus Operandi</italic>, and Licensing</article-title><source>J. Immunol. Res.</source><year>2016</year><volume>2016</volume><fpage>1459394</fpage><pub-id pub-id-type="doi">10.1155/2016/1459394</pub-id><pub-id pub-id-type="pmid">27274998</pub-id><pub-id pub-id-type="pmcid">PMC4870346</pub-id></element-citation></ref><ref id="B46-ijms-24-01701"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sarkar</surname><given-names>I.</given-names></name><name name-style="western"><surname>Garg</surname><given-names>R.</given-names></name><name name-style="western"><surname>van Drunen Littel-van den Hurk</surname><given-names>S.</given-names></name></person-group><article-title>Selection of adjuvants for vaccines targeting specific pathogens</article-title><source>Expert Rev. Vaccines</source><year>2019</year><volume>18</volume><fpage>505</fpage><lpage>521</lpage><pub-id pub-id-type="doi">10.1080/14760584.2019.1604231</pub-id><pub-id pub-id-type="pmid">31009255</pub-id><pub-id pub-id-type="pmcid">PMC7103699</pub-id></element-citation></ref><ref id="B47-ijms-24-01701"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Didierlaurent</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Morel</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lockman</surname><given-names>L.</given-names></name><name name-style="western"><surname>Giannini</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Bisteau</surname><given-names>M.</given-names></name><name name-style="western"><surname>Carlsen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kielland</surname><given-names>A.</given-names></name><name name-style="western"><surname>Vosters</surname><given-names>O.</given-names></name><name name-style="western"><surname>Vanderheyde</surname><given-names>N.</given-names></name><name name-style="western"><surname>Schiavetti</surname><given-names>F.</given-names></name><etal/></person-group><article-title>AS04, an Aluminum Salt- and TLR4 Agonist-Based Adjuvant System, Induces a Transient Localized Innate Immune Response Leading to Enhanced Adaptive Immunity</article-title><source>J. Immunol.</source><year>2009</year><volume>183</volume><fpage>6186</fpage><lpage>6197</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.0901474</pub-id><pub-id pub-id-type="pmid">19864596</pub-id></element-citation></ref><ref id="B48-ijms-24-01701"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aucouturier</surname><given-names>J.</given-names></name><name name-style="western"><surname>Dupuis</surname><given-names>L.</given-names></name><name name-style="western"><surname>Deville</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ascarateil</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ganne</surname><given-names>V.</given-names></name></person-group><article-title>Montanide ISA 720 and 51: A new generation of water in oil emulsions as adjuvants for human vaccines</article-title><source>Expert Rev. Vaccines</source><year>2002</year><volume>1</volume><fpage>111</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.1586/14760584.1.1.111</pub-id><pub-id pub-id-type="pmid">12908518</pub-id></element-citation></ref><ref id="B49-ijms-24-01701"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Petrovsky</surname><given-names>N.</given-names></name><name name-style="western"><surname>Cooper</surname><given-names>P.D.</given-names></name></person-group><article-title>Advax&#8482;, a novel microcrystalline polysaccharide particle engineered from delta inulin, provides robust adjuvant potency together with tolerability and safety</article-title><source>Vaccine</source><year>2015</year><volume>33</volume><fpage>5920</fpage><lpage>5926</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2015.09.030</pub-id><pub-id pub-id-type="pmid">26407920</pub-id><pub-id pub-id-type="pmcid">PMC4639457</pub-id></element-citation></ref><ref id="B50-ijms-24-01701"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bengtsson</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Karlsson</surname><given-names>K.H.</given-names></name><name name-style="western"><surname>Magnusson</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Reimer</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Stertman</surname><given-names>L.</given-names></name></person-group><article-title>Matrix-M&#8482; adjuvant: Enhancing immune responses by &#8216;setting the stage&#8217; for the antigen</article-title><source>Expert Rev. Vaccines</source><year>2013</year><volume>12</volume><fpage>821</fpage><lpage>823</lpage><pub-id pub-id-type="doi">10.1586/14760584.2013.814822</pub-id><pub-id pub-id-type="pmid">23984954</pub-id></element-citation></ref><ref id="B51-ijms-24-01701"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wijaya</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tham</surname><given-names>C.Y.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>Y.F.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>A.W.</given-names></name><name name-style="western"><surname>Li</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.-F.</given-names></name><name name-style="western"><surname>Bertoletti</surname><given-names>A.</given-names></name><name name-style="western"><surname>Low</surname><given-names>J.G.</given-names></name></person-group><article-title>An accelerated rabies vaccine schedule based on toll-like receptor 3 (TLR3) agonist PIKA adjuvant augments rabies virus specific antibody and T cell response in healthy adult volunteers</article-title><source>Vaccine</source><year>2017</year><volume>35</volume><fpage>1175</fpage><lpage>1183</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2016.12.031</pub-id><pub-id pub-id-type="pmid">28118938</pub-id></element-citation></ref><ref id="B52-ijms-24-01701"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cawlfield</surname><given-names>A.</given-names></name><name name-style="western"><surname>Genito</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Beck</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Bergmann-Leitner</surname><given-names>E.S.</given-names></name><name name-style="western"><surname>Bitzer</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Soto</surname><given-names>K.</given-names></name><name name-style="western"><surname>Zou</surname><given-names>X.</given-names></name><name name-style="western"><surname>Hadiwidjojo</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Gerbasi</surname><given-names>R.V.</given-names></name><name name-style="western"><surname>Mullins</surname><given-names>A.B.</given-names></name><etal/></person-group><article-title>Safety, toxicity and immunogenicity of a malaria vaccine based on the circumsporozoite protein (FMP013) with the adjuvant army liposome formulation containing QS21 (ALFQ)</article-title><source>Vaccine</source><year>2019</year><volume>37</volume><fpage>3793</fpage><lpage>3803</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2019.05.059</pub-id><pub-id pub-id-type="pmid">31151801</pub-id></element-citation></ref><ref id="B53-ijms-24-01701"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heitmann</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Bilich</surname><given-names>T.</given-names></name><name name-style="western"><surname>Tandler</surname><given-names>C.</given-names></name><name name-style="western"><surname>Nelde</surname><given-names>A.</given-names></name><name name-style="western"><surname>Maringer</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Marconato</surname><given-names>M.</given-names></name><name name-style="western"><surname>Reusch</surname><given-names>J.</given-names></name><name name-style="western"><surname>J&#228;ger</surname><given-names>S.</given-names></name><name name-style="western"><surname>Denk</surname><given-names>M.</given-names></name><name name-style="western"><surname>Richter</surname><given-names>M.</given-names></name><etal/></person-group><article-title>A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity</article-title><source>Nature</source><year>2021</year><volume>601</volume><fpage>617</fpage><lpage>622</lpage><pub-id pub-id-type="doi">10.1038/s41586-021-04232-5</pub-id><pub-id pub-id-type="pmid">34814158</pub-id><pub-id pub-id-type="pmcid">PMC8791831</pub-id></element-citation></ref><ref id="B54-ijms-24-01701"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Honda-Okubo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Barnard</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ong</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>B.-H.</given-names></name><name name-style="western"><surname>Tseng</surname><given-names>C.-T.K.</given-names></name><name name-style="western"><surname>Petrovsky</surname><given-names>N.</given-names></name></person-group><article-title>Severe Acute Respiratory Syndrome-Associated Coronavirus Vaccines Formulated with Delta Inulin Adjuvants Provide Enhanced Protection while Ameliorating Lung Eosinophilic Immunopathology</article-title><source>J. Virol.</source><year>2015</year><volume>89</volume><fpage>2995</fpage><lpage>3007</lpage><pub-id pub-id-type="doi">10.1128/JVI.02980-14</pub-id><pub-id pub-id-type="pmid">25520500</pub-id><pub-id pub-id-type="pmcid">PMC4337527</pub-id></element-citation></ref><ref id="B55-ijms-24-01701"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bolles</surname><given-names>M.</given-names></name><name name-style="western"><surname>Deming</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Long</surname><given-names>K.</given-names></name><name name-style="western"><surname>Agnihothram</surname><given-names>S.</given-names></name><name name-style="western"><surname>Whitmore</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ferris</surname><given-names>M.</given-names></name><name name-style="western"><surname>Funkhouser</surname><given-names>W.</given-names></name><name name-style="western"><surname>Gralinski</surname><given-names>L.</given-names></name><name name-style="western"><surname>Totura</surname><given-names>A.</given-names></name><name name-style="western"><surname>Heise</surname><given-names>M.</given-names></name><etal/></person-group><article-title>A Double-Inactivated Severe Acute Respiratory Syndrome Coronavirus Vaccine Provides Incomplete Protection in Mice and Induces Increased Eosinophilic Proinflammatory Pulmonary Response upon Challenge</article-title><source>J. Virol.</source><year>2011</year><volume>85</volume><fpage>12201</fpage><lpage>12215</lpage><pub-id pub-id-type="doi">10.1128/JVI.06048-11</pub-id><pub-id pub-id-type="pmid">21937658</pub-id><pub-id pub-id-type="pmcid">PMC3209347</pub-id></element-citation></ref><ref id="B56-ijms-24-01701"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iwata-Yoshikawa</surname><given-names>N.</given-names></name><name name-style="western"><surname>Uda</surname><given-names>A.</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>T.</given-names></name><name name-style="western"><surname>Tsunetsugu-Yokota</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sato</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Morikawa</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tashiro</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sata</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hasegawa</surname><given-names>H.</given-names></name><name name-style="western"><surname>Nagata</surname><given-names>N.</given-names></name></person-group><article-title>Effects of Toll-Like Receptor Stimulation on Eosinophilic Infiltration in Lungs of BALB/c Mice Immunized with UV-Inactivated Severe Acute Respiratory Syndrome-Related Coronavirus Vaccine</article-title><source>J. Virol.</source><year>2014</year><volume>88</volume><fpage>8597</fpage><lpage>8614</lpage><pub-id pub-id-type="doi">10.1128/JVI.00983-14</pub-id><pub-id pub-id-type="pmid">24850731</pub-id><pub-id pub-id-type="pmcid">PMC4135953</pub-id></element-citation></ref><ref id="B57-ijms-24-01701"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Heck</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lustigman</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>S.</given-names></name></person-group><article-title>Antigenic and Immunogenic Characterization of Recombinant Baculovirus-Expressed Severe Acute Respiratory Syndrome Coronavirus Spike Protein: Implication for Vaccine Design</article-title><source>J. Virol.</source><year>2006</year><volume>80</volume><fpage>5757</fpage><lpage>5767</lpage><pub-id pub-id-type="doi">10.1128/JVI.00083-06</pub-id><pub-id pub-id-type="pmid">16731915</pub-id><pub-id pub-id-type="pmcid">PMC1472569</pub-id></element-citation></ref><ref id="B58-ijms-24-01701"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ulitzky</surname><given-names>L.</given-names></name><name name-style="western"><surname>Silberstein</surname><given-names>E.</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Viscidi</surname><given-names>R.</given-names></name></person-group><article-title>Immunogenicity and Protection Efficacy of Monomeric and Trimeric Recombinant SARS Coronavirus Spike Protein Subunit Vaccine Candidates</article-title><source>Viral Immunol.</source><year>2013</year><volume>26</volume><fpage>126</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1089/vim.2012.0076</pub-id><pub-id pub-id-type="pmid">23573979</pub-id><pub-id pub-id-type="pmcid">PMC3624630</pub-id></element-citation></ref><ref id="B59-ijms-24-01701"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jaume</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yip</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Kam</surname><given-names>Y.W.</given-names></name><name name-style="western"><surname>Cheung</surname><given-names>C.Y.</given-names></name><name name-style="western"><surname>Kien</surname><given-names>F.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>A.</given-names></name><name name-style="western"><surname>Li</surname><given-names>P.H.</given-names></name><name name-style="western"><surname>Dutry</surname><given-names>I.</given-names></name><name name-style="western"><surname>Escriou</surname><given-names>N.</given-names></name><name name-style="western"><surname>Daeron</surname><given-names>M.</given-names></name><etal/></person-group><article-title>SARS CoV subunit vaccine: Antibody-mediated neutralisation and enhancement</article-title><source>Hong Kong Med. J.</source><year>2012</year><volume>18</volume><fpage>31</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">22311359</pub-id></element-citation></ref><ref id="B60-ijms-24-01701"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tay</surname><given-names>M.Z.</given-names></name><name name-style="western"><surname>Poh</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>R&#233;nia</surname><given-names>L.</given-names></name><name name-style="western"><surname>Macary</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Ng</surname><given-names>L.F.P.</given-names></name></person-group><article-title>The trinity of COVID-19: Immunity, inflammation and intervention</article-title><source>Nat. Rev. Immunol.</source><year>2020</year><volume>20</volume><fpage>363</fpage><lpage>374</lpage><pub-id pub-id-type="doi">10.1038/s41577-020-0311-8</pub-id><pub-id pub-id-type="pmid">32346093</pub-id><pub-id pub-id-type="pmcid">PMC7187672</pub-id></element-citation></ref><ref id="B61-ijms-24-01701"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kou</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><name name-style="western"><surname>Farzan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>S.</given-names></name></person-group><article-title>Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: Implication for developing subunit vaccine</article-title><source>Biochem. Biophys. Res. Commun.</source><year>2004</year><volume>324</volume><fpage>773</fpage><lpage>781</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2004.09.106</pub-id><pub-id pub-id-type="pmid">15474494</pub-id><pub-id pub-id-type="pmcid">PMC7092904</pub-id></element-citation></ref><ref id="B62-ijms-24-01701"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Du</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>G.</given-names></name><name name-style="western"><surname>He</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>B.-J.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name></person-group><article-title>Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model</article-title><source>Vaccine</source><year>2007</year><volume>25</volume><fpage>2832</fpage><lpage>2838</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2006.10.031</pub-id><pub-id pub-id-type="pmid">17092615</pub-id><pub-id pub-id-type="pmcid">PMC7115660</pub-id></element-citation></ref><ref id="B63-ijms-24-01701"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tai</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>G.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>S.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Tseng</surname><given-names>C.-T.K.</given-names></name><name name-style="western"><surname>Li</surname><given-names>F.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Du Lanying</surname><given-names>L.</given-names></name><etal/></person-group><article-title>A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection</article-title><source>Virology</source><year>2016</year><volume>499</volume><fpage>375</fpage><lpage>382</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2016.10.005</pub-id><pub-id pub-id-type="pmid">27750111</pub-id><pub-id pub-id-type="pmcid">PMC5167628</pub-id></element-citation></ref><ref id="B64-ijms-24-01701"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>X.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>G.F.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>W.</given-names></name></person-group><article-title>Tailoring Subunit Vaccine Immunity with Adjuvant Combinations and Delivery Routes Using the Middle East Respiratory Coronavirus (MERS-CoV) Receptor-Binding Domain as an Antigen</article-title><source>PLoS ONE</source><year>2014</year><volume>9</volume><elocation-id>e112602</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0112602</pub-id><pub-id pub-id-type="pmid">25405618</pub-id><pub-id pub-id-type="pmcid">PMC4236105</pub-id></element-citation></ref><ref id="B65-ijms-24-01701"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Bao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>G.F.</given-names></name><etal/></person-group><article-title>Recombinant Receptor Binding Domain Protein Induces Partial Protective Immunity in Rhesus Macaques Against Middle East Respiratory Syndrome Coronavirus Challenge</article-title><source>Ebiomedicine</source><year>2015</year><volume>2</volume><fpage>1438</fpage><lpage>1446</lpage><comment>Erratum in <italic toggle="yes">EBioMedicine</italic><bold>2021</bold>, <italic toggle="yes">72</italic>, 103608</comment><pub-id pub-id-type="doi">10.1016/j.ebiom.2015.08.031</pub-id><pub-id pub-id-type="pmid">26629538</pub-id><pub-id pub-id-type="pmcid">PMC4634622</pub-id></element-citation></ref><ref id="B66-ijms-24-01701"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dai</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>T.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>K.</given-names></name><name name-style="western"><surname>Han</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>E.</given-names></name><name name-style="western"><surname>An</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>S.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>M.</given-names></name><etal/></person-group><article-title>A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS</article-title><source>Cell</source><year>2020</year><volume>182</volume><fpage>722</fpage><lpage>733.e11</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.06.035</pub-id><pub-id pub-id-type="pmid">32645327</pub-id><pub-id pub-id-type="pmcid">PMC7321023</pub-id></element-citation></ref><ref id="B67-ijms-24-01701"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roopenian</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Akilesh</surname><given-names>S.</given-names></name></person-group><article-title>FcRn: The neonatal Fc receptor comes of age</article-title><source>Nat. Rev. Immunol.</source><year>2007</year><volume>7</volume><fpage>715</fpage><lpage>725</lpage><pub-id pub-id-type="doi">10.1038/nri2155</pub-id><pub-id pub-id-type="pmid">17703228</pub-id></element-citation></ref><ref id="B68-ijms-24-01701"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kontermann</surname><given-names>R.E.</given-names></name></person-group><article-title>Strategies for extended serum half-life of protein therapeutics</article-title><source>Curr. Opin. Biotechnol.</source><year>2011</year><volume>22</volume><fpage>868</fpage><lpage>876</lpage><pub-id pub-id-type="doi">10.1016/j.copbio.2011.06.012</pub-id><pub-id pub-id-type="pmid">21862310</pub-id></element-citation></ref><ref id="B69-ijms-24-01701"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carter</surname><given-names>P.J.</given-names></name></person-group><article-title>Introduction to current and future protein therapeutics: A protein engineering perspective</article-title><source>Exp. Cell Res.</source><year>2011</year><volume>317</volume><fpage>1261</fpage><lpage>1269</lpage><pub-id pub-id-type="doi">10.1016/j.yexcr.2011.02.013</pub-id><pub-id pub-id-type="pmid">21371474</pub-id></element-citation></ref><ref id="B70-ijms-24-01701"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nimmerjahn</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ravetch</surname><given-names>J.V.</given-names></name></person-group><article-title>Fc&#947; receptors as regulators of immune responses</article-title><source>Nat. Rev. Immunol.</source><year>2008</year><volume>8</volume><fpage>34</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1038/nri2206</pub-id><pub-id pub-id-type="pmid">18064051</pub-id></element-citation></ref><ref id="B71-ijms-24-01701"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Du</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kou</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>C.</given-names></name><name name-style="western"><surname>Tao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>G.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Tseng</surname><given-names>C.-T.K.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>A Truncated Receptor-Binding Domain of MERS-CoV Spike Protein Potently Inhibits MERS-CoV Infection and Induces Strong Neutralizing Antibody Responses: Implication for Developing Therapeutics and Vaccines</article-title><source>PLoS ONE</source><year>2013</year><volume>8</volume><elocation-id>e81587</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0081587</pub-id><pub-id pub-id-type="pmid">24324708</pub-id><pub-id pub-id-type="pmcid">PMC3852489</pub-id></element-citation></ref><ref id="B72-ijms-24-01701"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>C.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>G.</given-names></name><name name-style="western"><surname>Tao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Tseng</surname><given-names>C.-T.K.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Du</surname><given-names>L.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>S.</given-names></name></person-group><article-title>Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines</article-title><source>Vaccine</source><year>2014</year><volume>32</volume><fpage>2100</fpage><lpage>2108</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2014.02.004</pub-id><pub-id pub-id-type="pmid">24560617</pub-id><pub-id pub-id-type="pmcid">PMC4194189</pub-id></element-citation></ref><ref id="B73-ijms-24-01701"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tseng</surname><given-names>C.-T.K.</given-names></name><name name-style="western"><surname>Li</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Du</surname><given-names>L.</given-names></name></person-group><article-title>Searching for an ideal vaccine candidate among different MERS coronavirus receptor-binding fragments&#8212;The importance of immunofocusing in subunit vaccine design</article-title><source>Vaccine</source><year>2014</year><volume>32</volume><fpage>6170</fpage><lpage>6176</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2014.08.086</pub-id><pub-id pub-id-type="pmid">25240756</pub-id><pub-id pub-id-type="pmcid">PMC4194190</pub-id></element-citation></ref><ref id="B74-ijms-24-01701"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Tao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>G.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tseng</surname><given-names>C.-T.K.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Du</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name></person-group><article-title>Optimization of antigen dose for a receptor-binding domain-based subunit vaccine against MERS coronavirus</article-title><source>Hum. Vaccines Immunother.</source><year>2015</year><volume>11</volume><fpage>1244</fpage><lpage>1250</lpage><pub-id pub-id-type="doi">10.1080/21645515.2015.1021527</pub-id><pub-id pub-id-type="pmcid">PMC4514392</pub-id><pub-id pub-id-type="pmid">25874632</pub-id></element-citation></ref><ref id="B75-ijms-24-01701"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Channappanavar</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Garron</surname><given-names>T.</given-names></name><name name-style="western"><surname>Tao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Tasneem</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tseng</surname><given-names>C.-T.K.</given-names></name><etal/></person-group><article-title>Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus</article-title><source>Cell Mol. Immunol.</source><year>2015</year><volume>13</volume><fpage>180</fpage><lpage>190</lpage><pub-id pub-id-type="doi">10.1038/cmi.2015.03</pub-id><pub-id pub-id-type="pmid">25640653</pub-id><pub-id pub-id-type="pmcid">PMC4786625</pub-id></element-citation></ref><ref id="B76-ijms-24-01701"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nyon</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Du</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tseng</surname><given-names>C.-T.K.</given-names></name><name name-style="western"><surname>Seid</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Pollet</surname><given-names>J.</given-names></name><name name-style="western"><surname>Naceanceno</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Agrawal</surname><given-names>A.</given-names></name><name name-style="western"><surname>Algaissi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>B.-H.</given-names></name><name name-style="western"><surname>Tai</surname><given-names>W.</given-names></name><etal/></person-group><article-title>Engineering a stable CHO cell line for the expression of a MERS-coronavirus vaccine antigen</article-title><source>Vaccine</source><year>2018</year><volume>36</volume><fpage>1853</fpage><lpage>1862</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2018.02.065</pub-id><pub-id pub-id-type="pmid">29496347</pub-id><pub-id pub-id-type="pmcid">PMC5860679</pub-id></element-citation></ref><ref id="B77-ijms-24-01701"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>W.</given-names></name><name name-style="western"><surname>Joyce</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Modjarrad</surname><given-names>K.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Leung</surname><given-names>K.</given-names></name><name name-style="western"><surname>Lees</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yassine</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Kanekiyo</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Evaluation of candidate vaccine approaches for MERS-CoV</article-title><source>Nat. Commun.</source><year>2015</year><volume>6</volume><fpage>7712</fpage><pub-id pub-id-type="doi">10.1038/ncomms8712</pub-id><pub-id pub-id-type="pmid">26218507</pub-id><pub-id pub-id-type="pmcid">PMC4525294</pub-id></element-citation></ref><ref id="B78-ijms-24-01701"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adney</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>van Doremalen</surname><given-names>N.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kong</surname><given-names>W.-P.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Bushmaker</surname><given-names>T.</given-names></name><name name-style="western"><surname>Scott</surname><given-names>D.</given-names></name><name name-style="western"><surname>de Wit</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Efficacy of an Adjuvanted Middle East Respiratory Syndrome Coronavirus Spike Protein Vaccine in Dromedary Camels and Alpacas</article-title><source>Viruses</source><year>2019</year><volume>11</volume><elocation-id>212</elocation-id><pub-id pub-id-type="doi">10.3390/v11030212</pub-id><pub-id pub-id-type="pmid">30832356</pub-id><pub-id pub-id-type="pmcid">PMC6466352</pub-id></element-citation></ref><ref id="B79-ijms-24-01701"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>E.</given-names></name><name name-style="western"><surname>Erdos</surname><given-names>G.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kenniston</surname><given-names>T.W.</given-names></name><name name-style="western"><surname>Balmert</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Carey</surname><given-names>C.D.</given-names></name><name name-style="western"><surname>Raj</surname><given-names>V.S.</given-names></name><name name-style="western"><surname>Epperly</surname><given-names>M.W.</given-names></name><name name-style="western"><surname>Klimstra</surname><given-names>W.B.</given-names></name><name name-style="western"><surname>Haagmans</surname><given-names>B.L.</given-names></name><etal/></person-group><article-title>Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development</article-title><source>EBioMedicine</source><year>2020</year><volume>55</volume><fpage>102743</fpage><pub-id pub-id-type="doi">10.1016/j.ebiom.2020.102743</pub-id><pub-id pub-id-type="pmid">32249203</pub-id><pub-id pub-id-type="pmcid">PMC7128973</pub-id></element-citation></ref><ref id="B80-ijms-24-01701"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiaming</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yanfeng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>D.</given-names></name><name name-style="western"><surname>Yawei</surname><given-names>H.</given-names></name><name name-style="western"><surname>Linlin</surname><given-names>B.</given-names></name><name name-style="western"><surname>Baoying</surname><given-names>H.</given-names></name><name name-style="western"><surname>Jinghua</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>G.F.</given-names></name><name name-style="western"><surname>Chuan</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Wenjie</surname><given-names>T.</given-names></name></person-group><article-title>The recombinant N-terminal domain of spike proteins is a potential vaccine against Middle East respiratory syndrome coronavirus (MERS-CoV) infection</article-title><source>Vaccine</source><year>2016</year><volume>35</volume><fpage>10</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2016.11.064</pub-id><pub-id pub-id-type="pmid">27899228</pub-id><pub-id pub-id-type="pmcid">PMC7115548</pub-id></element-citation></ref><ref id="B81-ijms-24-01701"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z.</given-names></name></person-group><article-title>Elicitation of Immunity in Mice After Immunization with the S2 Subunit of the Severe Acute Respiratory Syndrome Coronavirus</article-title><source>DNA Cell Biol.</source><year>2005</year><volume>24</volume><fpage>510</fpage><lpage>515</lpage><pub-id pub-id-type="doi">10.1089/dna.2005.24.510</pub-id><pub-id pub-id-type="pmid">16101349</pub-id></element-citation></ref><ref id="B82-ijms-24-01701"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lip</surname><given-names>K.-M.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Keng</surname><given-names>C.-T.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>A.</given-names></name><name name-style="western"><surname>Oh</surname><given-names>H.-L.J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z.-H.</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>L.-A.</given-names></name><name name-style="western"><surname>Chou</surname><given-names>C.-F.</given-names></name><name name-style="western"><surname>Fielding</surname><given-names>B.C.</given-names></name><etal/></person-group><article-title>Monoclonal Antibodies Targeting the HR2 Domain and the Region Immediately Upstream of the HR2 of the S Protein Neutralize In Vitro Infection of Severe Acute Respiratory Syndrome Coronavirus</article-title><source>J. Virol.</source><year>2006</year><volume>80</volume><fpage>941</fpage><lpage>950</lpage><pub-id pub-id-type="doi">10.1128/JVI.80.2.941-950.2006</pub-id><pub-id pub-id-type="pmid">16378996</pub-id><pub-id pub-id-type="pmcid">PMC1346840</pub-id></element-citation></ref><ref id="B83-ijms-24-01701"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elshabrawy</surname><given-names>H.A.</given-names></name><name name-style="western"><surname>Coughlin</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Baker</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Prabhakar</surname><given-names>B.S.</given-names></name></person-group><article-title>Human Monoclonal Antibodies against Highly Conserved HR1 and HR2 Domains of the SARS-CoV Spike Protein Are More Broadly Neutralizing</article-title><source>PLoS ONE</source><year>2012</year><volume>7</volume><elocation-id>e50366</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0050366</pub-id><pub-id pub-id-type="pmid">23185609</pub-id><pub-id pub-id-type="pmcid">PMC3503966</pub-id></element-citation></ref><ref id="B84-ijms-24-01701"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>N.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>R.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>B.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Duan</surname><given-names>C.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>H.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>Q.</given-names></name></person-group><article-title>Boosted expression of the SARS-CoV nucleocapsid protein in tobacco and its immunogenicity in mice</article-title><source>Vaccine</source><year>2009</year><volume>27</volume><fpage>5001</fpage><lpage>5007</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2009.05.073</pub-id><pub-id pub-id-type="pmid">19523911</pub-id><pub-id pub-id-type="pmcid">PMC7115566</pub-id></element-citation></ref><ref id="B85-ijms-24-01701"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>S.-J.</given-names></name><name name-style="western"><surname>Leng</surname><given-names>C.-H.</given-names></name><name name-style="western"><surname>Lien</surname><given-names>S.-P.</given-names></name><name name-style="western"><surname>Chi</surname><given-names>H.-Y.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>C.-Y.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>C.-L.</given-names></name><name name-style="western"><surname>Lian</surname><given-names>W.-C.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C.-J.</given-names></name><name name-style="western"><surname>Hsieh</surname><given-names>S.-L.</given-names></name><name name-style="western"><surname>Chong</surname><given-names>P.</given-names></name></person-group><article-title>Immunological characterizations of the nucleocapsid protein based SARS vaccine candidates</article-title><source>Vaccine</source><year>2006</year><volume>24</volume><fpage>3100</fpage><lpage>3108</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2006.01.058</pub-id><pub-id pub-id-type="pmid">16494977</pub-id><pub-id pub-id-type="pmcid">PMC7115648</pub-id></element-citation></ref><ref id="B86-ijms-24-01701"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Siddiqui</surname><given-names>P.</given-names></name><name name-style="western"><surname>Niu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>S.</given-names></name></person-group><article-title>Identification of Immunodominant Epitopes on the Membrane Protein of the Severe Acute Respiratory Syndrome-Associated Coronavirus</article-title><source>J. Clin. Microbiol.</source><year>2005</year><volume>43</volume><fpage>3718</fpage><lpage>3726</lpage><pub-id pub-id-type="doi">10.1128/JCM.43.8.3718-3726.2005</pub-id><pub-id pub-id-type="pmid">16081901</pub-id><pub-id pub-id-type="pmcid">PMC1234014</pub-id></element-citation></ref><ref id="B87-ijms-24-01701"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Srivastava</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kamthania</surname><given-names>M.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>S.</given-names></name><name name-style="western"><surname>Saxena</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>N.</given-names></name></person-group><article-title>Structural basis of development of multi-epitope vaccine against Middle East respiratory syndrome using in silico approach</article-title><source>Infect. Drug Resist.</source><year>2018</year><volume>11</volume><fpage>2377</fpage><lpage>2391</lpage><pub-id pub-id-type="doi">10.2147/IDR.S175114</pub-id><pub-id pub-id-type="pmid">30538505</pub-id><pub-id pub-id-type="pmcid">PMC6254671</pub-id></element-citation></ref><ref id="B88-ijms-24-01701"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Srivastava</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kamthania</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pandey</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Saxena</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Saxena</surname><given-names>V.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>N.</given-names></name></person-group><article-title>Design of novel multi-epitope vaccines against severe acute respiratory syndrome validated through multistage molecular interaction and dynamics</article-title><source>J. Biomol. Struct. Dyn.</source><year>2019</year><volume>37</volume><fpage>4345</fpage><lpage>4360</lpage><pub-id pub-id-type="doi">10.1080/07391102.2018.1548977</pub-id><pub-id pub-id-type="pmid">30457455</pub-id></element-citation></ref><ref id="B89-ijms-24-01701"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tian</surname><given-names>J.-H.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>N.</given-names></name><name name-style="western"><surname>Haupt</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>H.</given-names></name><name name-style="western"><surname>Weston</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hammond</surname><given-names>H.</given-names></name><name name-style="western"><surname>Logue</surname><given-names>J.</given-names></name><name name-style="western"><surname>Portnoff</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Norton</surname><given-names>J.</given-names></name><name name-style="western"><surname>Guebre-Xabier</surname><given-names>M.</given-names></name><etal/></person-group><article-title>SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice</article-title><source>Nat. Commun.</source><year>2021</year><volume>12</volume><fpage>1</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1038/s41467-020-20653-8</pub-id><pub-id pub-id-type="pmid">33446655</pub-id><pub-id pub-id-type="pmcid">PMC7809486</pub-id></element-citation></ref><ref id="B90-ijms-24-01701"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Keech</surname><given-names>C.</given-names></name><name name-style="western"><surname>Albert</surname><given-names>G.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>I.</given-names></name><name name-style="western"><surname>Robertson</surname><given-names>A.</given-names></name><name name-style="western"><surname>Reed</surname><given-names>P.</given-names></name><name name-style="western"><surname>Neal</surname><given-names>S.</given-names></name><name name-style="western"><surname>Plested</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cloney-Clark</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Phase 1&#8211;2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine</article-title><source>N. Engl. J. Med.</source><year>2020</year><volume>383</volume><fpage>2320</fpage><lpage>2332</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2026920</pub-id><pub-id pub-id-type="pmid">32877576</pub-id><pub-id pub-id-type="pmcid">PMC7494251</pub-id></element-citation></ref><ref id="B91-ijms-24-01701"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heath</surname><given-names>P.T.</given-names></name><name name-style="western"><surname>Galiza</surname><given-names>E.P.</given-names></name><name name-style="western"><surname>Baxter</surname><given-names>D.N.</given-names></name><name name-style="western"><surname>Boffito</surname><given-names>M.</given-names></name><name name-style="western"><surname>Browne</surname><given-names>D.</given-names></name><name name-style="western"><surname>Burns</surname><given-names>F.</given-names></name><name name-style="western"><surname>Chadwick</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Clark</surname><given-names>R.</given-names></name><name name-style="western"><surname>Cosgrove</surname><given-names>C.</given-names></name><name name-style="western"><surname>Galloway</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine</article-title><source>New Engl. J. Med.</source><year>2021</year><volume>385</volume><fpage>1172</fpage><lpage>1183</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2107659</pub-id><pub-id pub-id-type="pmid">34192426</pub-id><pub-id pub-id-type="pmcid">PMC8262625</pub-id></element-citation></ref><ref id="B92-ijms-24-01701"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dunkle</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Kotloff</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Gay</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>&#193;&#241;ez</surname><given-names>G.</given-names></name><name name-style="western"><surname>Adelglass</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Hern&#225;ndez</surname><given-names>A.Q.B.</given-names></name><name name-style="western"><surname>Harper</surname><given-names>W.L.</given-names></name><name name-style="western"><surname>Duncanson</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>McArthur</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Florescu</surname><given-names>D.F.</given-names></name><etal/></person-group><article-title>Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico</article-title><source>New Engl. J. Med.</source><year>2022</year><volume>386</volume><fpage>531</fpage><lpage>543</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2116185</pub-id><pub-id pub-id-type="pmid">34910859</pub-id><pub-id pub-id-type="pmcid">PMC8693692</pub-id></element-citation></ref><ref id="B93-ijms-24-01701"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kuo</surname><given-names>T.-Y.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>M.-Y.</given-names></name><name name-style="western"><surname>Coffman</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Campbell</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Traquina</surname><given-names>P.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Y.-J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L.T.-C.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.-C.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>C.-C.</given-names></name><etal/></person-group><article-title>Development of CpG-adjuvanted stable prefusion SARS-CoV-2 spike antigen as a subunit vaccine against COVID-19</article-title><source>Sci. Rep.</source><year>2020</year><volume>10</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1038/s41598-020-77077-z</pub-id><pub-id pub-id-type="pmid">33208827</pub-id><pub-id pub-id-type="pmcid">PMC7676267</pub-id></element-citation></ref><ref id="B94-ijms-24-01701"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hsieh</surname><given-names>S.-M.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>M.-C.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.-H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>W.-S.</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>S.-J.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>S.-H.</given-names></name><name name-style="western"><surname>Ko</surname><given-names>W.-C.</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>K.-P.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>N.-C.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>Y.-L.</given-names></name><etal/></person-group><article-title>Safety and immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901: Interim results of a large-scale, double-blind, randomised, placebo-controlled phase 2 trial in Taiwan</article-title><source>Lancet Respir. Med.</source><year>2021</year><volume>9</volume><fpage>1396</fpage><lpage>1406</lpage><pub-id pub-id-type="doi">10.1016/S2213-2600(21)00402-1</pub-id><pub-id pub-id-type="pmid">34655522</pub-id><pub-id pub-id-type="pmcid">PMC8514195</pub-id></element-citation></ref><ref id="B95-ijms-24-01701"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>L.</given-names></name><name name-style="western"><surname>Honda-Okubo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Carlock</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Baldwin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Piplani</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bebin-Blackwell</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Forgacs</surname><given-names>D.</given-names></name><name name-style="western"><surname>Sakamoto</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Immunisation of ferrets and mice with recombinant SARS-CoV-2 spike protein formulated with Advax-SM adjuvant protects against COVID-19 infection</article-title><source>Vaccine</source><year>2021</year><volume>39</volume><fpage>5940</fpage><lpage>5953</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2021.07.087</pub-id><pub-id pub-id-type="pmid">34420786</pub-id><pub-id pub-id-type="pmcid">PMC8328570</pub-id></element-citation></ref><ref id="B96-ijms-24-01701"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>L.</given-names></name><name name-style="western"><surname>Honda-Okubo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Baldwin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bowen</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bielefeldt-Ohmann</surname><given-names>H.</given-names></name><name name-style="western"><surname>Petrovsky</surname><given-names>N.</given-names></name></person-group><article-title>Covax-19/Spikogen&#174; vaccine based on recombinant spike protein extracellular domain with Advax-CpG55.2 adjuvant provides single dose protection against SARS-CoV-2 infection in hamsters</article-title><source>Vaccine</source><year>2022</year><volume>40</volume><fpage>3182</fpage><lpage>3192</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2022.04.041</pub-id><pub-id pub-id-type="pmid">35465982</pub-id><pub-id pub-id-type="pmcid">PMC9013662</pub-id></element-citation></ref><ref id="B97-ijms-24-01701"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tabarsi</surname><given-names>P.</given-names></name><name name-style="western"><surname>Anjidani</surname><given-names>N.</given-names></name><name name-style="western"><surname>Shahpari</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mardani</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sabzvari</surname><given-names>A.</given-names></name><name name-style="western"><surname>Yazdani</surname><given-names>B.</given-names></name><name name-style="western"><surname>Roshanzamir</surname><given-names>K.</given-names></name><name name-style="western"><surname>Bayatani</surname><given-names>B.</given-names></name><name name-style="western"><surname>Taheri</surname><given-names>A.</given-names></name><name name-style="western"><surname>Petrovsky</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Safety and immunogenicity of SpikoGen&#174;, an Advax-CpG55.2-adjuvanted SARS-CoV-2 spike protein vaccine: A phase 2 randomized placebo-controlled trial in both seropositive and seronegative populations</article-title><source>Clin. Microbiol. Infect.</source><year>2022</year><volume>28</volume><fpage>1263</fpage><lpage>1271</lpage><pub-id pub-id-type="doi">10.1016/j.cmi.2022.04.004</pub-id><pub-id pub-id-type="pmid">35436611</pub-id><pub-id pub-id-type="pmcid">PMC9012510</pub-id></element-citation></ref><ref id="B98-ijms-24-01701"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Banihashemi</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Es-Haghi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mehrabadi</surname><given-names>M.H.F.</given-names></name><name name-style="western"><surname>Nofeli</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mokarram</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Ranjbar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Salman</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hajimoradi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Razaz</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Taghdiri</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Safety and Efficacy of Combined Intramuscular/Intranasal RAZI-COV PARS Vaccine Candidate Against SARS-CoV-2: A Preclinical Study in Several Animal Models</article-title><source>Front. Immunol.</source><year>2022</year><volume>13</volume><fpage>836745</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2022.836745</pub-id><pub-id pub-id-type="pmid">35693788</pub-id><pub-id pub-id-type="pmcid">PMC9179012</pub-id></element-citation></ref><ref id="B99-ijms-24-01701"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liang</surname><given-names>J.G.</given-names></name><name name-style="western"><surname>Su</surname><given-names>D.</given-names></name><name name-style="western"><surname>Song</surname><given-names>T.-Z.</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>R.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>P.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><etal/></person-group><article-title>S-Trimer, a COVID-19 subunit vaccine candidate, induces protective immunity in nonhuman primates</article-title><source>Nat. Commun.</source><year>2021</year><volume>12</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1038/s41467-021-21634-1</pub-id><pub-id pub-id-type="pmid">33649323</pub-id><pub-id pub-id-type="pmcid">PMC7921634</pub-id></element-citation></ref><ref id="B100-ijms-24-01701"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Richmond</surname><given-names>P.</given-names></name><name name-style="western"><surname>Hatchuel</surname><given-names>L.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>B.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Smolenov</surname><given-names>I.</given-names></name><name name-style="western"><surname>Li</surname><given-names>P.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Han</surname><given-names>H.H.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: A phase 1, randomised, double-blind, placebo-controlled trial</article-title><source>Lancet</source><year>2021</year><volume>397</volume><fpage>682</fpage><lpage>694</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(21)00241-5</pub-id><pub-id pub-id-type="pmid">33524311</pub-id><pub-id pub-id-type="pmcid">PMC7906655</pub-id></element-citation></ref><ref id="B101-ijms-24-01701"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bravo</surname><given-names>L.</given-names></name><name name-style="western"><surname>Smolenov</surname><given-names>I.</given-names></name><name name-style="western"><surname>Han</surname><given-names>H.H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>P.</given-names></name><name name-style="western"><surname>Hosain</surname><given-names>R.</given-names></name><name name-style="western"><surname>Rockhold</surname><given-names>F.</given-names></name><name name-style="western"><surname>Clemens</surname><given-names>S.A.C.</given-names></name><name name-style="western"><surname>Roa</surname><given-names>C.</given-names></name><name name-style="western"><surname>Borja-Tabora</surname><given-names>C.</given-names></name><name name-style="western"><surname>Quinsaat</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: A phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial</article-title><source>Lancet</source><year>2022</year><volume>399</volume><fpage>461</fpage><lpage>472</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(22)00055-1</pub-id><pub-id pub-id-type="pmid">35065705</pub-id><pub-id pub-id-type="pmcid">PMC8776284</pub-id></element-citation></ref><ref id="B102-ijms-24-01701"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tran</surname><given-names>T.N.M.</given-names></name><name name-style="western"><surname>May</surname><given-names>B.P.</given-names></name><name name-style="western"><surname>Ung</surname><given-names>T.T.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>T.T.T.</given-names></name><name name-style="western"><surname>Dinh</surname><given-names>V.L.</given-names></name><name name-style="western"><surname>Doan</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Tran</surname><given-names>T.V.</given-names></name><name name-style="western"><surname>Khong</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hua</surname><given-names>H.Q.H.</given-names></name><etal/></person-group><article-title>Preclinical Immune Response and Safety Evaluation of the Protein Subunit Vaccine Nanocovax for COVID-19</article-title><source>Front. Immunol.</source><year>2021</year><volume>12</volume><fpage>766112</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2021.766112</pub-id><pub-id pub-id-type="pmid">34938290</pub-id><pub-id pub-id-type="pmcid">PMC8685539</pub-id></element-citation></ref><ref id="B103-ijms-24-01701"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nguyen</surname><given-names>T.P.</given-names></name><name name-style="western"><surname>Do</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Phan</surname><given-names>L.T.</given-names></name><name name-style="western"><surname>Dinh</surname><given-names>D.V.</given-names></name><name name-style="western"><surname>Khong</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hoang</surname><given-names>L.V.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>T.V.</given-names></name><name name-style="western"><surname>Pham</surname><given-names>H.N.</given-names></name><name name-style="western"><surname>Chu</surname><given-names>M.V.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>T.T.</given-names></name><etal/></person-group><article-title>Safety and immunogenicity of Nanocovax, a SARS-CoV-2 recombinant spike protein vaccine: Interim results of a double-blind, randomised controlled phase 1 and 2 trial</article-title><source>Lancet Reg. Health-West. Pac.</source><year>2022</year><volume>24</volume><fpage>100474</fpage><pub-id pub-id-type="doi">10.1016/j.lanwpc.2022.100474</pub-id><pub-id pub-id-type="pmid">35602004</pub-id><pub-id pub-id-type="pmcid">PMC9108376</pub-id></element-citation></ref><ref id="B104-ijms-24-01701"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Francica</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Flynn</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Foulds</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Noe</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Werner</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Moore</surname><given-names>I.N.</given-names></name><name name-style="western"><surname>Gagne</surname><given-names>M.</given-names></name><name name-style="western"><surname>Johnston</surname><given-names>T.S.</given-names></name><name name-style="western"><surname>Tucker</surname><given-names>C.</given-names></name><name name-style="western"><surname>Davis</surname><given-names>R.L.</given-names></name><etal/></person-group><article-title>Vaccination with SARS-CoV-2 Spike Protein and AS03 Adjuvant Induces Rapid Anamnestic Antibodies in the Lung and Protects Against Virus Challenge in Nonhuman Primates</article-title><source>BioRxiv</source><year>2021</year><pub-id pub-id-type="doi">10.1101/2021.03.02.433390</pub-id><pub-id pub-id-type="arxiv">2021.03.02.433390</pub-id></element-citation></ref><ref id="B105-ijms-24-01701"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goepfert</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Chabanon</surname><given-names>A.-L.</given-names></name><name name-style="western"><surname>Bonaparte</surname><given-names>M.I.</given-names></name><name name-style="western"><surname>Davis</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Essink</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Frank</surname><given-names>I.</given-names></name><name name-style="western"><surname>Haney</surname><given-names>O.</given-names></name><name name-style="western"><surname>Janosczyk</surname><given-names>H.</given-names></name><name name-style="western"><surname>Keefer</surname><given-names>M.C.</given-names></name><etal/></person-group><article-title>Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: Interim results of a randomised, placebo-controlled, phase 1&#8211;2, dose-ranging study</article-title><source>Lancet Infect. Dis.</source><year>2021</year><volume>21</volume><fpage>1257</fpage><lpage>1270</lpage><comment>Erratum in <italic toggle="yes">Lancet Infect. Dis.</italic><bold>2022</bold>, <italic toggle="yes">22</italic>, e207</comment><pub-id pub-id-type="doi">10.1016/S1473-3099(21)00147-X</pub-id><pub-id pub-id-type="pmid">33887209</pub-id><pub-id pub-id-type="pmcid">PMC8055206</pub-id></element-citation></ref><ref id="B106-ijms-24-01701"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sridhar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Joaquin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bonaparte</surname><given-names>M.I.</given-names></name><name name-style="western"><surname>Bueso</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chabanon</surname><given-names>A.-L.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chicz</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Diemert</surname><given-names>D.</given-names></name><name name-style="western"><surname>Essink</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: Interim findings from a phase 2, randomised, dose-finding, multicentre study</article-title><source>Lancet Infect. Dis.</source><year>2022</year><volume>22</volume><fpage>636</fpage><lpage>648</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(21)00764-7</pub-id><pub-id pub-id-type="pmid">35090638</pub-id><pub-id pub-id-type="pmcid">PMC8789245</pub-id></element-citation></ref><ref id="B107-ijms-24-01701"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Dai</surname><given-names>L.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>X.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Han</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zou</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Fast and long-lasting immune response to S-trimer COVID-19 vaccine adjuvanted by PIKA</article-title><source>Mol. Biomed.</source><year>2021</year><volume>2</volume><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1186/s43556-021-00054-z</pub-id><pub-id pub-id-type="pmid">34766005</pub-id><pub-id pub-id-type="pmcid">PMC8475395</pub-id></element-citation></ref><ref id="B108-ijms-24-01701"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>C.</given-names></name><name name-style="western"><surname>An</surname><given-names>J.</given-names></name><name name-style="western"><surname>Song</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>P.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Development of recombinant COVID-19 vaccine based on CHO-produced, prefusion spike trimer and alum/CpG adjuvants</article-title><source>Vaccine</source><year>2021</year><volume>39</volume><fpage>7001</fpage><lpage>7011</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2021.10.066</pub-id><pub-id pub-id-type="pmid">34750014</pub-id><pub-id pub-id-type="pmcid">PMC8556577</pub-id></element-citation></ref><ref id="B109-ijms-24-01701"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Joyce</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W.-H.</given-names></name><name name-style="western"><surname>Sankhala</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Hajduczki</surname><given-names>A.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>P.V.</given-names></name><name name-style="western"><surname>Choe</surname><given-names>M.</given-names></name><name name-style="western"><surname>Martinez</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>W.C.</given-names></name><name name-style="western"><surname>Peterson</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Morrison</surname><given-names>E.B.</given-names></name><etal/></person-group><article-title>SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity</article-title><source>Cell Rep.</source><year>2021</year><volume>37</volume><fpage>110143</fpage><pub-id pub-id-type="doi">10.1016/j.celrep.2021.110143</pub-id><pub-id pub-id-type="pmid">34919799</pub-id><pub-id pub-id-type="pmcid">PMC8651551</pub-id></element-citation></ref><ref id="B110-ijms-24-01701"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carmen</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Shrivastava</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>A.</given-names></name><name name-style="western"><surname>Morrison</surname><given-names>E.B.</given-names></name><name name-style="western"><surname>Sankhala</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W.-H.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>W.C.</given-names></name><name name-style="western"><surname>Bolton</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Matyas</surname><given-names>G.R.</given-names></name><etal/></person-group><article-title>SARS-CoV-2 ferritin nanoparticle vaccine induces robust innate immune activity driving polyfunctional spike-specific T cell responses</article-title><source>NPJ Vaccines</source><year>2021</year><volume>6</volume><fpage>1</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1038/s41541-021-00414-4</pub-id><pub-id pub-id-type="pmid">34903722</pub-id><pub-id pub-id-type="pmcid">PMC8668928</pub-id></element-citation></ref><ref id="B111-ijms-24-01701"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Joyce</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>King</surname><given-names>H.A.D.</given-names></name><name name-style="western"><surname>Elakhal-Naouar</surname><given-names>I.</given-names></name><name name-style="western"><surname>Ahmed</surname><given-names>A.</given-names></name><name name-style="western"><surname>Peachman</surname><given-names>K.K.</given-names></name><name name-style="western"><surname>Cincotta</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Subra</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>P.V.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W.-H.</given-names></name><etal/></person-group><article-title>A SARS-CoV-2 ferritin nanoparticle vaccine elicits protective immune responses in nonhuman primates</article-title><source>Sci. Transl. Med.</source><year>2022</year><volume>14</volume><fpage>eabi5735</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.abi5735</pub-id><pub-id pub-id-type="pmid">34914540</pub-id></element-citation></ref><ref id="B112-ijms-24-01701"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hern&#225;ndez-Bernal</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ricardo-Cobas</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Mart&#237;n-Bauta</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Navarro-Rodr&#237;guez</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Pi&#241;era-Mart&#237;nez</surname><given-names>M.</given-names></name><name name-style="western"><surname>Quintana-Guerra</surname><given-names>J.</given-names></name><name name-style="western"><surname>Urrutia-P&#233;rez</surname><given-names>K.</given-names></name><name name-style="western"><surname>Urrutia-P&#233;rez</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ch&#225;vez-Chong</surname><given-names>C.O.</given-names></name><name name-style="western"><surname>Azor-Hern&#225;ndez</surname><given-names>J.L.</given-names></name><etal/></person-group><article-title>Safety, tolerability, and immunogenicity of a SARS-CoV-2 recombinant spike RBD protein vaccine: A randomised, double-blind, placebo-controlled, phase 1-2 clinical trial (ABDALA Study)</article-title><source>Eclinicalmedicine</source><year>2022</year><volume>46</volume><fpage>101383</fpage><pub-id pub-id-type="doi">10.1016/j.eclinm.2022.101383</pub-id><pub-id pub-id-type="pmid">35434578</pub-id><pub-id pub-id-type="pmcid">PMC8994669</pub-id></element-citation></ref><ref id="B113-ijms-24-01701"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Dai</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>He</surname><given-names>P.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: Two randomised, double-blind, placebo-controlled, phase 1 and 2 trials</article-title><source>Lancet Infect. Dis.</source><year>2021</year><volume>21</volume><fpage>1107</fpage><lpage>1119</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(21)00127-4</pub-id><pub-id pub-id-type="pmid">33773111</pub-id><pub-id pub-id-type="pmcid">PMC7990482</pub-id></element-citation></ref><ref id="B114-ijms-24-01701"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dai</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hadinegoro</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Erkin</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ying</surname><given-names>Z.</given-names></name><name name-style="western"><surname>He</surname><given-names>P.</given-names></name><name name-style="western"><surname>Girsang</surname><given-names>R.T.</given-names></name><name name-style="western"><surname>Vergara</surname><given-names>H.</given-names></name><name name-style="western"><surname>Akram</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Efficacy and Safety of the RBD-Dimer&#8211;Based Covid-19 Vaccine ZF2001 in Adults</article-title><source>N. Engl. J. Med.</source><year>2022</year><volume>386</volume><fpage>2097</fpage><lpage>2111</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2202261</pub-id><pub-id pub-id-type="pmid">35507481</pub-id><pub-id pub-id-type="pmcid">PMC9127771</pub-id></element-citation></ref><ref id="B115-ijms-24-01701"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Valdes-Balbin</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Santana-Mederos</surname><given-names>D.</given-names></name><name name-style="western"><surname>Quintero</surname><given-names>L.</given-names></name><name name-style="western"><surname>Fern&#225;ndez</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rodriguez</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ramirez</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>Perez-Nicado</surname><given-names>R.</given-names></name><name name-style="western"><surname>Acosta</surname><given-names>C.</given-names></name><name name-style="western"><surname>M&#233;ndez</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ricardo</surname><given-names>M.G.</given-names></name><etal/></person-group><article-title>SARS-CoV-2 RBD-Tetanus Toxoid Conjugate Vaccine Induces a Strong Neutralizing Immunity in Preclinical Studies</article-title><source>ACS Chem. Biol.</source><year>2021</year><volume>16</volume><fpage>1223</fpage><lpage>1233</lpage><pub-id pub-id-type="doi">10.1021/acschembio.1c00272</pub-id><pub-id pub-id-type="pmid">34219448</pub-id></element-citation></ref><ref id="B116-ijms-24-01701"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eugenia-Toledo-Roman&#237;</surname><given-names>M.</given-names></name><name name-style="western"><surname>Verdecia-S&#225;nchez</surname><given-names>L.</given-names></name><name name-style="western"><surname>Rodr&#237;guez-Gonz&#225;lez</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rodr&#237;guez-Noda</surname><given-names>L.</given-names></name><name name-style="western"><surname>Valenzuela-Silva</surname><given-names>C.</given-names></name><name name-style="western"><surname>Paredes-Moreno</surname><given-names>B.</given-names></name><name name-style="western"><surname>S&#225;nchez-Ram&#237;rez</surname><given-names>B.</given-names></name><name name-style="western"><surname>P&#233;rez-Nicado</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gonz&#225;lez-Mugica</surname><given-names>R.</given-names></name><name name-style="western"><surname>Hern&#225;ndez-Garc&#237;a</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme: Open label phase I and phase IIa clinical trials</article-title><source>Vaccine</source><year>2022</year><volume>40</volume><fpage>4220</fpage><lpage>4230</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2022.05.082</pub-id><pub-id pub-id-type="pmid">35691871</pub-id><pub-id pub-id-type="pmcid">PMC9167831</pub-id></element-citation></ref><ref id="B117-ijms-24-01701"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eugenia-Toledo-Roman&#237;</surname><given-names>M.</given-names></name><name name-style="western"><surname>Garc&#237;a-Carmenate</surname><given-names>M.</given-names></name><name name-style="western"><surname>Valenzuela-Silva</surname><given-names>C.</given-names></name><name name-style="western"><surname>Baldoqu&#237;n-Rodr&#237;guez</surname><given-names>W.</given-names></name><name name-style="western"><surname>Mart&#237;nez-P&#233;rez</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rodr&#237;guez-Gonz&#225;lez</surname><given-names>M.</given-names></name><name name-style="western"><surname>Paredes-Moreno</surname><given-names>B.</given-names></name><name name-style="western"><surname>Mendoza-Hern&#225;ndez</surname><given-names>I.</given-names></name><name name-style="western"><surname>Gonz&#225;lez-Mujica</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sam&#243;n-Tabio</surname><given-names>O.</given-names></name><etal/></person-group><article-title>Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combination with SOBERANA-PLUS: Double-blind, randomised, placebo-controlled phase 3 clinical trial</article-title><source>MedRxiv</source><year>2021</year><pub-id pub-id-type="arxiv">2021.10.31.21265703</pub-id><pub-id pub-id-type="doi">10.2139/ssrn.4174293</pub-id><pub-id pub-id-type="pmcid">PMC9803910</pub-id><pub-id pub-id-type="pmid">36618081</pub-id></element-citation></ref><ref id="B118-ijms-24-01701"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>W.-H.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kundu</surname><given-names>R.T.</given-names></name><name name-style="western"><surname>Adhikari</surname><given-names>R.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.</given-names></name><name name-style="western"><surname>Versteeg</surname><given-names>L.</given-names></name><name name-style="western"><surname>Poveda</surname><given-names>C.</given-names></name><name name-style="western"><surname>Keegan</surname><given-names>B.</given-names></name><name name-style="western"><surname>Villar</surname><given-names>M.J.</given-names></name><etal/></person-group><article-title>Genetic modification to design a stable yeast-expressed recombinant SARS-CoV-2 receptor binding domain as a COVID-19 vaccine candidate</article-title><source>Biochim. Biophys. Acta. BBA Gen. Subj.</source><year>2021</year><volume>1865</volume><fpage>129893</fpage><pub-id pub-id-type="doi">10.1016/j.bbagen.2021.129893</pub-id><pub-id pub-id-type="pmcid">PMC7955913</pub-id><pub-id pub-id-type="pmid">33731300</pub-id></element-citation></ref><ref id="B119-ijms-24-01701"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pollet</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W.-H.</given-names></name><name name-style="western"><surname>Versteeg</surname><given-names>L.</given-names></name><name name-style="western"><surname>Keegan</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zhan</surname><given-names>B.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kundu</surname><given-names>R.</given-names></name><name name-style="western"><surname>Adhikari</surname><given-names>R.</given-names></name><etal/></person-group><article-title>SARS-CoV-2 RBD219-N1C1: A yeast-expressed SARS-CoV-2 recombinant receptor-binding domain candidate vaccine stimulates virus neutralizing antibodies and T-cell immunity in mice</article-title><source>Hum. Vaccines Immunother.</source><year>2021</year><volume>17</volume><fpage>2356</fpage><lpage>2366</lpage><pub-id pub-id-type="doi">10.1080/21645515.2021.1901545</pub-id><pub-id pub-id-type="pmcid">PMC8054496</pub-id><pub-id pub-id-type="pmid">33847226</pub-id></element-citation></ref><ref id="B120-ijms-24-01701"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thuluva</surname><given-names>S.</given-names></name><name name-style="western"><surname>Paradkar</surname><given-names>V.</given-names></name><name name-style="western"><surname>Gunneri</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Yerroju</surname><given-names>V.</given-names></name><name name-style="western"><surname>Mogulla</surname><given-names>R.</given-names></name><name name-style="western"><surname>Turaga</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kyasani</surname><given-names>M.</given-names></name><name name-style="western"><surname>Manoharan</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Medigeshi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Evaluation of safety and immunogenicity of receptor-binding domain-based COVID-19 vaccine (Corbevax) to select the optimum formulation in open-label, multicentre, and randomised phase-1/2 and phase-2 clinical trials</article-title><source>Ebiomedicine</source><year>2022</year><volume>83</volume><fpage>104217</fpage><pub-id pub-id-type="doi">10.1016/j.ebiom.2022.104217</pub-id><pub-id pub-id-type="pmid">35970020</pub-id><pub-id pub-id-type="pmcid">PMC9372721</pub-id></element-citation></ref><ref id="B121-ijms-24-01701"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thuluva</surname><given-names>S.</given-names></name><name name-style="western"><surname>Paradkar</surname><given-names>V.</given-names></name><name name-style="western"><surname>Turaga</surname><given-names>K.</given-names></name><name name-style="western"><surname>Gunneri</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Yerroju</surname><given-names>V.</given-names></name><name name-style="western"><surname>Mogulla</surname><given-names>R.</given-names></name><name name-style="western"><surname>Suneetha</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kyasani</surname><given-names>M.</given-names></name><name name-style="western"><surname>Manoharan</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Adabala</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Immunogenic superiority and safety of Biological E&#8217;s CORBEVAX&#8482; vaccine compared to COVISHIELD&#8482; (ChAdOx1 nCoV-19) vaccine studied in a phase III, single blind, multicenter, randomized clinical trial</article-title><source>MedRxiv</source><year>2022</year><pub-id pub-id-type="doi">10.1101/2022.03.20.22271891</pub-id><pub-id pub-id-type="arxiv">2022.03.20.22271891</pub-id><pub-id pub-id-type="pmcid">PMC10294721</pub-id><pub-id pub-id-type="pmid">37113012</pub-id></element-citation></ref><ref id="B122-ijms-24-01701"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walls</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Fiala</surname><given-names>B.</given-names></name><name name-style="western"><surname>Sch&#228;fer</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wrenn</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pham</surname><given-names>M.N.</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tse</surname><given-names>L.V.</given-names></name><name name-style="western"><surname>Shehata</surname><given-names>L.</given-names></name><name name-style="western"><surname>O&#8217;Connor</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2</article-title><source>Cell</source><year>2020</year><volume>183</volume><fpage>1367</fpage><lpage>1382.e17</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.10.043</pub-id><pub-id pub-id-type="pmid">33160446</pub-id><pub-id pub-id-type="pmcid">PMC7604136</pub-id></element-citation></ref><ref id="B123-ijms-24-01701"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arunachalam</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Walls</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Golden</surname><given-names>N.</given-names></name><name name-style="western"><surname>Atyeo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Fischinger</surname><given-names>S.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>Aye</surname><given-names>P.</given-names></name><name name-style="western"><surname>Navarro</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Lai</surname><given-names>L.</given-names></name><name name-style="western"><surname>Edara</surname><given-names>V.V.</given-names></name><etal/></person-group><article-title>Adjuvanting a subunit COVID-19 vaccine to induce protective immunity</article-title><source>Nature</source><year>2021</year><volume>594</volume><fpage>253</fpage><lpage>258</lpage><pub-id pub-id-type="doi">10.1038/s41586-021-03530-2</pub-id><pub-id pub-id-type="pmid">33873199</pub-id></element-citation></ref><ref id="B124-ijms-24-01701"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>W.S.</given-names></name><name name-style="western"><surname>Heo</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Jung</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.-W.</given-names></name><name name-style="western"><surname>Park</surname><given-names>K.-H.</given-names></name><name name-style="western"><surname>Eom</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Jeong</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Safety and immunogenicity of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03: A randomised, placebo-controlled, observer-blinded phase 1/2 trial</article-title><source>Eclinicalmedicine</source><year>2022</year><volume>51</volume><fpage>101569</fpage><pub-id pub-id-type="doi">10.1016/j.eclinm.2022.101569</pub-id><pub-id pub-id-type="pmid">35879941</pub-id><pub-id pub-id-type="pmcid">PMC9304916</pub-id></element-citation></ref><ref id="B125-ijms-24-01701"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Pei</surname><given-names>R.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>P.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ou</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>J.</given-names></name><name name-style="western"><surname>Guan</surname><given-names>W.</given-names></name><etal/></person-group><article-title>Safety and immunogenicity of a recombinant interferon-armed RBD dimer vaccine (V-01) for COVID-19 in healthy adults: A randomized, double-blind, placebo-controlled, Phase I trial</article-title><source>Emerg. Microbes Infect.</source><year>2021</year><volume>10</volume><fpage>1589</fpage><lpage>1597</lpage><pub-id pub-id-type="doi">10.1080/22221751.2021.1951126</pub-id><pub-id pub-id-type="pmid">34197281</pub-id><pub-id pub-id-type="pmcid">PMC8366678</pub-id></element-citation></ref><ref id="B126-ijms-24-01701"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Song</surname><given-names>T.-Z.</given-names></name><name name-style="western"><surname>Pu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>L.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>J.</given-names></name><name name-style="western"><surname>Meng</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Interferon-armed RBD dimer enhances the immunogenicity of RBD for sterilizing immunity against SARS-CoV-2</article-title><source>Cell Res.</source><year>2021</year><volume>31</volume><fpage>1011</fpage><lpage>1023</lpage><comment>Erratum in <italic toggle="yes">Cell Res.</italic><bold>2021</bold>, <italic toggle="yes">31</italic>, 1222</comment><pub-id pub-id-type="doi">10.1038/s41422-021-00531-8</pub-id><pub-id pub-id-type="pmid">34267349</pub-id><pub-id pub-id-type="pmcid">PMC8280646</pub-id></element-citation></ref><ref id="B127-ijms-24-01701"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>X.-Y.</given-names></name><name name-style="western"><surname>Mahmood</surname><given-names>S.F.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>F.</given-names></name><name name-style="western"><surname>Cheah</surname><given-names>W.K.</given-names></name><name name-style="western"><surname>Ahmad</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sohail</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Ahmad</surname><given-names>W.</given-names></name><name name-style="western"><surname>Suppan</surname><given-names>V.K.</given-names></name><name name-style="western"><surname>Sayeed</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Luxmi</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Efficacy of heterologous boosting against SARS-CoV-2 using a recombinant interferon-armed fusion protein vaccine (V-01): A randomized, double-blind and placebo-controlled phase III trial</article-title><source>Emerg. Microbes Infect.</source><year>2022</year><volume>11</volume><fpage>1910</fpage><lpage>1919</lpage><pub-id pub-id-type="doi">10.1080/22221751.2022.2088406</pub-id><pub-id pub-id-type="pmid">35686572</pub-id><pub-id pub-id-type="pmcid">PMC9347473</pub-id></element-citation></ref><ref id="B128-ijms-24-01701"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Bi</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Bao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Mo</surname><given-names>F.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity</article-title><source>Nature</source><year>2020</year><volume>586</volume><fpage>572</fpage><lpage>577</lpage><comment>Erratum in <italic toggle="yes">Nature</italic><bold>2021</bold>, <italic toggle="yes">590</italic>, E23</comment><pub-id pub-id-type="doi">10.1038/s41586-020-2599-8</pub-id><pub-id pub-id-type="pmid">32726802</pub-id></element-citation></ref><ref id="B129-ijms-24-01701"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alleva</surname><given-names>D.G.</given-names></name><name name-style="western"><surname>Delpero</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Scully</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Murikipudi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ragupathy</surname><given-names>R.</given-names></name><name name-style="western"><surname>Greaves</surname><given-names>E.K.</given-names></name><name name-style="western"><surname>Sathiyaseelan</surname><given-names>T.</given-names></name><name name-style="western"><surname>Haworth</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Shah</surname><given-names>N.J.</given-names></name><name name-style="western"><surname>Rao</surname><given-names>V.</given-names></name><etal/></person-group><article-title>Development of an IgG-Fc fusion COVID-19 subunit vaccine, AKS-452</article-title><source>Vaccine</source><year>2021</year><volume>39</volume><fpage>6601</fpage><lpage>6613</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2021.09.077</pub-id><pub-id pub-id-type="pmid">34642088</pub-id><pub-id pub-id-type="pmcid">PMC8491978</pub-id></element-citation></ref><ref id="B130-ijms-24-01701"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Janssen</surname><given-names>Y.F.</given-names></name><name name-style="western"><surname>Feitsma</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Boersma</surname><given-names>H.H.</given-names></name><name name-style="western"><surname>Alleva</surname><given-names>D.G.</given-names></name><name name-style="western"><surname>Lancaster</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Sathiyaseelan</surname><given-names>T.</given-names></name><name name-style="western"><surname>Murikipudi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Delpero</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Scully</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Ragupathy</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Phase I interim results of a phase I/II study of the IgG-Fc fusion COVID-19 subunit vaccine, AKS-452</article-title><source>Vaccine</source><year>2022</year><volume>40</volume><fpage>1253</fpage><lpage>1260</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2022.01.043</pub-id><pub-id pub-id-type="pmid">35115195</pub-id><pub-id pub-id-type="pmcid">PMC8802018</pub-id></element-citation></ref><ref id="B131-ijms-24-01701"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Royal</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Simpson</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>McCormick</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Phillips</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hume</surname><given-names>S.</given-names></name><name name-style="western"><surname>Morton</surname><given-names>J.</given-names></name><name name-style="western"><surname>Shepherd</surname><given-names>J.</given-names></name><name name-style="western"><surname>Oh</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Swope</surname><given-names>K.</given-names></name><name name-style="western"><surname>DeBeauchamp</surname><given-names>J.L.</given-names></name><etal/></person-group><article-title>Development of a SARS-CoV-2 Vaccine Candidate Using Plant-Based Manufacturing and a Tobacco Mosaic Virus-like Nano-Particle</article-title><source>Vaccines</source><year>2021</year><volume>9</volume><elocation-id>1347</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines9111347</pub-id><pub-id pub-id-type="pmid">34835278</pub-id><pub-id pub-id-type="pmcid">PMC8619098</pub-id></element-citation></ref><ref id="B132-ijms-24-01701"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>DeMarco</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Royal</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Severson</surname><given-names>W.E.</given-names></name><name name-style="western"><surname>Gabbard</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Hume</surname><given-names>S.</given-names></name><name name-style="western"><surname>Morton</surname><given-names>J.</given-names></name><name name-style="western"><surname>Swope</surname><given-names>K.</given-names></name><name name-style="western"><surname>Simpson</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Shepherd</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Bratcher</surname><given-names>B.</given-names></name><etal/></person-group><article-title>CoV-RBD121-NP Vaccine Candidate Protects against Symptomatic Disease following SARS-CoV-2 Challenge in K18-hACE2 Mice and Induces Protective Responses That Prevent COVID-19-Associated Immunopathology</article-title><source>Vaccines</source><year>2021</year><volume>9</volume><elocation-id>1346</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines9111346</pub-id><pub-id pub-id-type="pmid">34835277</pub-id><pub-id pub-id-type="pmcid">PMC8618284</pub-id></element-citation></ref><ref id="B133-ijms-24-01701"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krasilnikov</surname><given-names>I.V.</given-names></name><name name-style="western"><surname>Kudriavtsev</surname><given-names>A.V.</given-names></name><name name-style="western"><surname>Vakhrusheva</surname><given-names>A.V.</given-names></name><name name-style="western"><surname>Frolova</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Ivanov</surname><given-names>A.V.</given-names></name><name name-style="western"><surname>Stukova</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Romanovskaya-Romanko</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Vasilyev</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Mushenkova</surname><given-names>N.V.</given-names></name><name name-style="western"><surname>Isaev</surname><given-names>A.A.</given-names></name></person-group><article-title>Design and Immunological Properties of the Novel Subunit Virus-like Vaccine against SARS-CoV-2</article-title><source>Vaccines</source><year>2022</year><volume>10</volume><elocation-id>69</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines10010069</pub-id><pub-id pub-id-type="pmid">35062730</pub-id><pub-id pub-id-type="pmcid">PMC8782008</pub-id></element-citation></ref><ref id="B134-ijms-24-01701"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Siriwattananon</surname><given-names>K.</given-names></name><name name-style="western"><surname>Manopwisedjaroen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shanmugaraj</surname><given-names>B.</given-names></name><name name-style="western"><surname>Rattanapisit</surname><given-names>K.</given-names></name><name name-style="western"><surname>Phumiamorn</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sapsutthipas</surname><given-names>S.</given-names></name><name name-style="western"><surname>Trisiriwanich</surname><given-names>S.</given-names></name><name name-style="western"><surname>Prompetchara</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ketloy</surname><given-names>C.</given-names></name><name name-style="western"><surname>Buranapraditkun</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Plant-Produced Receptor-Binding Domain of SARS-CoV-2 Elicits Potent Neutralizing Responses in Mice and Non-human Primates</article-title><source>Front. Plant Sci.</source><year>2021</year><volume>12</volume><fpage>682953</fpage><pub-id pub-id-type="doi">10.3389/fpls.2021.682953</pub-id><pub-id pub-id-type="pmid">34054909</pub-id><pub-id pub-id-type="pmcid">PMC8158422</pub-id></element-citation></ref><ref id="B135-ijms-24-01701"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shanmugaraj</surname><given-names>B.</given-names></name><name name-style="western"><surname>Khorattanakulchai</surname><given-names>N.</given-names></name><name name-style="western"><surname>Panapitakkul</surname><given-names>C.</given-names></name><name name-style="western"><surname>Malla</surname><given-names>A.</given-names></name><name name-style="western"><surname>Im-Erbsin</surname><given-names>R.</given-names></name><name name-style="western"><surname>Inthawong</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sunyakumthorn</surname><given-names>P.</given-names></name><name name-style="western"><surname>Hunsawong</surname><given-names>T.</given-names></name><name name-style="western"><surname>Klungthong</surname><given-names>C.</given-names></name><name name-style="western"><surname>Reed</surname><given-names>M.C.</given-names></name><etal/></person-group><article-title>Preclinical evaluation of a plant-derived SARS-CoV-2 subunit vaccine: Protective efficacy, immunogenicity, safety, and toxicity</article-title><source>Vaccine</source><year>2022</year><volume>40</volume><fpage>4440</fpage><lpage>4452</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2022.05.087</pub-id><pub-id pub-id-type="pmid">35697573</pub-id><pub-id pub-id-type="pmcid">PMC9167921</pub-id></element-citation></ref><ref id="B136-ijms-24-01701"><label>136.</label><element-citation publication-type="patent"><person-group person-group-type="author"><name name-style="western"><surname>Ryzhikov</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Ryzhikov</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Bogryantseva</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Gavrilova</surname><given-names>E.V.</given-names></name><name name-style="western"><surname>Danilenko</surname><given-names>E.D.</given-names></name><name name-style="western"><surname>Imatdinov</surname><given-names>I.R.</given-names></name><name name-style="western"><surname>Maksyutov</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Nechaeva</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Popova</surname><given-names>A.Y.</given-names></name><name name-style="western"><surname>Pyankov</surname><given-names>O.V.</given-names></name><etal/></person-group><article-title>Vaccine Composition against COVID-19</article-title><source>RU Patent</source><patent>NO. 2743595C1</patent><day>20</day><month>February</month><year>2021</year></element-citation></ref><ref id="B137-ijms-24-01701"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ryzhikov</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Ryzhikov</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bogryantseva</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Danilenko</surname><given-names>E.D.</given-names></name><name name-style="western"><surname>Imatdinov</surname><given-names>I.R.</given-names></name><name name-style="western"><surname>Nechaeva</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Pyankov</surname><given-names>O.V.</given-names></name><name name-style="western"><surname>Pyankova</surname><given-names>O.G.</given-names></name><name name-style="western"><surname>Susloparov</surname><given-names>I.M.</given-names></name><name name-style="western"><surname>Taranov</surname><given-names>O.S.</given-names></name><etal/></person-group><article-title>Immunogenicity and protectivity of the peptide candidate vaccine against SARS-CoV-2</article-title><source>Ann. Russ. Acad. Med. Sci.</source><year>2021</year><volume>76</volume><fpage>5</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.15690/vramn1528</pub-id></element-citation></ref><ref id="B138-ijms-24-01701"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ryzhikov</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Ryzhikov</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Bogryantseva</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Usova</surname><given-names>S.V.</given-names></name><name name-style="western"><surname>Danilenko</surname><given-names>E.D.</given-names></name><name name-style="western"><surname>Nechaeva</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Pyankov</surname><given-names>O.V.</given-names></name><name name-style="western"><surname>Pyankova</surname><given-names>O.G.</given-names></name><name name-style="western"><surname>Gudymo</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Bodnev</surname><given-names>S.A.</given-names></name><etal/></person-group><article-title>A single blind, placebo-controlled randomized study of the safety, reactogenicity and immunogenicity of the &#8220;EpiVacCorona&#8221; Vaccine for the prevention of COVID-19, in volunteers aged 18&#8211;60 years (phase I&#8211;II)</article-title><source>Russ. J. Infect. Immun.</source><year>2021</year><volume>11</volume><fpage>283</fpage><lpage>296</lpage><pub-id pub-id-type="doi">10.15789/2220-7619-ASB-1699</pub-id></element-citation></ref><ref id="B139-ijms-24-01701"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.Y.</given-names></name><name name-style="western"><surname>Kuo</surname><given-names>H.-K.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>W.-J.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>J.-H.</given-names></name><name name-style="western"><surname>Kuo</surname><given-names>B.-S.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>F.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.-J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>H.-T.</given-names></name><etal/></person-group><article-title>A novel RBD-protein/peptide vaccine elicits broadly neutralizing antibodies and protects mice and macaques against SARS-CoV-2</article-title><source>Emerg. Microbes Infect.</source><year>2022</year><volume>11</volume><fpage>2724</fpage><lpage>2734</lpage><pub-id pub-id-type="doi">10.1080/22221751.2022.2140608</pub-id><pub-id pub-id-type="pmid">36287714</pub-id><pub-id pub-id-type="pmcid">PMC9662039</pub-id></element-citation></ref><ref id="B140-ijms-24-01701"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>C.Y.</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>K.-P.</given-names></name><name name-style="western"><surname>Kuo</surname><given-names>H.-K.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>W.-J.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>Y.-H.</given-names></name><name name-style="western"><surname>Kuo</surname><given-names>B.-S.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>J.-H.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ho</surname><given-names>Y.-H.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>F.</given-names></name><etal/></person-group><article-title>A multitope SARS-CoV-2 vaccine provides long-lasting B cell and T cell immunity against Delta and Omicron variants</article-title><source>J. Clin. Investig.</source><year>2022</year><volume>132</volume><fpage>e157707</fpage><pub-id pub-id-type="doi">10.1172/JCI157707</pub-id><pub-id pub-id-type="pmid">35316221</pub-id><pub-id pub-id-type="pmcid">PMC9106357</pub-id></element-citation></ref><ref id="B141-ijms-24-01701"><label>141.</label><element-citation publication-type="patent"><person-group person-group-type="author"><name name-style="western"><surname>Belozerova</surname><given-names>N.S.</given-names></name><name name-style="western"><surname>Pletyukhina</surname><given-names>Y.V.</given-names></name><name name-style="western"><surname>Rabdano</surname><given-names>S.O.</given-names></name><name name-style="western"><surname>Savelev</surname><given-names>N.S.</given-names></name><name name-style="western"><surname>Fakhretdinova</surname><given-names>L.N.</given-names></name><name name-style="western"><surname>Trukhin</surname><given-names>V.P.</given-names></name><name name-style="western"><surname>Evtushenko</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Khaitov</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Skvortsova</surname><given-names>V.I.</given-names></name></person-group><article-title>Artificial Gene N1new, Encoding Nucleocapsid Protein of Coronavirus SARS-CoV-2, and Recombinant Plasmid pET-28a-N1new, Providing Expression of the Artificial Gene</article-title><source>RU Patent</source><patent>NO. 2762962C1</patent><day>24</day><month>December</month><year>2021</year></element-citation></ref><ref id="B142-ijms-24-01701"><label>142.</label><element-citation publication-type="patent"><person-group person-group-type="author"><name name-style="western"><surname>Belozerova</surname><given-names>N.S.</given-names></name><name name-style="western"><surname>Pletyukhina</surname><given-names>Y.V.</given-names></name><name name-style="western"><surname>Rabdano</surname><given-names>S.O.</given-names></name><name name-style="western"><surname>Savelev</surname><given-names>N.S.</given-names></name><name name-style="western"><surname>Fakhretdinova</surname><given-names>L.N.</given-names></name><name name-style="western"><surname>Savina</surname><given-names>N.N.</given-names></name><name name-style="western"><surname>Ekimov</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Trukhin</surname><given-names>V.P.</given-names></name><name name-style="western"><surname>Evtushenko</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Skvortsova</surname><given-names>V.I.</given-names></name><etal/></person-group><article-title>COVID-19 Vaccine Composition</article-title><source>RU Patent</source><patent>NO. 2766292C1</patent><day>14</day><month>March</month><year>2022</year></element-citation></ref><ref id="B143-ijms-24-01701"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ren</surname><given-names>W.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>H.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>G.F.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>G.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>G.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Recombinant SARS-CoV-2 spike S1-Fc fusion protein induced high levels of neutralizing responses in nonhuman primates</article-title><source>Vaccine</source><year>2020</year><volume>38</volume><fpage>5653</fpage><lpage>5658</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2020.06.066</pub-id><pub-id pub-id-type="pmid">32651113</pub-id><pub-id pub-id-type="pmcid">PMC7311893</pub-id></element-citation></ref><ref id="B144-ijms-24-01701"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marlin</surname><given-names>R.</given-names></name><name name-style="western"><surname>Godot</surname><given-names>V.</given-names></name><name name-style="western"><surname>Cardinaud</surname><given-names>S.</given-names></name><name name-style="western"><surname>Galhaut</surname><given-names>M.</given-names></name><name name-style="western"><surname>Coleon</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zurawski</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dereuddre-Bosquet</surname><given-names>N.</given-names></name><name name-style="western"><surname>Cavarelli</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gallou&#235;t</surname><given-names>A.-S.</given-names></name><name name-style="western"><surname>Maisonnasse</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Targeting SARS-CoV-2 receptor-binding domain to cells expressing CD40 improves protection to infection in convalescent macaques</article-title><source>Nat. Commun.</source><year>2021</year><volume>12</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1038/s41467-021-25382-0</pub-id><pub-id pub-id-type="pmid">34471122</pub-id><pub-id pub-id-type="pmcid">PMC8410935</pub-id></element-citation></ref><ref id="B145-ijms-24-01701"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Col&#233;on</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wiedemann</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sur&#233;naud</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lacabaratz</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hue</surname><given-names>S.</given-names></name><name name-style="western"><surname>Prague</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cervantes-Gonzalez</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Ellis</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sansoni</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Design, immunogenicity, and efficacy of a pan-sarbecovirus dendritic-cell targeting vaccine</article-title><source>Ebiomedicine</source><year>2022</year><volume>80</volume><fpage>104062</fpage><pub-id pub-id-type="doi">10.1016/j.ebiom.2022.104062</pub-id><pub-id pub-id-type="pmid">35594660</pub-id><pub-id pub-id-type="pmcid">PMC9113741</pub-id></element-citation></ref><ref id="B146-ijms-24-01701"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zou</surname><given-names>F.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Li</surname><given-names>R.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Song</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>Nanoparticle Vaccines Based on the Receptor Binding Domain (RBD) and Heptad Repeat (HR) of SARS-CoV-2 Elicit Robust Protective Immune Responses</article-title><source>Immunity</source><year>2020</year><volume>53</volume><fpage>1315</fpage><lpage>1330.e9</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2020.11.015</pub-id><pub-id pub-id-type="pmid">33275896</pub-id><pub-id pub-id-type="pmcid">PMC7687490</pub-id></element-citation></ref><ref id="B147-ijms-24-01701"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Trifonova</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Zenin</surname><given-names>V.A.</given-names></name><name name-style="western"><surname>Nikitin</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Yurkova</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Ryabchevskaya</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Putlyaev</surname><given-names>E.V.</given-names></name><name name-style="western"><surname>Donchenko</surname><given-names>E.K.</given-names></name><name name-style="western"><surname>Kondakova</surname><given-names>O.A.</given-names></name><name name-style="western"><surname>Fedorov</surname><given-names>A.N.</given-names></name><name name-style="western"><surname>Atabekov</surname><given-names>J.G.</given-names></name><etal/></person-group><article-title>Study of rubella candidate vaccine based on a structurally modified plant virus</article-title><source>Antivir. Res.</source><year>2017</year><volume>144</volume><fpage>27</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2017.05.006</pub-id><pub-id pub-id-type="pmid">28511994</pub-id></element-citation></ref><ref id="B148-ijms-24-01701"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ryabchevskaya</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Evtushenko</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Granovskiy</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Ivanov</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Atabekov</surname><given-names>J.G.</given-names></name><name name-style="western"><surname>Kondakova</surname><given-names>O.A.</given-names></name><name name-style="western"><surname>Nikitin</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Karpova</surname><given-names>O.V.</given-names></name></person-group><article-title>Two approaches for the stabilization of <italic toggle="yes">Bacillus anthracis</italic> recombinant protective antigen</article-title><source>Hum. Vaccines Immunother.</source><year>2020</year><volume>17</volume><fpage>560</fpage><lpage>565</lpage><pub-id pub-id-type="doi">10.1080/21645515.2020.1772632</pub-id><pub-id pub-id-type="pmid">32614657</pub-id><pub-id pub-id-type="pmcid">PMC7899644</pub-id></element-citation></ref><ref id="B149-ijms-24-01701"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ryabchevskaya</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Granovskiy</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Evtushenko</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Ivanov</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Kondakova</surname><given-names>O.A.</given-names></name><name name-style="western"><surname>Nikitin</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Karpova</surname><given-names>O.V.</given-names></name></person-group><article-title>Designing Stable <italic toggle="yes">Bacillus anthracis</italic> Antigens with a View to Recombinant Anthrax Vaccine Development</article-title><source>Pharmaceutics</source><year>2022</year><volume>14</volume><elocation-id>806</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics14040806</pub-id><pub-id pub-id-type="pmid">35456639</pub-id><pub-id pub-id-type="pmcid">PMC9025368</pub-id></element-citation></ref><ref id="B150-ijms-24-01701"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Watterson</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wijesundara</surname><given-names>D.K.</given-names></name><name name-style="western"><surname>Modhiran</surname><given-names>N.</given-names></name><name name-style="western"><surname>Mordant</surname><given-names>F.L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Avumegah</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>McMillan</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Lackenby</surname><given-names>J.</given-names></name><name name-style="western"><surname>Guilfoyle</surname><given-names>K.</given-names></name><name name-style="western"><surname>van Amerongen</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Preclinical development of a molecular clamp-stabilised subunit vaccine for severe acute respiratory syndrome coronavirus 2</article-title><source>Clin. Transl. Immunol.</source><year>2021</year><volume>10</volume><fpage>e1269</fpage><pub-id pub-id-type="doi">10.1002/cti2.1269</pub-id><pub-id pub-id-type="pmcid">PMC8021130</pub-id><pub-id pub-id-type="pmid">33841880</pub-id></element-citation></ref><ref id="B151-ijms-24-01701"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chappell</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Mordant</surname><given-names>F.L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wijesundara</surname><given-names>D.K.</given-names></name><name name-style="western"><surname>Ellenberg</surname><given-names>P.</given-names></name><name name-style="western"><surname>Lackenby</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Cheung</surname><given-names>S.T.M.</given-names></name><name name-style="western"><surname>Modhiran</surname><given-names>N.</given-names></name><name name-style="western"><surname>Avumegah</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Henderson</surname><given-names>C.L.</given-names></name><etal/></person-group><article-title>Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: A randomised, double-blind, placebo-controlled, phase 1 trial</article-title><source>Lancet Infect. Dis.</source><year>2021</year><volume>21</volume><fpage>1383</fpage><lpage>1394</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(21)00200-0</pub-id><pub-id pub-id-type="pmid">33887208</pub-id><pub-id pub-id-type="pmcid">PMC8055208</pub-id></element-citation></ref><ref id="B152-ijms-24-01701"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>C.-Y.</given-names></name><name name-style="western"><surname>Monie</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Hung</surname><given-names>C.-F.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>T.-C.</given-names></name></person-group><article-title>Improving therapeutic HPV peptide-based vaccine potency by enhancing CD4+ T help and dendritic cell activation</article-title><source>J. Biomed. Sci.</source><year>2010</year><volume>17</volume><fpage>88</fpage><pub-id pub-id-type="doi">10.1186/1423-0127-17-88</pub-id><pub-id pub-id-type="pmid">21092195</pub-id><pub-id pub-id-type="pmcid">PMC3000388</pub-id></element-citation></ref><ref id="B153-ijms-24-01701"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ahmed</surname><given-names>S.F.</given-names></name><name name-style="western"><surname>Quadeer</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>McKay</surname><given-names>M.R.</given-names></name></person-group><article-title>Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies</article-title><source>Viruses</source><year>2020</year><volume>12</volume><elocation-id>254</elocation-id><pub-id pub-id-type="doi">10.3390/v12030254</pub-id><pub-id pub-id-type="pmid">32106567</pub-id><pub-id pub-id-type="pmcid">PMC7150947</pub-id></element-citation></ref><ref id="B154-ijms-24-01701"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>W.J.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>M.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>K.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>K.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>G.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>W.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>G.F.</given-names></name></person-group><article-title>T-cell immunity of SARS-CoV: Implications for vaccine development against MERS-CoV</article-title><source>Antivir. Res.</source><year>2016</year><volume>137</volume><fpage>82</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2016.11.006</pub-id><pub-id pub-id-type="pmid">27840203</pub-id><pub-id pub-id-type="pmcid">PMC7113894</pub-id></element-citation></ref><ref id="B155-ijms-24-01701"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Joshi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Joshi</surname><given-names>B.C.</given-names></name><name name-style="western"><surname>Mannan</surname><given-names>M.A.-U.</given-names></name><name name-style="western"><surname>Kaushik</surname><given-names>V.</given-names></name></person-group><article-title>Epitope based vaccine prediction for SARS-COV-2 by deploying immuno-informatics approach</article-title><source>Inform. Med. Unlocked</source><year>2020</year><volume>19</volume><fpage>100338</fpage><pub-id pub-id-type="doi">10.1016/j.imu.2020.100338</pub-id><pub-id pub-id-type="pmid">32352026</pub-id><pub-id pub-id-type="pmcid">PMC7189872</pub-id></element-citation></ref><ref id="B156-ijms-24-01701"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Olsen</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Gentry</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Sambade</surname><given-names>M.</given-names></name><name name-style="western"><surname>Beck</surname><given-names>W.</given-names></name><name name-style="western"><surname>Garness</surname><given-names>J.</given-names></name><name name-style="western"><surname>Entwistle</surname><given-names>S.</given-names></name><name name-style="western"><surname>Willis</surname><given-names>C.</given-names></name><name name-style="western"><surname>Vensko</surname><given-names>S.</given-names></name><name name-style="western"><surname>Woods</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Landscape and selection of vaccine epitopes in SARS-CoV-2</article-title><source>Genome Med.</source><year>2021</year><volume>13</volume><fpage>101</fpage><pub-id pub-id-type="doi">10.1186/s13073-021-00910-1</pub-id><pub-id pub-id-type="pmid">34127050</pub-id><pub-id pub-id-type="pmcid">PMC8201469</pub-id></element-citation></ref><ref id="B157-ijms-24-01701"><label>157.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Enayatkhani</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hasaniazad</surname><given-names>M.</given-names></name><name name-style="western"><surname>Faezi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gouklani</surname><given-names>H.</given-names></name><name name-style="western"><surname>Davoodian</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ahmadi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Einakian</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Karmostaji</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ahmadi</surname><given-names>K.</given-names></name></person-group><article-title>Reverse vaccinology approach to design a novel multi-epitope vaccine candidate against COVID-19: An <italic toggle="yes">in silico</italic> study</article-title><source>J. Biomol. Struct. Dyn.</source><year>2020</year><volume>39</volume><fpage>2857</fpage><lpage>2872</lpage><comment>Erratum in <italic toggle="yes">Microb. Pathog.</italic><bold>2021</bold>, <italic toggle="yes">160</italic>, 104401</comment><pub-id pub-id-type="doi">10.1080/07391102.2020.1756411</pub-id><pub-id pub-id-type="pmid">32295479</pub-id><pub-id pub-id-type="pmcid">PMC7196925</pub-id></element-citation></ref><ref id="B158-ijms-24-01701"><label>158.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kalita</surname><given-names>P.</given-names></name><name name-style="western"><surname>Padhi</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>K.Y.</given-names></name><name name-style="western"><surname>Tripathi</surname><given-names>T.</given-names></name></person-group><article-title>Design of a peptide-based subunit vaccine against novel coronavirus SARS-CoV-2</article-title><source>Microb. Pathog.</source><year>2020</year><volume>145</volume><fpage>104236</fpage><pub-id pub-id-type="doi">10.1016/j.micpath.2020.104236</pub-id><pub-id pub-id-type="pmid">32376359</pub-id><pub-id pub-id-type="pmcid">PMC7196559</pub-id></element-citation></ref><ref id="B159-ijms-24-01701"><label>159.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sarkar</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ullah</surname><given-names>A.</given-names></name><name name-style="western"><surname>Johora</surname><given-names>F.T.</given-names></name><name name-style="western"><surname>Taniya</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Araf</surname><given-names>Y.</given-names></name></person-group><article-title>Immunoinformatics-guided designing of epitope-based subunit vaccines against the SARS Coronavirus-2 (SARS-CoV-2)</article-title><source>Immunobiology</source><year>2020</year><volume>225</volume><fpage>151955</fpage><pub-id pub-id-type="doi">10.1016/j.imbio.2020.151955</pub-id><pub-id pub-id-type="pmid">32517882</pub-id><pub-id pub-id-type="pmcid">PMC7211625</pub-id></element-citation></ref><ref id="B160-ijms-24-01701"><label>160.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tregoning</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>E.S.</given-names></name><name name-style="western"><surname>Cheeseman</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Flight</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Higham</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Lemm</surname><given-names>N.</given-names></name><name name-style="western"><surname>Pierce</surname><given-names>B.F.</given-names></name><name name-style="western"><surname>Stirling</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Pollock</surname><given-names>K.M.</given-names></name></person-group><article-title>Vaccines for COVID-19</article-title><source>Clin. Exp. Immunol.</source><year>2020</year><volume>202</volume><fpage>162</fpage><lpage>192</lpage><pub-id pub-id-type="doi">10.1111/cei.13517</pub-id><pub-id pub-id-type="pmid">32935331</pub-id><pub-id pub-id-type="pmcid">PMC7597597</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="ijms-24-01701-f001" orientation="portrait"><label>Figure 1</label><caption><p>SARS-CoV-2 S protein structure (<bold>A</bold>) and graphical overview of design strategies of recombinant S protein-based COVID-19 vaccines, being at the phase 3 of clinical trials or approved (<bold>B</bold>&#8211;<bold>G</bold>). (<bold>A</bold>) SARS-CoV-2 S protein monomer and trimer (open state with one RBD in the &#8220;up&#8221; conformation) structural model (PDB code: 7DK3) [<xref rid="B18-ijms-24-01701" ref-type="bibr">18</xref>,<xref rid="B19-ijms-24-01701" ref-type="bibr">19</xref>] and linear diagram of the full-length S protein domain structure in the same color scheme. A structural model was obtained for the prefusion-stabilized trimerized S protein ectodomain using cryoelectronic microscopy. Protein structures were visualized using Jmol 14.31.34 software (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.jmol.org">http://www.jmol.org</uri>, accessed on 3 September 2022). (<bold>B</bold>) Antigen was based on full-length S protein within NVX-CoV2373 nanoparticle vaccine. (<bold>C</bold>,<bold>D</bold>) S protein ectodomain was supplemented with either T4 fibritin trimerization motif (foldon) (within MVC-COV1901 and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-protein" xlink:href="VAT00002">VAT00002</ext-link> vaccines) (<bold>C</bold>) or Trimer-Tag (within SCB-2019 vaccine) (<bold>D</bold>). (<bold>E</bold>) Antigens of Razi Cov Pars vaccine: S protein (trimerized by foldon) as well as S1 and S2 subunits, both fused with human IgG Fc at the C-terminus. (<bold>F</bold>) S protein ectodomain as an antigen of COVAX-19 vaccine (14&#8211;1213 amino acids are included) or Nanocovax vaccine (1&#8211;1213 amino acids are included). (<bold>G</bold>) The summary of antigens design within RBD-based vaccines: individual RBD monomer (Abdala, Corbevax, West China Hospital COVID-19 vaccine); RBD dimer (ZF2001); RBD monomer conjugated with tetanus toxoid (several RBD molecules are conjugated with on toxoid molecule) (FINLAY-FR-2); RBD fused with I53&#8211;50A protein component, which together with I53-50B component formed self-assembled nanoparticle, displaying 60 copies of RBD (GBP-510); RBD is armed with interferon-&#945; (IFN&#945;) at the N-terminus and is dimerized by human IgG1 Fc at the C-terminus (V-01); and RBD fused with single chain fragment crystallizable region (sFc) of a human IgG1 and supplemented with synthetic peptides of N-, M- and S2-proteins of SARS-CoV-2 (UB-612). SS: signal sequence; NTD: N-terminal domain; RBD: receptor-binding domain; SD1/SD2: subdomains 1 and 2; FP: fusion peptide; HR1: heptad repeat 1; CH: central helix; CD: connector domain; HR2: heptad repeat 2; TM: transmembrane domain; and CT: cytoplasmic tail. Two protease cleavage sites are indicated: the RRAR furin site (S1/S2) and the S2&#8217; site. 2P mutation means the introduction of two proline mutations at residues 986 and 987.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ijms-24-01701-g001.jpg"/></fig><table-wrap position="float" id="ijms-24-01701-t001" orientation="portrait"><object-id pub-id-type="pii">ijms-24-01701-t001_Table 1</object-id><label>Table 1</label><caption><p>Some adjuvants used in recombinant protein COVID-19 vaccines approved for clinical trials *.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Adjuvant</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Composition</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Main Mechanism of Action</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Aluminum compounds</td><td align="center" valign="middle" rowspan="1" colspan="1">Aluminum hydroxide, aluminum phosphate, etc.</td><td align="center" valign="middle" rowspan="1" colspan="1">Depot effect, enhancement of phagocytosis of the antigen and activation of the pro-inflammatory NLRP3 pathway [<xref rid="B39-ijms-24-01701" ref-type="bibr">39</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CpG oligodeoxynucleotides (CpG ODN)</td><td align="center" valign="middle" rowspan="1" colspan="1">Synthetic oligodeoxynucleotides containing unmethylated CpG repeats</td><td align="center" valign="middle" rowspan="1" colspan="1">Toll-like receptor 9 (TLR9) agonists [<xref rid="B45-ijms-24-01701" ref-type="bibr">45</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Monophosphoryl lipid A (MPL)</td><td align="center" valign="middle" rowspan="1" colspan="1">Detoxified lipopolysaccharide derivative of gram-negative bacterium <italic toggle="yes">Salmonella minnesota</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">TLR4 agonist [<xref rid="B47-ijms-24-01701" ref-type="bibr">47</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Montanide ISA51 and 720</td><td align="center" valign="middle" rowspan="1" colspan="1">Emulsions consisting of oils and monooleate mannide surfactant</td><td align="center" valign="middle" rowspan="1" colspan="1">Antigen depot, recruitment of antigen-presenting cells (APCs) and induction of lymphocyte migration into draining lymph nodes [<xref rid="B48-ijms-24-01701" ref-type="bibr">48</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">MF59</td><td align="center" valign="middle" rowspan="1" colspan="1">Squalene-based emulsion adjuvant</td><td align="center" valign="middle" rowspan="1" colspan="1">Induction of cytokines and chemokines, recruitment of immune cells [<xref rid="B45-ijms-24-01701" ref-type="bibr">45</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Advax</td><td align="center" valign="middle" rowspan="1" colspan="1">Delta inulin adjuvant</td><td align="center" valign="middle" rowspan="1" colspan="1">Activation of the complement alternative pathway, enhancement of humoral and cellular immune responses with the lack of induction of pro-inflammatory cytokines production [<xref rid="B49-ijms-24-01701" ref-type="bibr">49</xref>] </td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Matrix-M</td><td align="center" valign="middle" rowspan="1" colspan="1">Saponin adjuvant</td><td align="center" valign="middle" rowspan="1" colspan="1">Induction of leukocyte migration into draining lymph nodes [<xref rid="B50-ijms-24-01701" ref-type="bibr">50</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">AS03</td><td align="center" valign="middle" rowspan="1" colspan="1">Oil emulsion containing squalene, &#945;-tocopherol and polysorbate 80</td><td align="center" valign="middle" rowspan="1" colspan="1">Action similar to the MF59 adjuvant, as well as increased antigen uptake, in particular by monocytes, antigen presentation in draining lymph nodes [<xref rid="B46-ijms-24-01701" ref-type="bibr">46</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">PIKA</td><td align="center" valign="middle" rowspan="1" colspan="1">Synthetic chemical analogue of dsRNA, polyinosinic-polycytidylic acid with kanamycin and calcium</td><td align="center" valign="middle" rowspan="1" colspan="1">TLR3 agonist [<xref rid="B51-ijms-24-01701" ref-type="bibr">51</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">ALFQ</td><td align="center" valign="middle" rowspan="1" colspan="1">Liposomes containing saponin QS-21 and synthetic monophosphoryl lipid A (3D-PHAD<sup>&#174;</sup>)</td><td align="center" valign="middle" rowspan="1" colspan="1">MPL is a TLR4 agonist, saponin QS21 activates NLRP3 [<xref rid="B52-ijms-24-01701" ref-type="bibr">52</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">XS15</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Synthetic lipopeptide</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TLR1 and TLR2 agonist [<xref rid="B53-ijms-24-01701" ref-type="bibr">53</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>* There are currently no recombinant protein SARS and MERS vaccines approved for clinical trials.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="ijms-24-01701-t002" orientation="portrait"><object-id pub-id-type="pii">ijms-24-01701-t002_Table 2</object-id><label>Table 2</label><caption><p>Several recombinant protein vaccines against COVID-19 in clinical trials and pre-clinical studies as of 25 October 2022.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Developer</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Vaccine Name</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Antigen/Technology</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Target Antigen Expression System</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Type of Adjuvant</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Clinical Phase</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Approvals</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td colspan="8" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Full-length S protein-based vaccines</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Novavax<break/>(Gaithersburg, MD, USA)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NVX-CoV2373<break/>(Nuvaxovid<italic toggle="yes">)</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nanoparticle vaccine composed of trimeric <break/>full-length S proteins </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sf9 insect cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Matrix-M</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 (EUCTR2020-004123-16,<break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04583995">NCT04583995</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04611802">NCT04611802</ext-link>,<break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05249816">NCT05249816</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05556720">NCT05556720</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05463068">NCT05463068</ext-link> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05372588">NCT05372588</ext-link>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">40 countries<break/>(USA, European countries and others) </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B89-ijms-24-01701" ref-type="bibr">89</xref>,<xref rid="B90-ijms-24-01701" ref-type="bibr">90</xref>,<xref rid="B91-ijms-24-01701" ref-type="bibr">91</xref>,<xref rid="B92-ijms-24-01701" ref-type="bibr">92</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Medigen Vaccine Biologics Corporation (Taipei, Taiwan)/NIAID (Rockville, MD, USA)/<break/>Dynavax (Emeryville, CA, USA)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MVC-COV1901</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prefusion-stabilized <break/>trimeric S protein<break/>(S-2P)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CHO cells </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CpG 1018 (Dynavax)<break/>and Al(OH)3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05426343">NCT05426343</ext-link>,<break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05198596">NCT05198596</ext-link> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05011526">NCT05011526</ext-link>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Eswatini, Paraguay, Somaliland and Taiwan</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B93-ijms-24-01701" ref-type="bibr">93</xref>,<xref rid="B94-ijms-24-01701" ref-type="bibr">94</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vaxine Pty Ltd. (Adelaide, Australia)/<break/>CinnaGen Co. (Tehran, Iran)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">COVAX-19<break/>(SpikoGen)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">S protein ectodomain </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tni insect cells </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Advax-CpG55.2<break/>(Advax-SM)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05005559">NCT05005559</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05542862">NCT05542862</ext-link> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05175625">NCT05175625</ext-link>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Iran</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B95-ijms-24-01701" ref-type="bibr">95</xref>,<xref rid="B96-ijms-24-01701" ref-type="bibr">96</xref>,<xref rid="B97-ijms-24-01701" ref-type="bibr">97</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Razi Vaccine and Serum Research Institute (Karaj, Iran)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Razi Cov Pars</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">S-Trimer, <break/>S1 and S2 subunits </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Expi293F human cells, ExpiCHO-S&#8482; Cells </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RAS-01 (Razi Adjuvant System-01)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 (IRCT20201214049709N3)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Iran</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B98-ijms-24-01701" ref-type="bibr">98</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Clover Biopharmaceuticals Inc. (Shanghai, China)/<break/>GSK (Brentford, United Kingdom)/Dynavax (Emeryville, CA, USA) </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SCB-2019</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">S-Trimer<break/>(Trimer-Tag technology) </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CHO cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AS03(GSK) or CpG 1018<break/>and Al(OH)3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05188677">NCT05188677</ext-link> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05470803">NCT05470803</ext-link>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B99-ijms-24-01701" ref-type="bibr">99</xref>,<xref rid="B100-ijms-24-01701" ref-type="bibr">100</xref>,<xref rid="B101-ijms-24-01701" ref-type="bibr">101</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nanogen Pharmaceutical Biotechnology JSC (Ho Chi Minh City, Vietnam)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nanocovax</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prefusion-stabilized <break/>S protein </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CHO cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Aluminium hydroxide</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04922788">NCT04922788</ext-link>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B102-ijms-24-01701" ref-type="bibr">102</xref>,<xref rid="B103-ijms-24-01701" ref-type="bibr">103</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sanofi Pasteur (Lyon, France)/<break/>GSK (Brentford, United Kingdom)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-protein" xlink:href="VAT00002">VAT00002</ext-link><break/>(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-protein" xlink:href="VAT00008">VAT00008</ext-link>, Vidprevtyn)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prefusion-stabilized <break/>trimeric S protein</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">expresSF<sup>+</sup>
<break/>insect <break/>cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AS03 (GSK)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04904549">NCT04904549</ext-link>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B104-ijms-24-01701" ref-type="bibr">104</xref>,<xref rid="B105-ijms-24-01701" ref-type="bibr">105</xref>,<xref rid="B106-ijms-24-01701" ref-type="bibr">106</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yisheng Biopharma<break/>(Beijing, China)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PIKA<break/>COVID-19 Vaccine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prefusion-stabilized <break/>trimeric S protein</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CHO cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PIKA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2/3 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05463419">NCT05463419</ext-link>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B107-ijms-24-01701" ref-type="bibr">107</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Shanghai Zerun Biotechnology (Shanghai, China) /<break/>Walvax Biotechnology (Kunming, China)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ZR-202-CoV <break/>(202-CoV)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prefusion-stabilized <break/>trimeric S protein</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CHO cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CpG 7909 <break/>and Al(OH)3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04990544">NCT04990544</ext-link>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B108-ijms-24-01701" ref-type="bibr">108</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">US Army Medical Research and Development Command ( Frederick, MD, USA) </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SpFN<break/>COVID-19 Vaccine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Spike-ferritin nanoparticle </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Expi293F cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ALFQ</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04784767">NCT04784767</ext-link>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B109-ijms-24-01701" ref-type="bibr">109</xref>,<xref rid="B110-ijms-24-01701" ref-type="bibr">110</xref>,<xref rid="B111-ijms-24-01701" ref-type="bibr">111</xref>]</td></tr><tr><td colspan="8" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold>RBD-based vaccines</bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Center for Genetic Engineering and Biotechnology (CIGB) (Havana, Cuba)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Abdala<break/>(CIGB-66)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Monomeric RBD </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">P. pastoris</italic> yeast</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Aluminium hydroxide</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 (RPCEC00000359)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cuba, Mexico, Nicaragua, Saint Vincent and the Grenadines, Venezuela and Vietnam</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B112-ijms-24-01701" ref-type="bibr">112</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Anhui Zhifei Longcom Biopharmaceutical (Hefei, China)/<break/>Institute of Microbiology, Chinese Academy of Sciences (Beijing, China)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ZF2001<break/>(Zifivax)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tandem-repeat dimeric RBD</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CHO cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Aluminium hydroxide</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04646590">NCT04646590</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05128643">NCT05128643</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05091411">NCT05091411</ext-link> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05107375">NCT05107375</ext-link>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">China, Colombia, Indonesia and Uzbekistan</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B66-ijms-24-01701" ref-type="bibr">66</xref>,<xref rid="B113-ijms-24-01701" ref-type="bibr">113</xref>,<xref rid="B114-ijms-24-01701" ref-type="bibr">114</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Instituto Finlay de Vacunas (Havana, Cuba)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">FINLAY-FR-2 (Soberana 02)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Conjugated vaccine <break/>(RBD and tetanus toxoid)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CHO cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Aluminium hydroxide</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 (IFV/COR/09)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cuba, Iran, Nicaragua and Venezuela</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B115-ijms-24-01701" ref-type="bibr">115</xref>,<xref rid="B116-ijms-24-01701" ref-type="bibr">116</xref>,<xref rid="B117-ijms-24-01701" ref-type="bibr">117</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Biological E. Limited (Hyderabad, India)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Corbevax (BECOV2A)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Recombinant RBD</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">P. pastoris</italic> yeast</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CpG 1018 (Dynavax) and Al(OH)3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 (CTRI/2021/08/036074)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Botswana and India</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B118-ijms-24-01701" ref-type="bibr">118</xref>,<xref rid="B119-ijms-24-01701" ref-type="bibr">119</xref>,<xref rid="B120-ijms-24-01701" ref-type="bibr">120</xref>,<xref rid="B121-ijms-24-01701" ref-type="bibr">121</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SK Bioscience Co., Ltd. (Seongnam, Republic of Korea)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GBP510 (SKYCovione)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Self-assembled <break/>two-component nanoparticle vaccine displaying RBD </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Expi293F cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AS03 (GSK)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05007951">NCT05007951</ext-link> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05501522">NCT05501522</ext-link>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Republic of Korea</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B122-ijms-24-01701" ref-type="bibr">122</xref>,<xref rid="B123-ijms-24-01701" ref-type="bibr">123</xref>,<xref rid="B124-ijms-24-01701" ref-type="bibr">124</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Livzon Mabpharm Inc (Zhuhai, China)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">V-01</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IFN-PADRE-<break/>RBD-Fc dimer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CHO cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Aluminium hydroxide</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05096832">NCT05096832</ext-link>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">China</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B125-ijms-24-01701" ref-type="bibr">125</xref>,<xref rid="B126-ijms-24-01701" ref-type="bibr">126</xref>,<xref rid="B127-ijms-24-01701" ref-type="bibr">127</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">West China Hospital, Sichuan University (Chengdu, China)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">West China Hospital COVID-19 vaccine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Recombinant RBD</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sf9 insect cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Aluminium hydroxide</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04904471">NCT04904471</ext-link> and NCT04887207)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B128-ijms-24-01701" ref-type="bibr">128</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">University Medical Center Groningen (Groningen, Netherlands)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AKS-452</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RBD-Fc</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CHO cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Montanide<sup>TM</sup> ISA 720</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2/3 (CTRI/2021/10/037269)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B129-ijms-24-01701" ref-type="bibr">129</xref>,<xref rid="B130-ijms-24-01701" ref-type="bibr">130</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Kentucky Bioprocessing (Owensboro, KY, USA)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">KBP-201</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RBD-Fc</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">N.benthamiana</italic><break/>plants</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CpG</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/2 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04473690">NCT04473690</ext-link>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B131-ijms-24-01701" ref-type="bibr">131</xref>,<xref rid="B132-ijms-24-01701" ref-type="bibr">132</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Human Stem Cell Institute (Moscow, Russia)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Betuvax-CoV-2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RBD-SD1-Fc</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CHO cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Betulin </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/2 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05270954">NCT05270954</ext-link>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B133-ijms-24-01701" ref-type="bibr">133</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Baiya Phytopharm Co Ltd. (Bangkok, Thailand)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Baiya SARS-CoV-2 Vax 1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RBD-Fc</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">N.benthamiana</italic> plants</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Aluminium hydroxide</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04953078">NCT04953078</ext-link>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B134-ijms-24-01701" ref-type="bibr">134</xref>,<xref rid="B135-ijms-24-01701" ref-type="bibr">135</xref>]</td></tr><tr><td colspan="8" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold>Multi-epitope vaccines</bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
Vector State Research Center of Virology and Biotechnology (Koltsovo, Russia)
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EpiVacCorona</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chemically synthesized peptide immunogens of the SARS-CoV-2<break/>S protein conjugated to a carrier protein<break/>(SARS-CoV-2 N protein and bacterial maltose-binding protein)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">E. coli</italic> for carrier protein expression </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Aluminium hydroxide</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05021016">NCT05021016</ext-link> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04780035">NCT04780035</ext-link>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Russia, Cambodia, Turkmenistan and<break/>Venezuela</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B136-ijms-24-01701" ref-type="bibr">136</xref>,<xref rid="B137-ijms-24-01701" ref-type="bibr">137</xref>,<xref rid="B138-ijms-24-01701" ref-type="bibr">138</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">COVAXX (Hauppauge, NY, USA)/United Biomedical Inc. Asia (Taipei, Taiwan)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">UB-612</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RBD-Fc and peptides representing conserved epitopes from the N-, M- and S2 proteins </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CHO cells for <break/>RBD-Fc expression</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">UBITh1a<sup>&#174;</sup>,<break/>CpG and<break/>Aluminum phosphate </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05293665">NCT05293665</ext-link>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B139-ijms-24-01701" ref-type="bibr">139</xref>,<xref rid="B140-ijms-24-01701" ref-type="bibr">140</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">University Hospital T&#252;bingen (T&#252;bingen, Germany)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CoVac-1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Synthetic peptides <break/>from the <break/>S-, N-, M-, E- <break/>and ORF8 proteins</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">XS15 emulsified in Montanide ISA51 VG</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/2 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04954469">NCT04954469</ext-link>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B53-ijms-24-01701" ref-type="bibr">53</xref>]</td></tr><tr><td colspan="8" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold>Vaccines Based on Non-S Structural Proteins</bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">St. Petersburg Research Institute of Vaccines and Sera (Saint Petersburg, Russia)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Convacell</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N protein </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">E. coli</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Squalane, <break/>&#945;-tocopherol and polysorbate 80</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/2 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05156723">NCT05156723</ext-link>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B141-ijms-24-01701" ref-type="bibr">141</xref>,<xref rid="B142-ijms-24-01701" ref-type="bibr">142</xref>]</td></tr><tr><td colspan="8" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold>Several vaccines in pre-clinical studies</bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Developer</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Antigen/technology</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Target antigen expression system</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Type of adjuvant</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Developments based on the same approach</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">References</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Univ. of Pittsburgh<break/>(Pittsburgh, PA, USA)</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Microneedle array delivered S1 subunit</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HEK293 cells</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">RS09</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MERS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B79-ijms-24-01701" ref-type="bibr">79</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AnyGo Technology<break/>(Beijing, China)</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">S1-Fc</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CHO cells</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">AD20Gold<sup>+</sup> or <break/>CFA and AD11.10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RBD-Fc</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B143-ijms-24-01701" ref-type="bibr">143</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IMVA-HB/IDMIT, VRI, Inserm (Fontenay-aux-<break/>Roses/Creteil/Paris, France) </td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">A vaccine that targets the SARS-CoV-2 RBD to the CD40 receptor (&#945;CD40.RBD)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CHO cells</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Poly-IC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#945;CD40.HIVenv vaccine based on HIV envelope gp140 glycoprotein </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B144-ijms-24-01701" ref-type="bibr">144</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LinkinVax, VRI, Inserm<break/>(Paris/Creteil, France)</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">A vaccine that targets antigens based on conserved T- and B-cell epitopes from the S and N proteins to the CD40 receptor (CD40.CoV2)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CHO-S cells</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Poly-IC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> &#945;CD40.RBD vaccine </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B144-ijms-24-01701" ref-type="bibr">144</xref>,<xref rid="B145-ijms-24-01701" ref-type="bibr">145</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sun Yat-Sen University, Institute of Human Virology (Guangzhou, China)</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Ferritin nanoparticles conjugated to the SARS-CoV-2 RBD and HR <break/>(SpyTag/SpyCatcher system)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CHO-S cells</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">SAS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">H. pylori</italic> ferritin-based influenza nanoparticle vaccines (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03186781">NCT03186781</ext-link> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03814720">NCT03814720</ext-link>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B146-ijms-24-01701" ref-type="bibr">146</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lomonosov Moscow State University<break/>(Moscow, Russia)</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Recombinant antigens based on the RBD and the highly conserved antigenic fragments of the S2 subunit </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">E. coli</italic>
</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">TMV SPs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rubella and Anthrax</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B43-ijms-24-01701" ref-type="bibr">43</xref>,<xref rid="B147-ijms-24-01701" ref-type="bibr">147</xref>,<xref rid="B148-ijms-24-01701" ref-type="bibr">148</xref>,<xref rid="B149-ijms-24-01701" ref-type="bibr">149</xref>]</td></tr></tbody></table></table-wrap></floats-group></article></pmc-articleset>